WO2020075790A1 - Sting作動化合物 - Google Patents
Sting作動化合物 Download PDFInfo
- Publication number
- WO2020075790A1 WO2020075790A1 PCT/JP2019/039941 JP2019039941W WO2020075790A1 WO 2020075790 A1 WO2020075790 A1 WO 2020075790A1 JP 2019039941 W JP2019039941 W JP 2019039941W WO 2020075790 A1 WO2020075790 A1 WO 2020075790A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino
- pyridin
- isoxazolo
- pyrazol
- cancer
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 387
- 229940044665 STING agonist Drugs 0.000 title claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 112
- 201000011510 cancer Diseases 0.000 claims abstract description 74
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 62
- 239000004480 active ingredient Substances 0.000 claims abstract description 18
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 16
- -1 methyl -d 3 group Chemical group 0.000 claims description 188
- 150000003839 salts Chemical class 0.000 claims description 160
- 239000012453 solvate Substances 0.000 claims description 135
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 55
- 229910052757 nitrogen Inorganic materials 0.000 claims description 43
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 42
- WDFCXKMHINMQOK-UHFFFAOYSA-N ethyl 2-amino-5-[3-amino-7-[1-(phosphonooxymethyl)pyrazol-4-yl]-[1,2]oxazolo[4,5-c]pyridin-4-yl]-4-fluorobenzoate Chemical compound NC1=C(C(=O)OCC)C=C(C(=C1)F)C1=NC=C(C2=C1C(=NO2)N)C=2C=NN(C2)COP(=O)(O)O WDFCXKMHINMQOK-UHFFFAOYSA-N 0.000 claims description 36
- 229910019142 PO4 Inorganic materials 0.000 claims description 29
- 239000010452 phosphate Substances 0.000 claims description 29
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 27
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 24
- PPVADNNKDQPXSF-UHFFFAOYSA-N 4-(4-amino-2-fluoro-3-methoxyphenyl)-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-3-amine Chemical compound NC1=C(C(=C(C=C1)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)F)OC PPVADNNKDQPXSF-UHFFFAOYSA-N 0.000 claims description 23
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 23
- 125000005842 heteroatom Chemical group 0.000 claims description 21
- 208000015181 infectious disease Diseases 0.000 claims description 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 19
- 125000004434 sulfur atom Chemical group 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 17
- 229910052717 sulfur Inorganic materials 0.000 claims description 16
- KYZZDINTLXUBRZ-UHFFFAOYSA-N 2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]-4-fluorobenzoic acid Chemical compound NC1=C(C(=O)O)C=C(C(=C1)F)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2 KYZZDINTLXUBRZ-UHFFFAOYSA-N 0.000 claims description 15
- 125000005843 halogen group Chemical group 0.000 claims description 15
- 206010009944 Colon cancer Diseases 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 208000029742 colonic neoplasm Diseases 0.000 claims description 13
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 13
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 11
- KJDZIQSQUKAYBX-UHFFFAOYSA-N methyl 2-amino-5-[3-amino-7-[1-(phosphonooxymethyl)pyrazol-4-yl]-[1,2]oxazolo[4,5-c]pyridin-4-yl]-4-fluorobenzoate Chemical compound NC1=C(C(=O)OC)C=C(C(=C1)F)C1=NC=C(C2=C1C(=NO2)N)C=2C=NN(C2)COP(=O)(O)O KJDZIQSQUKAYBX-UHFFFAOYSA-N 0.000 claims description 11
- 229940127084 other anti-cancer agent Drugs 0.000 claims description 11
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 9
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 9
- 201000001441 melanoma Diseases 0.000 claims description 9
- 206010025323 Lymphomas Diseases 0.000 claims description 8
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 125000001620 monocyclic carbocycle group Chemical group 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 150000003536 tetrazoles Chemical class 0.000 claims description 8
- 150000003852 triazoles Chemical class 0.000 claims description 8
- PWLHWAARAJDKCT-FIBGUPNXSA-N 4-[4-amino-2-fluoro-5-(trideuteriomethoxy)phenyl]-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-3-amine Chemical compound NC1=CC(=C(C=C1OC([2H])([2H])[2H])C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)F PWLHWAARAJDKCT-FIBGUPNXSA-N 0.000 claims description 7
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 7
- 229910052783 alkali metal Inorganic materials 0.000 claims description 7
- 125000002947 alkylene group Chemical group 0.000 claims description 7
- 125000003277 amino group Chemical group 0.000 claims description 7
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 7
- NUGRPZFDGUZEPW-UHFFFAOYSA-N methyl 2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]-4-fluorobenzoate Chemical compound NC1=C(C(=O)OC)C=C(C(=C1)F)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2 NUGRPZFDGUZEPW-UHFFFAOYSA-N 0.000 claims description 7
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 6
- MJUUZZSMBBSHTP-UHFFFAOYSA-N 2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]-4-fluoro-N-methylbenzamide Chemical compound NC1=C(C(=O)NC)C=C(C(=C1)F)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2 MJUUZZSMBBSHTP-UHFFFAOYSA-N 0.000 claims description 6
- RVISIVQEGFHZGI-UHFFFAOYSA-N 2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]-4-fluorobenzamide Chemical compound NC1=C(C(=O)N)C=C(C(=C1)F)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2 RVISIVQEGFHZGI-UHFFFAOYSA-N 0.000 claims description 6
- VJJKTXNNGGUFTR-UHFFFAOYSA-N 4-(4-amino-2-fluoro-5-methylsulfanylphenyl)-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-3-amine Chemical compound NC1=CC(=C(C=C1SC)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)F VJJKTXNNGGUFTR-UHFFFAOYSA-N 0.000 claims description 6
- INVFBBPUZZBJJD-UHFFFAOYSA-N 4-(4-amino-2-fluoro-5-methylsulfinylphenyl)-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-3-amine Chemical compound NC1=CC(=C(C=C1S(=O)C)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)F INVFBBPUZZBJJD-UHFFFAOYSA-N 0.000 claims description 6
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 6
- 125000002950 monocyclic group Chemical group 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 5
- ZDQYTUBEMHLJFE-UHFFFAOYSA-N 1-[2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]-4-fluorophenyl]ethanone Chemical compound NC1=C(C=C(C(=C1)F)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)C(C)=O ZDQYTUBEMHLJFE-UHFFFAOYSA-N 0.000 claims description 5
- WGZGWSNFTNFCFB-UHFFFAOYSA-N 4-(4-amino-2-chloro-5-methylsulfanylphenyl)-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-3-amine Chemical compound NC1=CC(=C(C=C1SC)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)Cl WGZGWSNFTNFCFB-UHFFFAOYSA-N 0.000 claims description 5
- PWLHWAARAJDKCT-UHFFFAOYSA-N 4-(4-amino-2-fluoro-5-methoxyphenyl)-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-3-amine Chemical compound NC1=CC(=C(C=C1OC)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)F PWLHWAARAJDKCT-UHFFFAOYSA-N 0.000 claims description 5
- FAOWAHOTVSCQEC-UHFFFAOYSA-N 4-(4-amino-2-fluoro-5-methoxyphenyl)-7-(5-methyl-1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-3-amine Chemical compound NC1=CC(=C(C=C1OC)C1=NC=C(C2=C1C(=NO2)N)C=2C(=NNC2)C)F FAOWAHOTVSCQEC-UHFFFAOYSA-N 0.000 claims description 5
- NREUAAKBKNPNKX-UHFFFAOYSA-N 4-(4-amino-2-fluoro-5-methylsulfonylphenyl)-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-3-amine Chemical compound NC1=CC(=C(C=C1S(=O)(=O)C)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)F NREUAAKBKNPNKX-UHFFFAOYSA-N 0.000 claims description 5
- GZOSBWSAZZJQOM-UHFFFAOYSA-N 4-(4-amino-5-ethylsulfanyl-2-fluorophenyl)-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-3-amine Chemical compound NC1=CC(=C(C=C1SCC)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)F GZOSBWSAZZJQOM-UHFFFAOYSA-N 0.000 claims description 5
- 206010061424 Anal cancer Diseases 0.000 claims description 5
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 5
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 239000002955 immunomodulating agent Substances 0.000 claims description 5
- LYOZDCBEZDXVSR-UHFFFAOYSA-N 1-[2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]-4-fluorophenyl]propan-1-one Chemical compound NC1=C(C=C(C(=C1)F)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)C(CC)=O LYOZDCBEZDXVSR-UHFFFAOYSA-N 0.000 claims description 4
- VUFHPBPWOIBDGK-UHFFFAOYSA-N 2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]-N-ethylbenzamide Chemical compound NC1=C(C(=O)NCC)C=C(C=C1)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2 VUFHPBPWOIBDGK-UHFFFAOYSA-N 0.000 claims description 4
- YNTURPJHANIJQY-UHFFFAOYSA-N 4-(2-fluoro-5-methoxy-4-nitrophenyl)-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-3-amine Chemical compound FC1=C(C=C(C(=C1)[N+](=O)[O-])OC)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2 YNTURPJHANIJQY-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 201000005787 hematologic cancer Diseases 0.000 claims description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 4
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 3
- LSTJLJYRJLFTJD-UHFFFAOYSA-N 1-[2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]-4-fluorophenyl]butan-1-one Chemical compound NC1=C(C=C(C(=C1)F)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)C(CCC)=O LSTJLJYRJLFTJD-UHFFFAOYSA-N 0.000 claims description 3
- DOMUPAPZOLMKRZ-UHFFFAOYSA-N 1-[2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]-4-hydroxyphenyl]ethanone Chemical compound NC1=C(C=C(C(=C1)O)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)C(C)=O DOMUPAPZOLMKRZ-UHFFFAOYSA-N 0.000 claims description 3
- DTIOWIXJIMZWTL-UHFFFAOYSA-N 1-[2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]phenyl]butan-1-one Chemical compound NC1=C(C=C(C=C1)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)C(CCC)=O DTIOWIXJIMZWTL-UHFFFAOYSA-N 0.000 claims description 3
- UMUFWMJHSBRMIO-UHFFFAOYSA-N 1-[2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]phenyl]ethanone Chemical compound NC1=C(C=C(C=C1)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)C(C)=O UMUFWMJHSBRMIO-UHFFFAOYSA-N 0.000 claims description 3
- ZKAQPCMSICOAKT-UHFFFAOYSA-N 1-[2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]phenyl]propan-1-one Chemical compound NC1=C(C=C(C=C1)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)C(CC)=O ZKAQPCMSICOAKT-UHFFFAOYSA-N 0.000 claims description 3
- SKZIOYDQLATRFA-UHFFFAOYSA-N 1-[2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]thiazolo[4,5-c]pyridin-4-yl]-4-fluorophenyl]ethanone Chemical compound NC1=C(C=C(C(=C1)F)C1=NC=C(C2=C1C(=NS2)N)C=2C=NNC2)C(C)=O SKZIOYDQLATRFA-UHFFFAOYSA-N 0.000 claims description 3
- BGMWFYXYJZUNJA-UHFFFAOYSA-N 2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]-4-chloro-N-ethylbenzamide Chemical compound NC1=C(C(=O)NCC)C=C(C(=C1)Cl)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2 BGMWFYXYJZUNJA-UHFFFAOYSA-N 0.000 claims description 3
- HGUTWJDKLXVXBF-UHFFFAOYSA-N 2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]-4-fluoro-N-propylbenzamide Chemical compound NC1=C(C(=O)NCCC)C=C(C(=C1)F)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2 HGUTWJDKLXVXBF-UHFFFAOYSA-N 0.000 claims description 3
- OKNUSGOSKGSQQK-UHFFFAOYSA-N 2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]-N-ethyl-4-fluorobenzamide Chemical compound NC1=C(C(=O)NCC)C=C(C(=C1)F)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2 OKNUSGOSKGSQQK-UHFFFAOYSA-N 0.000 claims description 3
- XDSWQNMGJJKWLP-UHFFFAOYSA-N 2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]-N-methylbenzamide Chemical compound NC1=C(C(=O)NC)C=C(C=C1)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2 XDSWQNMGJJKWLP-UHFFFAOYSA-N 0.000 claims description 3
- PCCPHFKIFNKXAO-UHFFFAOYSA-N 2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]-N-propylbenzamide Chemical compound NC1=C(C(=O)NCCC)C=C(C=C1)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2 PCCPHFKIFNKXAO-UHFFFAOYSA-N 0.000 claims description 3
- HHJDAJHHWHTQJE-UHFFFAOYSA-N 2-hydroxyethyl 2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]-4-fluorobenzoate Chemical compound NC1=C(C(=O)OCCO)C=C(C(=C1)F)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2 HHJDAJHHWHTQJE-UHFFFAOYSA-N 0.000 claims description 3
- KTFVQPMFMICGKC-UHFFFAOYSA-N 4-(4-amino-2-fluoro-5-methoxyphenyl)-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[5,4-c]pyridin-3-amine Chemical compound NC1=CC(=C(C=C1OC)C1=C2C(=C(N=C1)C=1C=NNC1)ON=C2N)F KTFVQPMFMICGKC-UHFFFAOYSA-N 0.000 claims description 3
- KQOPQATWGFWENY-UHFFFAOYSA-N 4-(4-amino-3-methoxyphenyl)-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-3-amine Chemical compound NC1=C(C=C(C=C1)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)OC KQOPQATWGFWENY-UHFFFAOYSA-N 0.000 claims description 3
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000032494 Clear cell adenocarcinoma of the ovary Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 201000001342 Fallopian tube cancer Diseases 0.000 claims description 3
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims description 3
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 3
- 208000021309 Germ cell tumor Diseases 0.000 claims description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 3
- 208000000172 Medulloblastoma Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 3
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 3
- 206010034299 Penile cancer Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 201000000582 Retinoblastoma Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 206010047741 Vulval cancer Diseases 0.000 claims description 3
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 3
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
- 201000011165 anus cancer Diseases 0.000 claims description 3
- 201000009036 biliary tract cancer Diseases 0.000 claims description 3
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 3
- 206010006007 bone sarcoma Diseases 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 3
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 210000003236 esophagogastric junction Anatomy 0.000 claims description 3
- LTNQZWRIIQLCQY-UHFFFAOYSA-N ethyl 2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]-4-fluorobenzoate Chemical compound NC1=C(C(=O)OCC)C=C(C(=C1)F)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2 LTNQZWRIIQLCQY-UHFFFAOYSA-N 0.000 claims description 3
- 201000010175 gallbladder cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 3
- CAAULPUQFIIOTL-UHFFFAOYSA-N methyl dihydrogen phosphate Chemical compound COP(O)(O)=O CAAULPUQFIIOTL-UHFFFAOYSA-N 0.000 claims description 3
- 230000002071 myeloproliferative effect Effects 0.000 claims description 3
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims description 3
- 201000011519 neuroendocrine tumor Diseases 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
- 125000004043 oxo group Chemical group O=* 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 201000002314 small intestine cancer Diseases 0.000 claims description 3
- 208000037959 spinal tumor Diseases 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 206010046885 vaginal cancer Diseases 0.000 claims description 3
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 3
- 201000005102 vulva cancer Diseases 0.000 claims description 3
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 2
- 206010004593 Bile duct cancer Diseases 0.000 claims description 2
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 208000029559 malignant endocrine neoplasm Diseases 0.000 claims description 2
- 208000006178 malignant mesothelioma Diseases 0.000 claims description 2
- 201000005282 malignant pleural mesothelioma Diseases 0.000 claims description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 230000001270 agonistic effect Effects 0.000 abstract description 9
- 239000000126 substance Substances 0.000 abstract description 9
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 3
- 238000011835 investigation Methods 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 235000002639 sodium chloride Nutrition 0.000 description 160
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 141
- 150000001204 N-oxides Chemical class 0.000 description 109
- 239000000203 mixture Substances 0.000 description 96
- 239000000243 solution Substances 0.000 description 86
- 230000014759 maintenance of location Effects 0.000 description 70
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 69
- 238000006243 chemical reaction Methods 0.000 description 61
- 238000005160 1H NMR spectroscopy Methods 0.000 description 57
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 53
- 229940002612 prodrug Drugs 0.000 description 53
- 239000000651 prodrug Substances 0.000 description 53
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 52
- 239000003112 inhibitor Substances 0.000 description 50
- 239000003814 drug Substances 0.000 description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 46
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 43
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 42
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 39
- 238000000034 method Methods 0.000 description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 32
- 229940079593 drug Drugs 0.000 description 32
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 21
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 20
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
- 238000010898 silica gel chromatography Methods 0.000 description 19
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 18
- 238000001914 filtration Methods 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- 229910052938 sodium sulfate Inorganic materials 0.000 description 18
- 235000011152 sodium sulphate Nutrition 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 17
- 239000002585 base Substances 0.000 description 17
- 239000012044 organic layer Substances 0.000 description 17
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 17
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 16
- 230000000704 physical effect Effects 0.000 description 16
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 239000007864 aqueous solution Substances 0.000 description 14
- 239000002244 precipitate Substances 0.000 description 14
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 13
- 241000700605 Viruses Species 0.000 description 13
- 239000012071 phase Substances 0.000 description 13
- 238000002054 transplantation Methods 0.000 description 13
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 108020001507 fusion proteins Proteins 0.000 description 12
- 102000037865 fusion proteins Human genes 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 239000013078 crystal Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 239000012299 nitrogen atmosphere Substances 0.000 description 11
- 239000003960 organic solvent Substances 0.000 description 11
- 239000003755 preservative agent Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 239000003963 antioxidant agent Substances 0.000 description 10
- 235000006708 antioxidants Nutrition 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- 239000002246 antineoplastic agent Substances 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 150000001721 carbon Chemical group 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 230000002335 preservative effect Effects 0.000 description 9
- 238000004007 reversed phase HPLC Methods 0.000 description 9
- 238000007920 subcutaneous administration Methods 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 8
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 8
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 8
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 108010074708 B7-H1 Antigen Proteins 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 7
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 7
- 229910000024 caesium carbonate Inorganic materials 0.000 description 7
- 238000010511 deprotection reaction Methods 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 7
- 235000019798 tripotassium phosphate Nutrition 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 6
- 208000010201 Exanthema Diseases 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 6
- 241000700647 Variola virus Species 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 6
- 239000004327 boric acid Substances 0.000 description 6
- 235000010338 boric acid Nutrition 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical group OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 201000005884 exanthem Diseases 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 206010037844 rash Diseases 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 5
- 108091054729 IRF family Proteins 0.000 description 5
- 102000016854 Interferon Regulatory Factors Human genes 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 229940014259 gelatin Drugs 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229940098779 methanesulfonic acid Drugs 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 159000000000 sodium salts Chemical class 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 4
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- 241000712891 Arenavirus Species 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 241000711549 Hepacivirus C Species 0.000 description 4
- 241000724675 Hepatitis E virus Species 0.000 description 4
- 208000037262 Hepatitis delta Diseases 0.000 description 4
- 241000724709 Hepatitis delta virus Species 0.000 description 4
- 208000017604 Hodgkin disease Diseases 0.000 description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 241000701806 Human papillomavirus Species 0.000 description 4
- 102000017578 LAG3 Human genes 0.000 description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 208000000389 T-cell leukemia Diseases 0.000 description 4
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 4
- 229940124532 absorption promoter Drugs 0.000 description 4
- 238000009098 adjuvant therapy Methods 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 230000000340 anti-metabolite Effects 0.000 description 4
- 229940100197 antimetabolite Drugs 0.000 description 4
- 239000002256 antimetabolite Substances 0.000 description 4
- 229960000686 benzalkonium chloride Drugs 0.000 description 4
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 4
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 4
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 4
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical compound C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 4
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 4
- LNJAJHJFSKUCIR-UHFFFAOYSA-N ditert-butyl chloromethyl phosphate Chemical compound CC(C)(C)OP(=O)(OCCl)OC(C)(C)C LNJAJHJFSKUCIR-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 201000009277 hairy cell leukemia Diseases 0.000 description 4
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229940043355 kinase inhibitor Drugs 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 229910003002 lithium salt Inorganic materials 0.000 description 4
- 159000000002 lithium salts Chemical class 0.000 description 4
- 208000003747 lymphoid leukemia Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229960002621 pembrolizumab Drugs 0.000 description 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- OQJVXNHMUWQQEW-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrazine Chemical compound C1CNC=CN1 OQJVXNHMUWQQEW-UHFFFAOYSA-N 0.000 description 3
- OTPDWCMLUKMQNO-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine Chemical compound C1NCC=CN1 OTPDWCMLUKMQNO-UHFFFAOYSA-N 0.000 description 3
- UUZJJNBYJDFQHL-UHFFFAOYSA-N 1,2,3-triazolidine Chemical compound C1CNNN1 UUZJJNBYJDFQHL-UHFFFAOYSA-N 0.000 description 3
- QYMGRIFMUQCAJW-UHFFFAOYSA-N 1,2-dihydropyrazine Chemical compound C1NC=CN=C1 QYMGRIFMUQCAJW-UHFFFAOYSA-N 0.000 description 3
- BKWQKVJYXODDAC-UHFFFAOYSA-N 1,2-dihydropyridazine Chemical compound N1NC=CC=C1 BKWQKVJYXODDAC-UHFFFAOYSA-N 0.000 description 3
- CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 3
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 3
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 description 3
- DKYBVKMIZODYKL-UHFFFAOYSA-N 1,3-diazinane Chemical compound C1CNCNC1 DKYBVKMIZODYKL-UHFFFAOYSA-N 0.000 description 3
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 3
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 3
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 3
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 3
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 3
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 3
- FJRPOHLDJUJARI-UHFFFAOYSA-N 2,3-dihydro-1,2-oxazole Chemical compound C1NOC=C1 FJRPOHLDJUJARI-UHFFFAOYSA-N 0.000 description 3
- YTQQIHUQLOZOJI-UHFFFAOYSA-N 2,3-dihydro-1,2-thiazole Chemical compound C1NSC=C1 YTQQIHUQLOZOJI-UHFFFAOYSA-N 0.000 description 3
- ZABMHLDQFJHDSC-UHFFFAOYSA-N 2,3-dihydro-1,3-oxazole Chemical compound C1NC=CO1 ZABMHLDQFJHDSC-UHFFFAOYSA-N 0.000 description 3
- OYJGEOAXBALSMM-UHFFFAOYSA-N 2,3-dihydro-1,3-thiazole Chemical compound C1NC=CS1 OYJGEOAXBALSMM-UHFFFAOYSA-N 0.000 description 3
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 3
- PZJFUNZDCRKXPZ-UHFFFAOYSA-N 2,5-dihydro-1h-tetrazole Chemical compound C1NNN=N1 PZJFUNZDCRKXPZ-UHFFFAOYSA-N 0.000 description 3
- CAYWSDTYVXMDQC-UHFFFAOYSA-N 2-chloro-4-fluoro-5-iodopyridine Chemical compound FC1=CC(Cl)=NC=C1I CAYWSDTYVXMDQC-UHFFFAOYSA-N 0.000 description 3
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 3
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 3
- QMEQBOSUJUOXMX-UHFFFAOYSA-N 2h-oxadiazine Chemical compound N1OC=CC=N1 QMEQBOSUJUOXMX-UHFFFAOYSA-N 0.000 description 3
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 3
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 3
- BOLMDIXLULGTBD-UHFFFAOYSA-N 3,4-dihydro-2h-oxazine Chemical compound C1CC=CON1 BOLMDIXLULGTBD-UHFFFAOYSA-N 0.000 description 3
- NWWJFMCCTZLKNT-UHFFFAOYSA-N 3,4-dihydro-2h-thiazine Chemical compound C1CC=CSN1 NWWJFMCCTZLKNT-UHFFFAOYSA-N 0.000 description 3
- ATVJJNGVPSKBGO-UHFFFAOYSA-N 3,4-dihydro-2h-thiopyran Chemical compound C1CSC=CC1 ATVJJNGVPSKBGO-UHFFFAOYSA-N 0.000 description 3
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 3
- 206010071975 EGFR gene mutation Diseases 0.000 description 3
- 206010017533 Fungal infection Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000031888 Mycoses Diseases 0.000 description 3
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 3
- 208000030852 Parasitic disease Diseases 0.000 description 3
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 3
- JZFICWYCTCCINF-UHFFFAOYSA-N Thiadiazin Chemical compound S=C1SC(C)NC(C)N1CCN1C(=S)SC(C)NC1C JZFICWYCTCCINF-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 150000001483 arginine derivatives Chemical class 0.000 description 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- HTJWUNNIRKDDIV-UHFFFAOYSA-N bis(1-adamantyl)-butylphosphane Chemical compound C1C(C2)CC(C3)CC2CC13P(CCCC)C1(C2)CC(C3)CC2CC3C1 HTJWUNNIRKDDIV-UHFFFAOYSA-N 0.000 description 3
- RFCBNSCSPXMEBK-INFSMZHSSA-N c-GMP-AMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 RFCBNSCSPXMEBK-INFSMZHSSA-N 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 description 3
- 229960004926 chlorobutanol Drugs 0.000 description 3
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 3
- 239000003405 delayed action preparation Substances 0.000 description 3
- HTFFABIIOAKIBH-UHFFFAOYSA-N diazinane Chemical compound C1CCNNC1 HTFFABIIOAKIBH-UHFFFAOYSA-N 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 3
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229950009791 durvalumab Drugs 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229960005386 ipilimumab Drugs 0.000 description 3
- AWJUIBRHMBBTKR-UHFFFAOYSA-N iso-quinoline Natural products C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 3
- 159000000003 magnesium salts Chemical class 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 229960002900 methylcellulose Drugs 0.000 description 3
- 230000025090 microtubule depolymerization Effects 0.000 description 3
- 230000029115 microtubule polymerization Effects 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 229960003301 nivolumab Drugs 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 229940060184 oil ingredients Drugs 0.000 description 3
- XCRJTRCPEJKXLR-UHFFFAOYSA-N oxadiazinane Chemical compound C1CNNOC1 XCRJTRCPEJKXLR-UHFFFAOYSA-N 0.000 description 3
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 3
- DTHHUAXKOMWYBI-UHFFFAOYSA-N oxadiazolidine Chemical compound C1CONN1 DTHHUAXKOMWYBI-UHFFFAOYSA-N 0.000 description 3
- IVMHDOBGNQOUHO-UHFFFAOYSA-N oxathiane Chemical compound C1CCSOC1 IVMHDOBGNQOUHO-UHFFFAOYSA-N 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000004144 purine metabolism Effects 0.000 description 3
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 3
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 3
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 229940121497 sintilimab Drugs 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- KHVCOYGKHDJPBZ-WDCZJNDASA-N tetrahydrooxazine Chemical compound OC[C@H]1ONC[C@@H](O)[C@@H]1O KHVCOYGKHDJPBZ-WDCZJNDASA-N 0.000 description 3
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 3
- ZYXWYDDFNXBTFO-UHFFFAOYSA-N tetrazolidine Chemical compound C1NNNN1 ZYXWYDDFNXBTFO-UHFFFAOYSA-N 0.000 description 3
- BXVYJQULAWJPSR-UHFFFAOYSA-N thiadiazepine Chemical compound S1C=CC=CN=N1 BXVYJQULAWJPSR-UHFFFAOYSA-N 0.000 description 3
- TVQOEGVBMRCMFR-UHFFFAOYSA-N thiadiazinane Chemical compound C1CNNSC1 TVQOEGVBMRCMFR-UHFFFAOYSA-N 0.000 description 3
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 3
- RLTPJVKHGBFGQA-UHFFFAOYSA-N thiadiazolidine Chemical compound C1CSNN1 RLTPJVKHGBFGQA-UHFFFAOYSA-N 0.000 description 3
- IESUHWAVIFVNFM-UHFFFAOYSA-N thiane-2,3-dione Chemical compound O=C1CCCSC1=O IESUHWAVIFVNFM-UHFFFAOYSA-N 0.000 description 3
- AJZGFFKDLABHDD-UHFFFAOYSA-N thiazinane Chemical compound C1CCSNC1 AJZGFFKDLABHDD-UHFFFAOYSA-N 0.000 description 3
- 229930192474 thiophene Natural products 0.000 description 3
- IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 description 3
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- JQIZHNLEFQMDCQ-UHFFFAOYSA-N 1,2,3,4-tetrahydropyridazine Chemical compound C1CC=CNN1 JQIZHNLEFQMDCQ-UHFFFAOYSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- AGSHYIAAUGKFEA-UHFFFAOYSA-N 1,2,5-oxadiazolidine Chemical compound C1CNON1 AGSHYIAAUGKFEA-UHFFFAOYSA-N 0.000 description 2
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 2
- WCFAPJDPAPDDAQ-UHFFFAOYSA-N 1,2-dihydropyrimidine Chemical compound C1NC=CC=N1 WCFAPJDPAPDDAQ-UHFFFAOYSA-N 0.000 description 2
- YYSLAWXDXHVRHU-UHFFFAOYSA-N 1-(oxan-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(C2OCCCC2)N=C1 YYSLAWXDXHVRHU-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- SCEIUGQQBYRBPP-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-azepine Chemical compound C1CCC=CNC1 SCEIUGQQBYRBPP-UHFFFAOYSA-N 0.000 description 2
- YYVKQFQZKSLYFN-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-diazepine Chemical compound C1CNNC=CC1 YYVKQFQZKSLYFN-UHFFFAOYSA-N 0.000 description 2
- GLCYMVDVOVIDBB-UHFFFAOYSA-N 2,3,4,5-tetrahydrooxadiazepine Chemical compound C1CC=CONN1 GLCYMVDVOVIDBB-UHFFFAOYSA-N 0.000 description 2
- ABQOPHYTASMWLA-UHFFFAOYSA-N 2,3,4,5-tetrahydrooxazepine Chemical compound C1CNOC=CC1 ABQOPHYTASMWLA-UHFFFAOYSA-N 0.000 description 2
- SOHIYESEPVZKHS-UHFFFAOYSA-N 2,3,4,5-tetrahydrooxepine Chemical compound C1CCC=COC1 SOHIYESEPVZKHS-UHFFFAOYSA-N 0.000 description 2
- WHUAPUGLAGYTQS-UHFFFAOYSA-N 2,3,4,5-tetrahydrothiadiazepine Chemical compound C1CC=CSNN1 WHUAPUGLAGYTQS-UHFFFAOYSA-N 0.000 description 2
- IFPKIMVCYSSDDJ-UHFFFAOYSA-N 2,3,4,5-tetrahydrothiazepine Chemical compound C1CNSC=CC1 IFPKIMVCYSSDDJ-UHFFFAOYSA-N 0.000 description 2
- VRKPANGTGANDRQ-UHFFFAOYSA-N 2,3,4,5-tetrahydrothiepine Chemical compound C1CCC=CSC1 VRKPANGTGANDRQ-UHFFFAOYSA-N 0.000 description 2
- BEWVAZNECYSPMT-UHFFFAOYSA-N 2,3-dihydro-1h-azepine Chemical compound C1CC=CC=CN1 BEWVAZNECYSPMT-UHFFFAOYSA-N 0.000 description 2
- QHYXWSXPPUTDRA-UHFFFAOYSA-N 2,3-dihydro-1h-diazepine Chemical compound C1NNC=CC=C1 QHYXWSXPPUTDRA-UHFFFAOYSA-N 0.000 description 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- WLGQUBABAPAJNB-UHFFFAOYSA-N 2,3-dihydrooxepine Chemical compound C1CC=CC=CO1 WLGQUBABAPAJNB-UHFFFAOYSA-N 0.000 description 2
- IZEOXCXHDBQQAP-UHFFFAOYSA-N 2,3-dihydrothiazepine Chemical compound C1NSC=CC=C1 IZEOXCXHDBQQAP-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- RPHQHEBXMAGQKB-UHFFFAOYSA-N 2-amino-5-bromo-4-fluorobenzoic acid Chemical compound NC1=CC(F)=C(Br)C=C1C(O)=O RPHQHEBXMAGQKB-UHFFFAOYSA-N 0.000 description 2
- GDUDRXJJRWOFBC-UHFFFAOYSA-N 2-amino-5-bromo-N-ethyl-4-fluorobenzamide Chemical compound NC1=C(C(=O)NCC)C=C(C(=C1)F)Br GDUDRXJJRWOFBC-UHFFFAOYSA-N 0.000 description 2
- RQZNAXATYZBUAB-UHFFFAOYSA-N 2-amino-N-ethyl-4-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide Chemical compound NC1=C(C(=O)NCC)C=C(C(=C1)F)B1OC(C(O1)(C)C)(C)C RQZNAXATYZBUAB-UHFFFAOYSA-N 0.000 description 2
- LIOLIMKSCNQPLV-UHFFFAOYSA-N 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1C1=NN2C(CC=3C=C4C=CC=NC4=CC=3)=CN=C2N=C1 LIOLIMKSCNQPLV-UHFFFAOYSA-N 0.000 description 2
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- GUSKXWBKZXULSP-UHFFFAOYSA-N 3-(4,7-dimethoxy-1,3-benzodioxol-5-yl)-6,7-dimethoxychromen-4-one Chemical compound COC1=C(OC)C=C2C(=O)C(C=3C=C(C=4OCOC=4C=3OC)OC)=COC2=C1 GUSKXWBKZXULSP-UHFFFAOYSA-N 0.000 description 2
- WRXAKIDFFKPDQR-UHFFFAOYSA-N 4-bromo-5-fluoro-2-iodoaniline Chemical compound NC1=CC(F)=C(Br)C=C1I WRXAKIDFFKPDQR-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- OEKXUEWGXWCENG-UHFFFAOYSA-N 5-bromo-2-chloro-3-fluoropyridine Chemical compound FC1=CC(Br)=CN=C1Cl OEKXUEWGXWCENG-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 229940123702 Adenosine A2a receptor antagonist Drugs 0.000 description 2
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 2
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010002412 Angiocentric lymphomas Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 229940124291 BTK inhibitor Drugs 0.000 description 2
- 241000193738 Bacillus anthracis Species 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- 229940123189 CD40 agonist Drugs 0.000 description 2
- XRGHVVFAJBPWID-UHFFFAOYSA-N CS(=O)(=O)c1cc(Br)c(F)cc1N Chemical compound CS(=O)(=O)c1cc(Br)c(F)cc1N XRGHVVFAJBPWID-UHFFFAOYSA-N 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241001493160 California encephalitis virus Species 0.000 description 2
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 241000242722 Cestoda Species 0.000 description 2
- 241001502567 Chikungunya virus Species 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 208000030808 Clear cell renal carcinoma Diseases 0.000 description 2
- 206010065859 Congenital fibrosarcoma Diseases 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 description 2
- 108030002637 Cyclic GMP-AMP synthases Proteins 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 2
- 241000725619 Dengue virus Species 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 2
- 241001115402 Ebolavirus Species 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 208000002460 Enteropathy-Associated T-Cell Lymphoma Diseases 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 description 2
- 208000016937 Extranodal nasal NK/T cell lymphoma Diseases 0.000 description 2
- 241000242711 Fasciola hepatica Species 0.000 description 2
- 201000006353 Filariasis Diseases 0.000 description 2
- 241000711950 Filoviridae Species 0.000 description 2
- 241000710831 Flavivirus Species 0.000 description 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 2
- 102000000802 Galectin 3 Human genes 0.000 description 2
- 108010001517 Galectin 3 Proteins 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 229940121727 Glutaminase inhibitor Drugs 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 206010061192 Haemorrhagic fever Diseases 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 208000001688 Herpes Genitalis Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 description 2
- 238000003692 Hiyama coupling reaction Methods 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 101000931098 Homo sapiens DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 description 2
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 2
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 2
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 2
- 229940083346 IAP antagonist Drugs 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 238000005577 Kumada cross-coupling reaction Methods 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 101150030213 Lag3 gene Proteins 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 206010023825 Laryngeal cancer Diseases 0.000 description 2
- 241000712902 Lassa mammarenavirus Species 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 201000003791 MALT lymphoma Diseases 0.000 description 2
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 2
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 2
- 241001115401 Marburgvirus Species 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000032818 Microsatellite Instability Diseases 0.000 description 2
- 241000711386 Mumps virus Species 0.000 description 2
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 206010028811 Natural killer-cell leukaemia Diseases 0.000 description 2
- 238000006411 Negishi coupling reaction Methods 0.000 description 2
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 241000714209 Norwalk virus Species 0.000 description 2
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 206010067152 Oral herpes Diseases 0.000 description 2
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 2
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 2
- 241000713112 Orthobunyavirus Species 0.000 description 2
- 241000150452 Orthohantavirus Species 0.000 description 2
- 239000012661 PARP inhibitor Substances 0.000 description 2
- 229940123751 PD-L1 antagonist Drugs 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical class NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000008691 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 2
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 2
- 241000702263 Reovirus sp. Species 0.000 description 2
- 229940127395 Ribonucleotide Reductase Inhibitors Drugs 0.000 description 2
- 241000710799 Rubella virus Species 0.000 description 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 2
- 206010061934 Salivary gland cancer Diseases 0.000 description 2
- 208000009359 Sezary Syndrome Diseases 0.000 description 2
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 2
- 208000020982 T-lymphoblastic lymphoma Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 229940123803 TIM3 antagonist Drugs 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 2
- 206010062129 Tongue neoplasm Diseases 0.000 description 2
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 2
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 2
- 206010046392 Ureteric cancer Diseases 0.000 description 2
- 206010046431 Urethral cancer Diseases 0.000 description 2
- 206010046458 Urethral neoplasms Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006593 Urologic Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 201000005969 Uveal melanoma Diseases 0.000 description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 101150040313 Wee1 gene Proteins 0.000 description 2
- 241000710772 Yellow fever virus Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical compound CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 description 2
- 229960001171 acetohydroxamic acid Drugs 0.000 description 2
- PXAJQJMDEXJWFB-UHFFFAOYSA-N acetone oxime Chemical compound CC(C)=NO PXAJQJMDEXJWFB-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000002467 adenosine A2a receptor antagonist Substances 0.000 description 2
- 239000001361 adipic acid Substances 0.000 description 2
- 235000011037 adipic acid Nutrition 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 201000006966 adult T-cell leukemia Diseases 0.000 description 2
- 208000015230 aggressive NK-cell leukemia Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 201000007696 anal canal cancer Diseases 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000002494 anti-cea effect Effects 0.000 description 2
- 230000003388 anti-hormonal effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940125644 antibody drug Drugs 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 239000003886 aromatase inhibitor Substances 0.000 description 2
- 229940046844 aromatase inhibitors Drugs 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 229960003852 atezolizumab Drugs 0.000 description 2
- 229950002916 avelumab Drugs 0.000 description 2
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 2
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- QSRFYFHZPSGRQX-UHFFFAOYSA-N benzyl(tributyl)azanium Chemical class CCCC[N+](CCCC)(CCCC)CC1=CC=CC=C1 QSRFYFHZPSGRQX-UHFFFAOYSA-N 0.000 description 2
- VBQDSLGFSUGBBE-UHFFFAOYSA-N benzyl(triethyl)azanium Chemical class CC[N+](CC)(CC)CC1=CC=CC=C1 VBQDSLGFSUGBBE-UHFFFAOYSA-N 0.000 description 2
- YOUGRGFIHBUKRS-UHFFFAOYSA-N benzyl(trimethyl)azanium Chemical class C[N+](C)(C)CC1=CC=CC=C1 YOUGRGFIHBUKRS-UHFFFAOYSA-N 0.000 description 2
- 150000003939 benzylamines Chemical class 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229950007712 camrelizumab Drugs 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 229940121420 cemiplimab Drugs 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000013056 classic Hodgkin lymphoma Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 2
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical class NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 229940127276 delta-like ligand 3 Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- QPMLSUSACCOBDK-UHFFFAOYSA-N diazepane Chemical compound C1CCNNCC1 QPMLSUSACCOBDK-UHFFFAOYSA-N 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 150000004656 dimethylamines Chemical class 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940121432 dostarlimab Drugs 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 229940125436 dual inhibitor Drugs 0.000 description 2
- 229940056913 eftilagimod alfa Drugs 0.000 description 2
- 229940121647 egfr inhibitor Drugs 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 108010018033 endothelial PAS domain-containing protein 1 Proteins 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 150000002169 ethanolamines Chemical class 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 238000000105 evaporative light scattering detection Methods 0.000 description 2
- 208000006275 fascioliasis Diseases 0.000 description 2
- 229940124981 favezelimab Drugs 0.000 description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 201000003444 follicular lymphoma Diseases 0.000 description 2
- 201000004946 genital herpes Diseases 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 208000002409 gliosarcoma Diseases 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 201000006866 hypopharynx cancer Diseases 0.000 description 2
- 229950010245 ibalizumab Drugs 0.000 description 2
- 230000000091 immunopotentiator Effects 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000011542 interferon-beta production Effects 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 description 2
- 208000011824 leiomyosarcoma of the corpus uteri Diseases 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- 229960003881 letrozole Drugs 0.000 description 2
- 239000000436 ligase inhibitor Substances 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 201000003866 lung sarcoma Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 2
- 229940124302 mTOR inhibitor Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 2
- 208000021937 marginal zone lymphoma Diseases 0.000 description 2
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 2
- HXGJCSUGNPFGDZ-UHFFFAOYSA-N methyl 2-amino-4-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate Chemical compound C1=C(N)C(C(=O)OC)=CC(B2OC(C)(C)C(C)(C)O2)=C1F HXGJCSUGNPFGDZ-UHFFFAOYSA-N 0.000 description 2
- 150000003956 methylamines Chemical class 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- ZUZLIXGTXQBUDC-UHFFFAOYSA-N methyltrioctylammonium Chemical class CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC ZUZLIXGTXQBUDC-UHFFFAOYSA-N 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003883 ointment base Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 201000006958 oropharynx cancer Diseases 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- OTLYTKRAADUASA-UHFFFAOYSA-N oxadiazepane Chemical compound C1CCONNC1 OTLYTKRAADUASA-UHFFFAOYSA-N 0.000 description 2
- RYDICHIKLKVOEJ-UHFFFAOYSA-N oxadiazepine Chemical compound O1C=CC=CN=N1 RYDICHIKLKVOEJ-UHFFFAOYSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- AQNQGBUEVCAVML-UHFFFAOYSA-N oxazepane Chemical compound C1CCNOCC1 AQNQGBUEVCAVML-UHFFFAOYSA-N 0.000 description 2
- SFJGCXYXEFWEBK-UHFFFAOYSA-N oxazepine Chemical compound O1C=CC=CC=N1 SFJGCXYXEFWEBK-UHFFFAOYSA-N 0.000 description 2
- ATYBXHSAIOKLMG-UHFFFAOYSA-N oxepin Chemical compound O1C=CC=CC=C1 ATYBXHSAIOKLMG-UHFFFAOYSA-N 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 150000003053 piperidines Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 2
- 150000003222 pyridines Chemical class 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 150000003248 quinolines Chemical class 0.000 description 2
- 150000003254 radicals Chemical group 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 102200055464 rs113488022 Human genes 0.000 description 2
- 201000004409 schistosomiasis Diseases 0.000 description 2
- 125000005920 sec-butoxy group Chemical group 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 229940037001 sodium edetate Drugs 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 239000004328 sodium tetraborate Substances 0.000 description 2
- 229950007213 spartalizumab Drugs 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 230000002483 superagonistic effect Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 2
- RWXZKKKYLRFREK-UHFFFAOYSA-N thiadiazepane Chemical compound C1CCSNNC1 RWXZKKKYLRFREK-UHFFFAOYSA-N 0.000 description 2
- PGAZQSBUJDVGIX-UHFFFAOYSA-N thiazepane Chemical compound C1CCNSCC1 PGAZQSBUJDVGIX-UHFFFAOYSA-N 0.000 description 2
- NYERMPLPURRVGM-UHFFFAOYSA-N thiazepine Chemical compound S1C=CC=CC=N1 NYERMPLPURRVGM-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- JWCVYQRPINPYQJ-UHFFFAOYSA-N thiepane Chemical compound C1CCCSCC1 JWCVYQRPINPYQJ-UHFFFAOYSA-N 0.000 description 2
- BISQTCXKVNCDDA-UHFFFAOYSA-N thiepine Chemical compound S1C=CC=CC=C1 BISQTCXKVNCDDA-UHFFFAOYSA-N 0.000 description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 2
- 229950007123 tislelizumab Drugs 0.000 description 2
- 201000006134 tongue cancer Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 229950005972 urelumab Drugs 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 229940051021 yellow-fever virus Drugs 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- UWNXGZKSIKQKAH-SSEXGKCCSA-N (2R)-2-[[2-[(3-cyanophenyl)methoxy]-4-[[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]methoxy]-5-methylphenyl]methylamino]-3-hydroxypropanoic acid Chemical compound Cc1cc(CN[C@H](CO)C(O)=O)c(OCc2cccc(c2)C#N)cc1OCc1cccc(c1C)-c1ccc2OCCOc2c1 UWNXGZKSIKQKAH-SSEXGKCCSA-N 0.000 description 1
- NQUUPTGRJYIXSL-YPDXTJLXSA-N (2R)-3-[(3R)-1-[3-[2-[2-[2-[2-[2-[2-[2-[2-[3-[[(2S)-1-[[(2S)-1-[4-[[(6S,6aS)-3-[5-[[(6aS)-2-methoxy-8-methyl-11-oxo-6a,7-dihydropyrrolo[2,1-c][1,4]benzodiazepin-3-yl]oxy]pentoxy]-6-hydroxy-2-methoxy-8-methyl-11-oxo-6a,7-dihydro-6H-pyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl]oxymethyl]anilino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-3-oxopropyl]-2,5-dioxopyrrolidin-3-yl]sulfanyl-2-aminopropanoic acid Chemical compound COc1cc2c(cc1OCCCCCOc1cc3N([C@@H](O)[C@@H]4CC(C)=CN4C(=O)c3cc1OC)C(=O)OCc1ccc(NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCNC(=O)CCN3C(=O)C[C@@H](SC[C@H](N)C(O)=O)C3=O)C(C)C)cc1)N=C[C@@H]1CC(C)=CN1C2=O NQUUPTGRJYIXSL-YPDXTJLXSA-N 0.000 description 1
- ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 description 1
- SDOFMBGMRVAJNF-SLPGGIOYSA-N (2r,3r,4r,5s)-6-aminohexane-1,2,3,4,5-pentol Chemical class NC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SDOFMBGMRVAJNF-SLPGGIOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- ZBOYJODMIAUJHH-SANMLTNESA-N (2s)-1-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methyl]piperidine-2-carboxylic acid Chemical compound C=1C(OC)=C(CN2[C@@H](CCCC2)C(O)=O)C(OC)=CC=1OCC(C=1C)=CC=CC=1C1=CC=CC=C1 ZBOYJODMIAUJHH-SANMLTNESA-N 0.000 description 1
- BNGXYYYYKUGPPF-UHFFFAOYSA-M (3-methylphenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].CC1=CC=CC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 BNGXYYYYKUGPPF-UHFFFAOYSA-M 0.000 description 1
- ZEZZLZKHZPMELC-SDQLLZIZSA-N (3R)-4-[[(2R)-1-[[(2R)-5-amino-1-[[(2R)-1-[[(2R)-1-[[(1R)-1-carboxy-2-phenylethyl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-[[(2R,3S)-2-[[(2R)-1-[(2R)-6-amino-2-[[(2R)-2-[[(2R)-2-[[(2R)-2,4-diamino-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoic acid Chemical compound C[C@H](O)[C@@H](NC(=O)[C@H]1CCCN1C(=O)[C@@H](CCCCN)NC(=O)[C@@H](CO)NC(=O)[C@@H](Cc1ccc(O)cc1)NC(=O)[C@H](N)CC(N)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](Cc1ccc(O)cc1)C(=O)N[C@H](Cc1c[nH]cn1)C(=O)N[C@H](Cc1ccccc1)C(O)=O ZEZZLZKHZPMELC-SDQLLZIZSA-N 0.000 description 1
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 1
- ZBJUUYIGBAQYBN-QKLNNLIKSA-N (4S)-5-amino-4-[[(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-bis[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-4-amino-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCCNC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N ZBJUUYIGBAQYBN-QKLNNLIKSA-N 0.000 description 1
- ZQPDJCIXJHUERQ-QWRGUYRKSA-N (4r)-4-[3-[(1s)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one Chemical compound CCOC1=C([C@H](C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(F)=C1[C@@H]1CNC(=O)C1 ZQPDJCIXJHUERQ-QWRGUYRKSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- RNOAOAWBMHREKO-QFIPXVFZSA-N (7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C(C=C)(=O)N1CCC(CC1)[C@@H]1CCNC=2N1N=C(C=2C(=O)N)C1=CC=C(C=C1)OC1=CC=CC=C1 RNOAOAWBMHREKO-QFIPXVFZSA-N 0.000 description 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- AEBWATHAIVJLTA-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropentalene Chemical compound C1CCC2CCCC21 AEBWATHAIVJLTA-UHFFFAOYSA-N 0.000 description 1
- ODJQFZXHKPCJMD-UHFFFAOYSA-N 1,2,3,3a,4,5,6,7,8,8a-decahydroazulene Chemical compound C1CCCCC2CCCC21 ODJQFZXHKPCJMD-UHFFFAOYSA-N 0.000 description 1
- PIHAUZGWAXLKCA-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydro-1,8-naphthyridine Chemical compound N1CCCC2CCCNC21 PIHAUZGWAXLKCA-UHFFFAOYSA-N 0.000 description 1
- NENLYAQPNATJSU-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline Chemical compound C1NCCC2CCCCC21 NENLYAQPNATJSU-UHFFFAOYSA-N 0.000 description 1
- AEBKORRYDYKJLT-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydrophthalazine Chemical compound C1NNCC2CCCCC21 AEBKORRYDYKJLT-UHFFFAOYSA-N 0.000 description 1
- HZNXIPDYYIWDNM-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinazoline Chemical compound N1CNCC2CCCCC21 HZNXIPDYYIWDNM-UHFFFAOYSA-N 0.000 description 1
- POTIYWUALSJREP-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinoline Chemical compound N1CCCC2CCCCC21 POTIYWUALSJREP-UHFFFAOYSA-N 0.000 description 1
- MDEXMBGPIZUUBI-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinoxaline Chemical compound N1CCNC2CCCCC21 MDEXMBGPIZUUBI-UHFFFAOYSA-N 0.000 description 1
- ZCZVGQCBSJLDDS-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,8-naphthyridine Chemical compound C1=CC=C2CCCNC2=N1 ZCZVGQCBSJLDDS-UHFFFAOYSA-N 0.000 description 1
- WXRSSOIHEAVYLL-UHFFFAOYSA-N 1,2,3,4-tetrahydrocinnoline Chemical compound C1=CC=C2NNCCC2=C1 WXRSSOIHEAVYLL-UHFFFAOYSA-N 0.000 description 1
- STIWEDICJHIFJT-UHFFFAOYSA-N 1,2,3,4-tetrahydrophthalazine Chemical compound C1=CC=C2CNNCC2=C1 STIWEDICJHIFJT-UHFFFAOYSA-N 0.000 description 1
- PKORYTIUMAOPED-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinazoline Chemical compound C1=CC=C2NCNCC2=C1 PKORYTIUMAOPED-UHFFFAOYSA-N 0.000 description 1
- HORKYAIEVBUXGM-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoxaline Chemical compound C1=CC=C2NCCNC2=C1 HORKYAIEVBUXGM-UHFFFAOYSA-N 0.000 description 1
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical compound C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 description 1
- DPHVWRMZSWGLLA-UHFFFAOYSA-N 1,2-benzodithiine Chemical compound C1=CC=C2C=CSSC2=C1 DPHVWRMZSWGLLA-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- XEYKWYIXHMEQGM-UHFFFAOYSA-N 1,2-dihydro-1,8-naphthyridine Chemical compound C1=CC=C2C=CCNC2=N1 XEYKWYIXHMEQGM-UHFFFAOYSA-N 0.000 description 1
- QRDNXAYNXUKMOO-UHFFFAOYSA-N 1,2-dihydrocinnoline Chemical compound C1=CC=C2C=CNNC2=C1 QRDNXAYNXUKMOO-UHFFFAOYSA-N 0.000 description 1
- IOEPOEDBBPRAEI-UHFFFAOYSA-N 1,2-dihydroisoquinoline Chemical compound C1=CC=C2CNC=CC2=C1 IOEPOEDBBPRAEI-UHFFFAOYSA-N 0.000 description 1
- KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical compound C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 description 1
- IRFSXVIRXMYULF-UHFFFAOYSA-N 1,2-dihydroquinoline Chemical compound C1=CC=C2C=CCNC2=C1 IRFSXVIRXMYULF-UHFFFAOYSA-N 0.000 description 1
- XXBQLHATYQHJQC-UHFFFAOYSA-N 1,2-dihydroquinoxaline Chemical compound C1=CC=C2N=CCNC2=C1 XXBQLHATYQHJQC-UHFFFAOYSA-N 0.000 description 1
- SJXUGVWKLLOJDR-UHFFFAOYSA-N 1,3,3a,4,5,6,7,7a-octahydro-2-benzothiophene Chemical compound C1CCCC2CSCC21 SJXUGVWKLLOJDR-UHFFFAOYSA-N 0.000 description 1
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- GWYPDXLJACEENP-UHFFFAOYSA-N 1,3-cycloheptadiene Chemical compound C1CC=CC=CC1 GWYPDXLJACEENP-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- MCKAIVUMHVLUIO-UHFFFAOYSA-N 1-(2-amino-5-bromo-4-fluorophenyl)ethanone Chemical compound C(=O)(C)C1=C(N)C=C(F)C(Br)=C1 MCKAIVUMHVLUIO-UHFFFAOYSA-N 0.000 description 1
- OBSFXHDOLBYWRJ-UHFFFAOYSA-N 1-(4-fluorophenyl)-n-[3-fluoro-4-(1h-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide Chemical compound C1=CC(F)=CC=C1N1C(=O)C(C(=O)NC=2C=C(F)C(OC=3C=4C=CNC=4N=CC=3)=CC=2)=CC=C1 OBSFXHDOLBYWRJ-UHFFFAOYSA-N 0.000 description 1
- KXMZDGSRSGHMMK-VWLOTQADSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[(7s)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5h-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound N1([C@H]2CCC3=CC=C(C=C3CC2)NC=2N=C(N(N=2)C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)N)CCCC1 KXMZDGSRSGHMMK-VWLOTQADSA-N 0.000 description 1
- WMFFLWVVJYARQO-UHFFFAOYSA-N 1-[2-amino-4-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethanone Chemical compound NC1=C(C=C(C(=C1)F)B1OC(C(O1)(C)C)(C)C)C(C)=O WMFFLWVVJYARQO-UHFFFAOYSA-N 0.000 description 1
- SUIJMKFJDCZZBF-UHFFFAOYSA-N 1-[2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]-4-fluorophenyl]butan-1-one hydrochloride Chemical compound Cl.NC1=C(C=C(C(=C1)F)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)C(CCC)=O SUIJMKFJDCZZBF-UHFFFAOYSA-N 0.000 description 1
- RAUVCLDITSKYBK-UHFFFAOYSA-N 1-[2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]-4-fluorophenyl]propan-1-one hydrochloride Chemical compound Cl.NC1=C(C=C(C(=C1)F)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)C(CC)=O RAUVCLDITSKYBK-UHFFFAOYSA-N 0.000 description 1
- ICHWOTCOWDHKFX-UHFFFAOYSA-N 1-[2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]phenyl]butan-1-one hydrochloride Chemical compound Cl.NC1=C(C=C(C=C1)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)C(CCC)=O ICHWOTCOWDHKFX-UHFFFAOYSA-N 0.000 description 1
- XUKBKQSAQVPZNG-UHFFFAOYSA-N 1-[2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]phenyl]ethanone hydrochloride Chemical compound Cl.NC1=C(C=C(C=C1)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)C(C)=O XUKBKQSAQVPZNG-UHFFFAOYSA-N 0.000 description 1
- QBVAEEDIOOXSRQ-UHFFFAOYSA-N 1-[2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]thiazolo[4,5-c]pyridin-4-yl]-4-fluorophenyl]ethanone 2,2,2-trifluoroacetic acid Chemical compound FC(C(=O)O)(F)F.NC1=C(C=C(C(=C1)F)C1=NC=C(C2=C1C(=NS2)N)C=2C=NNC2)C(C)=O QBVAEEDIOOXSRQ-UHFFFAOYSA-N 0.000 description 1
- VCRFWXUAZDMVBA-UHFFFAOYSA-N 1-[2-amino-5-[3-amino-7-[1-(oxan-2-yl)pyrazol-4-yl]-[1,2]oxazolo[4,5-c]pyridin-4-yl]-4-fluorophenyl]ethanone Chemical compound NC1=C(C=C(C(=C1)F)C1=NC=C(C2=C1C(=NO2)N)C=1C=NN(C=1)C1OCCCC1)C(C)=O VCRFWXUAZDMVBA-UHFFFAOYSA-N 0.000 description 1
- NYSYZGJAQLZDRX-UHFFFAOYSA-N 1-[2-amino-5-[3-amino-7-[1-(oxan-2-yl)pyrazol-4-yl]-[1,2]oxazolo[4,5-c]pyridin-4-yl]-4-hydroxyphenyl]ethanone Chemical compound NC1=C(C=C(C(=C1)O)C1=NC=C(C2=C1C(=NO2)N)C=1C=NN(C=1)C1OCCCC1)C(C)=O NYSYZGJAQLZDRX-UHFFFAOYSA-N 0.000 description 1
- OGTKAIXKAHDFTJ-UHFFFAOYSA-N 1-[2-amino-5-[3-amino-7-[1-(oxan-2-yl)pyrazol-4-yl]-[1,2]thiazolo[4,5-c]pyridin-4-yl]-4-fluorophenyl]ethanone Chemical compound NC1=C(C=C(C(=C1)F)C1=NC=C(C2=C1C(=NS2)N)C=1C=NN(C=1)C1OCCCC1)C(C)=O OGTKAIXKAHDFTJ-UHFFFAOYSA-N 0.000 description 1
- BKWJAKQVGHWELA-UHFFFAOYSA-N 1-[6-(2-hydroxypropan-2-yl)-2-pyridinyl]-6-[4-(4-methyl-1-piperazinyl)anilino]-2-prop-2-enyl-3-pyrazolo[3,4-d]pyrimidinone Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C2C(=O)N(CC=C)N(C=3N=C(C=CC=3)C(C)(C)O)C2=N1 BKWJAKQVGHWELA-UHFFFAOYSA-N 0.000 description 1
- ZOHXWSHGANNQGO-DSIKUUPMSA-N 1-amino-4-[[5-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-2-methyl-5-oxopentan-2-yl]disulfanyl]-1-oxobutane-2-sulfonic acid Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SSCCC(C(N)=O)S(O)(=O)=O)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ZOHXWSHGANNQGO-DSIKUUPMSA-N 0.000 description 1
- BSLJYGDKCQWDIF-UHFFFAOYSA-N 1-bromo-2-fluoro-5-methylsulfanyl-4-nitrobenzene Chemical compound CSc1cc(Br)c(F)cc1[N+]([O-])=O BSLJYGDKCQWDIF-UHFFFAOYSA-N 0.000 description 1
- 125000004776 1-fluoroethyl group Chemical group [H]C([H])([H])C([H])(F)* 0.000 description 1
- WLAVZAAODLTUSW-UHFFFAOYSA-N 1-n'-[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound N1=CC(CNCCOC)=CC=C1C1=CC2=NC=CC(OC=3C(=CC(NC(=O)C4(CC4)C(=O)NC=4C=CC(F)=CC=4)=CC=3)F)=C2S1 WLAVZAAODLTUSW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- JCZAVVUIFWZMQI-UHFFFAOYSA-N 1h-thieno[2,3-d]imidazole Chemical compound N1C=NC2=C1C=CS2 JCZAVVUIFWZMQI-UHFFFAOYSA-N 0.000 description 1
- LJMZRBZETLXDSO-UHFFFAOYSA-N 1h-thieno[3,2-c]pyrazole Chemical compound N1N=CC2=C1C=CS2 LJMZRBZETLXDSO-UHFFFAOYSA-N 0.000 description 1
- AWBOSXFRPFZLOP-UHFFFAOYSA-N 2,1,3-benzoxadiazole Chemical compound C1=CC=CC2=NON=C21 AWBOSXFRPFZLOP-UHFFFAOYSA-N 0.000 description 1
- 125000004797 2,2,2-trichloroethoxy group Chemical group ClC(CO*)(Cl)Cl 0.000 description 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- OGHHATWOTABYKY-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1,3-benzothiazole Chemical compound C1CCCC2SCNC21 OGHHATWOTABYKY-UHFFFAOYSA-N 0.000 description 1
- XLRZZUUFKAXBGZ-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1,3-benzoxazole Chemical compound C1CCCC2OCNC21 XLRZZUUFKAXBGZ-UHFFFAOYSA-N 0.000 description 1
- DNZWAKVIOXCEHH-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1-benzofuran Chemical compound C1CCCC2OCCC21 DNZWAKVIOXCEHH-UHFFFAOYSA-N 0.000 description 1
- NZOBCFVNZQYCCZ-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1-benzothiophene Chemical compound C1CCCC2SCCC21 NZOBCFVNZQYCCZ-UHFFFAOYSA-N 0.000 description 1
- MDNGXAFGRWQHNZ-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-benzimidazole Chemical compound C1CCCC2NCNC21 MDNGXAFGRWQHNZ-UHFFFAOYSA-N 0.000 description 1
- LVJPACZOEKXFAY-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-indazole Chemical compound C1CCCC2CNNC21 LVJPACZOEKXFAY-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- HRCMXYXVAWHBTH-UHFFFAOYSA-N 2,3-dihydro-1,3-benzoxazole Chemical compound C1=CC=C2OCNC2=C1 HRCMXYXVAWHBTH-UHFFFAOYSA-N 0.000 description 1
- YJUFGFXVASPYFQ-UHFFFAOYSA-N 2,3-dihydro-1-benzothiophene Chemical compound C1=CC=C2SCCC2=C1 YJUFGFXVASPYFQ-UHFFFAOYSA-N 0.000 description 1
- QDKGOMZIPXGDDJ-UHFFFAOYSA-N 2,3-dihydro-1h-indazole Chemical compound C1=CC=C2CNNC2=C1 QDKGOMZIPXGDDJ-UHFFFAOYSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- VLIUIBXPEDFJRF-UHFFFAOYSA-N 2-(n-(2-chlorophenyl)anilino)-n-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NCCCCCCC(=O)NO)=CN=C1N(C=1C(=CC=CC=1)Cl)C1=CC=CC=C1 VLIUIBXPEDFJRF-UHFFFAOYSA-N 0.000 description 1
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 1
- PIMQWRZWLQKKBJ-SFHVURJKSA-N 2-[(2S)-1-[3-ethyl-7-[(1-oxido-3-pyridin-1-iumyl)methylamino]-5-pyrazolo[1,5-a]pyrimidinyl]-2-piperidinyl]ethanol Chemical compound C=1C(N2[C@@H](CCCC2)CCO)=NC2=C(CC)C=NN2C=1NCC1=CC=C[N+]([O-])=C1 PIMQWRZWLQKKBJ-SFHVURJKSA-N 0.000 description 1
- KTBSXLIQKWEBRB-UHFFFAOYSA-N 2-[1-[1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=CN=C(C(F)(F)F)C(F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 KTBSXLIQKWEBRB-UHFFFAOYSA-N 0.000 description 1
- PDGKHKMBHVFCMG-UHFFFAOYSA-N 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyrazino[5,6]pyrrolo[1,2-d]pyrimidine-9,1'-cyclohexane]-6-one Chemical compound C1CN(C)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C2N3C4(CCCCC4)CNC2=O)C3=N1 PDGKHKMBHVFCMG-UHFFFAOYSA-N 0.000 description 1
- TUZCELPUBCGBPT-UHFFFAOYSA-N 2-amino-4-chloro-N-ethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide Chemical compound CCNC(=O)c1cc(B2OC(C)(C)C(C)(C)O2)c(Cl)cc1N TUZCELPUBCGBPT-UHFFFAOYSA-N 0.000 description 1
- HSPKYASDEMYQPD-UHFFFAOYSA-N 2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]-4-fluorobenzamide hydrochloride Chemical compound Cl.NC1=C(C(=O)N)C=C(C(=C1)F)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2 HSPKYASDEMYQPD-UHFFFAOYSA-N 0.000 description 1
- MAEFWCQDQFDSPT-UHFFFAOYSA-N 2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]-N-ethyl-4-fluorobenzamide hydrochloride Chemical compound CCNC(=O)C1=C(C=C(C(=C1)C2=NC=C(C3=C2C(=NO3)N)C4=CNN=C4)F)N.Cl MAEFWCQDQFDSPT-UHFFFAOYSA-N 0.000 description 1
- PONBEGZPWRUPNQ-UHFFFAOYSA-N 2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]-N-methylbenzamide hydrochloride Chemical compound Cl.NC1=C(C(=O)NC)C=C(C=C1)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2 PONBEGZPWRUPNQ-UHFFFAOYSA-N 0.000 description 1
- PNKGPNVGUYEEGN-UHFFFAOYSA-N 2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]-N-propylbenzamide hydrochloride Chemical compound Cl.NC1=C(C(=O)NCCC)C=C(C=C1)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2 PNKGPNVGUYEEGN-UHFFFAOYSA-N 0.000 description 1
- XUMALORDVCFWKV-IBGZPJMESA-N 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C[C@H](NC(=O)C1=C2N=CC=CN2N=C1N)C1=CC2=CC=CC(C#CC3=CN(C)N=C3)=C2C(=O)N1C1=CC=CC=C1 XUMALORDVCFWKV-IBGZPJMESA-N 0.000 description 1
- QSPOQCXMGPDIHI-UHFFFAOYSA-N 2-amino-n,n-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3h-1-benzazepine-4-carboxamide Chemical compound C1=C2N=C(N)CC(C(=O)N(CCC)CCC)=CC2=CC=C1C(C=C1)=CC=C1C(=O)N1CCCC1 QSPOQCXMGPDIHI-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- LYTMVABTDYMBQK-UHFFFAOYSA-N 2-benzothiophene Chemical compound C1=CC=CC2=CSC=C21 LYTMVABTDYMBQK-UHFFFAOYSA-N 0.000 description 1
- DPTHYMHTGSZJSX-UHFFFAOYSA-N 2-chloro-4-fluoro-5-iodopyridine-3-carbonitrile Chemical compound ClC1=C(C#N)C(=C(C=N1)I)F DPTHYMHTGSZJSX-UHFFFAOYSA-N 0.000 description 1
- 125000006012 2-chloroethoxy group Chemical group 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- XULHFMYCBKQGEE-UHFFFAOYSA-N 2-hexyl-1-Decanol Chemical compound CCCCCCCCC(CO)CCCCCC XULHFMYCBKQGEE-UHFFFAOYSA-N 0.000 description 1
- LHSKFXWGLOKUTK-UHFFFAOYSA-N 2-hydroxyethyl 2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]-4-fluorobenzoate hydrochloride Chemical compound Cl.NC1=C(C(=O)OCCO)C=C(C(=C1)F)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2 LHSKFXWGLOKUTK-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- FSUYMKXZLQOFQY-UHFFFAOYSA-N 3,4-dihydro-1,2-benzodithiine Chemical compound C1=CC=C2SSCCC2=C1 FSUYMKXZLQOFQY-UHFFFAOYSA-N 0.000 description 1
- NTOIMCSZPGZTND-UHFFFAOYSA-N 3,4-dihydro-1,2-benzoxathiine Chemical compound C1=CC=C2OSCCC2=C1 NTOIMCSZPGZTND-UHFFFAOYSA-N 0.000 description 1
- IDUSJBBWEKNWAK-UHFFFAOYSA-N 3,4-dihydro-2h-1,2-benzothiazine Chemical compound C1=CC=C2SNCCC2=C1 IDUSJBBWEKNWAK-UHFFFAOYSA-N 0.000 description 1
- BGDOLELXXPTPFX-UHFFFAOYSA-N 3,4-dihydro-2h-1,2-benzoxazine Chemical compound C1=CC=C2ONCCC2=C1 BGDOLELXXPTPFX-UHFFFAOYSA-N 0.000 description 1
- NDTSIDOTKVWMRI-UHFFFAOYSA-N 3,4-dihydro-2h-pyrazino[2,3-b][1,4]oxazine Chemical compound C1=CN=C2NCCOC2=N1 NDTSIDOTKVWMRI-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- RSNPAKAFCAAMBH-UHFFFAOYSA-N 3-(5-amino-2-methyl-4-oxoquinazolin-3-yl)piperidine-2,6-dione Chemical compound CC1=NC2=CC=CC(N)=C2C(=O)N1C1CCC(=O)NC1=O RSNPAKAFCAAMBH-UHFFFAOYSA-N 0.000 description 1
- XYDNMOZJKOGZLS-NSHDSACASA-N 3-[(1s)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine Chemical compound N1=C2N([C@H](C3=CN4C=CN=C4C=C3)C)N=NC2=NC=C1C=1C=NN(C)C=1 XYDNMOZJKOGZLS-NSHDSACASA-N 0.000 description 1
- JUSFANSTBFGBAF-IRXDYDNUSA-N 3-[2,4-bis[(3s)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(C=2N=C3N=C(N=C(C3=CC=2)N2[C@H](COCC2)C)N2[C@H](COCC2)C)=C1 JUSFANSTBFGBAF-IRXDYDNUSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- VKRFJPYJBOIVPD-UHFFFAOYSA-N 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol Chemical compound OCCCNP(=O)(N(CCCl)CCCl)OCCCCl VKRFJPYJBOIVPD-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- WHGMHGPIJZTKTI-UHFFFAOYSA-N 3h-1,2-benzodithiole Chemical compound C1=CC=C2CSSC2=C1 WHGMHGPIJZTKTI-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- UCFSYHMCKWNKAH-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CC1(C)OBOC1(C)C UCFSYHMCKWNKAH-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- MJJVCPOFCFRAPX-UHFFFAOYSA-N 4-(4-amino-2-chloro-5-methylsulfanylphenyl)-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-3-amine hydrochloride Chemical compound Cl.NC1=CC(=C(C=C1SC)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)Cl MJJVCPOFCFRAPX-UHFFFAOYSA-N 0.000 description 1
- IESZIZNSNOMIDN-UHFFFAOYSA-N 4-(4-amino-2-fluoro-3-methoxyphenyl)-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-3-amine hydrochloride Chemical compound Cl.NC1=C(C(=C(C=C1)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)F)OC IESZIZNSNOMIDN-UHFFFAOYSA-N 0.000 description 1
- KXCHNMMMHKTIKT-UHFFFAOYSA-N 4-(4-amino-2-fluoro-5-methoxyphenyl)-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-3-amine hydrochloride Chemical compound Cl.NC1=CC(=C(C=C1OC)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)F KXCHNMMMHKTIKT-UHFFFAOYSA-N 0.000 description 1
- KMZCMFQISSYCQB-UHFFFAOYSA-N 4-(4-amino-2-fluoro-5-methoxyphenyl)-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[5,4-c]pyridin-3-amine hydrochloride Chemical compound Cl.NC1=CC(=C(C=C1OC)C1=C2C(=C(N=C1)C=1C=NNC1)ON=C2N)F KMZCMFQISSYCQB-UHFFFAOYSA-N 0.000 description 1
- AUSJDIUHLQTUEE-UHFFFAOYSA-N 4-(4-amino-2-fluoro-5-methylsulfanylphenyl)-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-3-amine hydrochloride Chemical compound Cl.NC1=CC(=C(C=C1SC)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)F AUSJDIUHLQTUEE-UHFFFAOYSA-N 0.000 description 1
- KUCWIZXXRMHVKR-UHFFFAOYSA-N 4-(4-amino-2-fluoro-5-methylsulfanylphenyl)-7-[1-(oxan-2-yl)pyrazol-4-yl]-[1,2]oxazolo[4,5-c]pyridin-3-amine Chemical compound NC1=CC(=C(C=C1SC)C1=NC=C(C2=C1C(=NO2)N)C=1C=NN(C=1)C1OCCCC1)F KUCWIZXXRMHVKR-UHFFFAOYSA-N 0.000 description 1
- CNTYAMBNEDFPIR-UHFFFAOYSA-N 4-(4-amino-2-fluoro-5-methylsulfonylphenyl)-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-3-amine hydrochloride Chemical compound CS(=O)(=O)C1=C(C=C(C(=C1)C2=NC=C(C3=C2C(=NO3)N)C4=CNN=C4)F)N.Cl CNTYAMBNEDFPIR-UHFFFAOYSA-N 0.000 description 1
- CSHXNRUGQUYAAN-UHFFFAOYSA-N 4-(4-amino-3-methoxyphenyl)-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-3-amine hydrochloride Chemical compound Cl.NC1=C(C=C(C=C1)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)OC CSHXNRUGQUYAAN-UHFFFAOYSA-N 0.000 description 1
- KXCHNMMMHKTIKT-NIIDSAIPSA-N 4-[4-amino-2-fluoro-5-(trideuteriomethoxy)phenyl]-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-3-amine hydrochloride Chemical compound Cl.NC1=CC(=C(C=C1OC([2H])([2H])[2H])C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)F KXCHNMMMHKTIKT-NIIDSAIPSA-N 0.000 description 1
- DCGYCUQIYSBJFO-UHFFFAOYSA-N 4-[4-amino-2-fluoro-5-(trifluoromethyl)phenyl]-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-3-amine Chemical compound NC1=CC(=C(C=C1C(F)(F)F)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)F DCGYCUQIYSBJFO-UHFFFAOYSA-N 0.000 description 1
- ADZBMFGQQWPHMJ-RHSMWYFYSA-N 4-[[2-[[(1r,2r)-2-hydroxycyclohexyl]amino]-1,3-benzothiazol-6-yl]oxy]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C3SC(N[C@H]4[C@@H](CCCC4)O)=NC3=CC=2)=C1 ADZBMFGQQWPHMJ-RHSMWYFYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical compound [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 description 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- OGLAFHMYVSFZTG-UHFFFAOYSA-N 4-bromo-7-[1-(oxan-2-yl)pyrazol-4-yl]-[1,2]oxazolo[4,5-c]pyridin-3-amine Chemical compound BrC1=NC=C(C2=C1C(=NO2)N)C=2C=NN(C2)C2OCCCC2 OGLAFHMYVSFZTG-UHFFFAOYSA-N 0.000 description 1
- KXOQGKVUIBMUBV-UHFFFAOYSA-N 4-bromo-7-[1-(oxan-2-yl)pyrazol-4-yl]-[1,2]thiazolo[4,5-c]pyridin-3-amine Chemical compound BrC1=NC=C(C2=C1C(=NS2)N)C=2C=NN(C2)C2OCCCC2 KXOQGKVUIBMUBV-UHFFFAOYSA-N 0.000 description 1
- MPZXJYAORUYUNK-UHFFFAOYSA-N 4-bromo-7-iodo-[1,2]oxazolo[4,5-c]pyridin-3-amine Chemical compound Nc1noc2c(I)cnc(Br)c12 MPZXJYAORUYUNK-UHFFFAOYSA-N 0.000 description 1
- WPJJNNPCDARVFV-UHFFFAOYSA-N 4-bromo-7-iodo-[1,2]thiazolo[4,5-c]pyridin-3-amine Chemical compound BrC1=NC=C(C2=C1C(=NS2)N)I WPJJNNPCDARVFV-UHFFFAOYSA-N 0.000 description 1
- PWZDOLGAQUWZJZ-UHFFFAOYSA-N 4-chloro-7-iodo-[1,2]thiazolo[4,5-c]pyridin-3-amine Chemical compound ClC1=NC=C(C2=C1C(=NS2)N)I PWZDOLGAQUWZJZ-UHFFFAOYSA-N 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- CRHLWUBHASGMSC-UHFFFAOYSA-N 5-(4-amino-2-fluoro-5-methoxyphenyl)-2-chloro-3-fluoropyridine-4-carbonitrile Chemical compound NC1=CC(=C(C=C1OC)C1=CN=C(C(=C1C#N)F)Cl)F CRHLWUBHASGMSC-UHFFFAOYSA-N 0.000 description 1
- DCOYLGFBUXWMSZ-UHFFFAOYSA-N 5-(4-amino-2-fluoro-5-methoxyphenyl)-3-fluoro-2-[1-(oxan-2-yl)pyrazol-4-yl]pyridine-4-carbonitrile Chemical compound NC1=CC(=C(C=C1OC)C1=CN=C(C(=C1C#N)F)C=1C=NN(C1)C1OCCCC1)F DCOYLGFBUXWMSZ-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- DNFMUFQWRGFEIB-UHFFFAOYSA-N 5-bromo-2-chloro-3-fluoropyridine-4-carbonitrile Chemical compound BrC1=CN=C(C(=C1C#N)F)Cl DNFMUFQWRGFEIB-UHFFFAOYSA-N 0.000 description 1
- SJLPQFWITSQVQQ-UHFFFAOYSA-N 5-fluoro-2-methylsulfanyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline Chemical compound FC=1C(=CC(=C(N)C=1)SC)B1OC(C(O1)(C)C)(C)C SJLPQFWITSQVQQ-UHFFFAOYSA-N 0.000 description 1
- ZNDDFFGLPQIWOH-UHFFFAOYSA-N 5-fluoro-2-methylsulfonyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline Chemical compound FC=1C(=CC(=C(N)C=1)S(=O)(=O)C)B1OC(C(O1)(C)C)(C)C ZNDDFFGLPQIWOH-UHFFFAOYSA-N 0.000 description 1
- VHHWHDFVZGPKRT-UHFFFAOYSA-N 5h-pyrazolo[3,4-d][1,3]thiazole Chemical compound N1=NC2=NCSC2=C1 VHHWHDFVZGPKRT-UHFFFAOYSA-N 0.000 description 1
- NCWQLHHDGDXIJN-UHFFFAOYSA-N 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine Chemical compound ClC1=NC(C)=CC(C=2C(=NC(N)=NN=2)C=2C=CC(F)=CC=2)=C1 NCWQLHHDGDXIJN-UHFFFAOYSA-N 0.000 description 1
- GLYMPHUVMRFTFV-QLFBSQMISA-N 6-amino-5-[(1r)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-n-[4-[(3r,5s)-3,5-dimethylpiperazine-1-carbonyl]phenyl]pyridazine-3-carboxamide Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NN=1)N)=CC=1C(=O)NC(C=C1)=CC=C1C(=O)N1C[C@H](C)N[C@H](C)C1 GLYMPHUVMRFTFV-QLFBSQMISA-N 0.000 description 1
- SEJLPXCPMNSRAM-GOSISDBHSA-N 6-amino-9-[(3r)-1-but-2-ynoylpyrrolidin-3-yl]-7-(4-phenoxyphenyl)purin-8-one Chemical compound C1N(C(=O)C#CC)CC[C@H]1N1C(=O)N(C=2C=CC(OC=3C=CC=CC=3)=CC=2)C2=C(N)N=CN=C21 SEJLPXCPMNSRAM-GOSISDBHSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- KURQKNMKCGYWRJ-HNNXBMFYSA-N 7-(5-methylfuran-2-yl)-3-[[6-[[(3s)-oxolan-3-yl]oxymethyl]pyridin-2-yl]methyl]triazolo[4,5-d]pyrimidin-5-amine Chemical compound O1C(C)=CC=C1C1=NC(N)=NC2=C1N=NN2CC1=CC=CC(CO[C@@H]2COCC2)=N1 KURQKNMKCGYWRJ-HNNXBMFYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 108010057840 ALT-803 Proteins 0.000 description 1
- 229940125979 ALX148 Drugs 0.000 description 1
- 108700001691 ALX148 Proteins 0.000 description 1
- VRQMAABPASPXMW-HDICACEKSA-N AZD4547 Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(=CC=3)N3C[C@@H](C)N[C@@H](C)C3)C=2)=C1 VRQMAABPASPXMW-HDICACEKSA-N 0.000 description 1
- 206010069408 Acanthamoeba keratitis Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- 239000005964 Acibenzolar-S-methyl Substances 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 208000000230 African Trypanosomiasis Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 description 1
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 229940080328 Arginase inhibitor Drugs 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 229940125565 BMS-986016 Drugs 0.000 description 1
- 229940125557 BMS-986207 Drugs 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000244183 Baylisascaris procyonis Species 0.000 description 1
- 229940118364 Bcr-Abl inhibitor Drugs 0.000 description 1
- PKWRMUKBEYJEIX-DXXQBUJASA-N Birinapant Chemical compound CN[C@@H](C)C(=O)N[C@@H](CC)C(=O)N1C[C@@H](O)C[C@H]1CC1=C(C2=C(C3=CC=C(F)C=C3N2)C[C@H]2N(C[C@@H](O)C2)C(=O)[C@H](CC)NC(=O)[C@H](C)NC)NC2=CC(F)=CC=C12 PKWRMUKBEYJEIX-DXXQBUJASA-N 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 0 C/C1=N\C(\c2ncc(*3CC*(*)C*(*)CCCC3)c3c2c(*)n[o]3)=C(/*)\CC/C=[U]1\* Chemical compound C/C1=N\C(\c2ncc(*3CC*(*)C*(*)CCCC3)c3c2c(*)n[o]3)=C(/*)\CC/C=[U]1\* 0.000 description 1
- XQRJRSNJDCETCD-UHFFFAOYSA-N CC(c(cc(cc1)-c2ncc(-c3c[n](COP(O)(O)=O)nc3)c3c2c(N)n[o]3)c1N)=O Chemical compound CC(c(cc(cc1)-c2ncc(-c3c[n](COP(O)(O)=O)nc3)c3c2c(N)n[o]3)c1N)=O XQRJRSNJDCETCD-UHFFFAOYSA-N 0.000 description 1
- 108010036239 CD4-IgG(2) Proteins 0.000 description 1
- 229940122004 CD47 antagonist Drugs 0.000 description 1
- 229940038671 CDX-1401 vaccine Drugs 0.000 description 1
- 229940044663 CMP-001 Drugs 0.000 description 1
- JEDPSOYOYVELLZ-UHFFFAOYSA-N COc1nc(OCc2cccc(c2C)-c2ccccc2)ccc1CNCCNC(C)=O Chemical compound COc1nc(OCc2cccc(c2C)-c2ccccc2)ccc1CNCCNC(C)=O JEDPSOYOYVELLZ-UHFFFAOYSA-N 0.000 description 1
- CHASYUQOZXGOOI-UHFFFAOYSA-N CSc1cc(Br)c(F)cc1N Chemical compound CSc1cc(Br)c(F)cc1N CHASYUQOZXGOOI-UHFFFAOYSA-N 0.000 description 1
- HFOBENSCBRZVSP-LKXGYXEUSA-N C[C@@H](O)[C@H](NC(=O)N[C@@H](CC(N)=O)c1nc(no1)[C@@H](N)CO)C(O)=O Chemical compound C[C@@H](O)[C@H](NC(=O)N[C@@H](CC(N)=O)c1nc(no1)[C@@H](N)CO)C(O)=O HFOBENSCBRZVSP-LKXGYXEUSA-N 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- QRXBPPWUGITQLE-UHFFFAOYSA-N Cc1c(COc2ccc(CN3CCCCC3C(O)=O)cc2Br)cccc1-c1ccccc1 Chemical compound Cc1c(COc2ccc(CN3CCCCC3C(O)=O)cc2Br)cccc1-c1ccccc1 QRXBPPWUGITQLE-UHFFFAOYSA-N 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- RWFGTYTZDWKZBT-UHFFFAOYSA-N ClC1=C(C#N)C(=C(C=N1)I)ON=C(C)C Chemical compound ClC1=C(C#N)C(=C(C=N1)I)ON=C(C)C RWFGTYTZDWKZBT-UHFFFAOYSA-N 0.000 description 1
- AOJAEGQYWAFVMW-UHFFFAOYSA-N ClC1=NC=C(C2=C1C(=NO2)N)I Chemical compound ClC1=NC=C(C2=C1C(=NO2)N)I AOJAEGQYWAFVMW-UHFFFAOYSA-N 0.000 description 1
- QBXVXKRWOVBUDB-GRKNLSHJSA-N ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C Chemical compound ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C QBXVXKRWOVBUDB-GRKNLSHJSA-N 0.000 description 1
- 241000222290 Cladosporium Species 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000223203 Coccidioides Species 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- NTURVSFTOYPGON-UHFFFAOYSA-N Dihydroquinazoline Chemical compound C1=CC=C2C=NCNC2=C1 NTURVSFTOYPGON-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000012824 ERK inhibitor Substances 0.000 description 1
- 206010014096 Echinococciasis Diseases 0.000 description 1
- 208000009366 Echinococcosis Diseases 0.000 description 1
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000498255 Enterobius vermicularis Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 229940124783 FAK inhibitor Drugs 0.000 description 1
- ZRVWGSGVILMFEU-UHFFFAOYSA-N FC(C(=O)O)(F)F.NC1=C(C(=O)NC)C=C(C(=C1)F)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2 Chemical compound FC(C(=O)O)(F)F.NC1=C(C(=O)NC)C=C(C(=C1)F)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2 ZRVWGSGVILMFEU-UHFFFAOYSA-N 0.000 description 1
- VQUSQKKAIBXLNA-UHFFFAOYSA-N FC(C(=O)O)(F)F.NC1=C(C(=O)NCC)C=C(C(=C1)Cl)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2 Chemical compound FC(C(=O)O)(F)F.NC1=C(C(=O)NCC)C=C(C(=C1)Cl)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2 VQUSQKKAIBXLNA-UHFFFAOYSA-N 0.000 description 1
- XVUUGLJRUFVKGT-UHFFFAOYSA-N FC(C(=O)O)(F)F.NC1=C(C(=O)NCCC)C=C(C(=C1)F)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2 Chemical compound FC(C(=O)O)(F)F.NC1=C(C(=O)NCCC)C=C(C(=C1)F)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2 XVUUGLJRUFVKGT-UHFFFAOYSA-N 0.000 description 1
- XMRPJXQYKYOBFX-UHFFFAOYSA-N FC(C(=O)O)(F)F.NC1=C(C=C(C(=C1)O)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)C(C)=O Chemical compound FC(C(=O)O)(F)F.NC1=C(C=C(C(=C1)O)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)C(C)=O XMRPJXQYKYOBFX-UHFFFAOYSA-N 0.000 description 1
- RDUAUMWXCAPGST-UHFFFAOYSA-N FC(C(=O)O)(F)F.NC1=C(C=C(C=C1)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)C(CC)=O Chemical compound FC(C(=O)O)(F)F.NC1=C(C=C(C=C1)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)C(CC)=O RDUAUMWXCAPGST-UHFFFAOYSA-N 0.000 description 1
- NRLMJIKJGSINBC-UHFFFAOYSA-N FC(C(=O)O)(F)F.NC1=CC(=C(C=C1OC)C1=NC=C(C2=C1C(=NO2)N)C=2C(=NNC2)C)F Chemical compound FC(C(=O)O)(F)F.NC1=CC(=C(C=C1OC)C1=NC=C(C2=C1C(=NO2)N)C=2C(=NNC2)C)F NRLMJIKJGSINBC-UHFFFAOYSA-N 0.000 description 1
- DKHUQEFGRMSDIO-UHFFFAOYSA-N FC(C(=O)O)(F)F.NC1=CC(=C(C=C1SCC)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)F Chemical compound FC(C(=O)O)(F)F.NC1=CC(=C(C=C1SCC)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)F DKHUQEFGRMSDIO-UHFFFAOYSA-N 0.000 description 1
- 239000001293 FEMA 3089 Substances 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 229940125407 FGF401 Drugs 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102100037813 Focal adhesion kinase 1 Human genes 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000967216 Homo sapiens Eosinophil cationic protein Proteins 0.000 description 1
- 101000878536 Homo sapiens Focal adhesion kinase 1 Proteins 0.000 description 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 101001051777 Homo sapiens Protein kinase C alpha type Proteins 0.000 description 1
- 101000712530 Homo sapiens RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
- IVRXNBXKWIJUQB-UHFFFAOYSA-N LY-2157299 Chemical compound CC1=CC=CC(C=2C(=C3CCCN3N=2)C=2C3=CC(=CC=C3N=CC=2)C(N)=O)=N1 IVRXNBXKWIJUQB-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 229940113306 Ligase inhibitor Drugs 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- KPQQGHGDBBJGFA-QNGWXLTQSA-N MK-8353 Chemical compound C([C@@](C1)(SC)C(=O)NC=2C=C3C(C=4C=NC(OC(C)C)=CC=4)=NNC3=CC=2)CN1CC(=O)N(CC=1)CCC=1C(C=C1)=CC=C1C=1N=CN(C)N=1 KPQQGHGDBBJGFA-QNGWXLTQSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000940612 Medina Species 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- BHKDKKZMPODMIQ-UHFFFAOYSA-N N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide Chemical compound COCCNc1cc(NC(=O)N2CCCc3cc(CN4CCN(C)CC4=O)c(C=O)nc23)ncc1C#N BHKDKKZMPODMIQ-UHFFFAOYSA-N 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- KSIJIGHGXBEURD-UHFFFAOYSA-N N1(CCCCC1)CCOC1=CC=C(C=C1)C1=NN(C(=C1)C1=CC=C(C=C1)O)C1=CC=C(C=C1)O Chemical compound N1(CCCCC1)CCOC1=CC=C(C=C1)C1=NN(C(=C1)C1=CC=C(C=C1)O)C1=CC=C(C=C1)O KSIJIGHGXBEURD-UHFFFAOYSA-N 0.000 description 1
- XTMIFEBGTLYRKT-UHFFFAOYSA-N NC1=C(C=C(C(=C1)F)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)CC Chemical compound NC1=C(C=C(C(=C1)F)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2)CC XTMIFEBGTLYRKT-UHFFFAOYSA-N 0.000 description 1
- 108700031757 NKTR-214 Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000243985 Onchocerca volvulus Species 0.000 description 1
- 229940124060 PD-1 antagonist Drugs 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241000935974 Paralichthys dentatus Species 0.000 description 1
- 206010061336 Pelvic neoplasm Diseases 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 241000233614 Phytophthora Species 0.000 description 1
- 206010035603 Pleural mesothelioma Diseases 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 102100024924 Protein kinase C alpha type Human genes 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 229940125566 REGN3767 Drugs 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 229920002536 Scavenger resin Polymers 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241001149962 Sporothrix Species 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 238000006619 Stille reaction Methods 0.000 description 1
- 101150037787 Sting gene Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- VWMJHAFYPMOMGF-ZCFIWIBFSA-N TAK-580 Chemical compound N([C@H](C)C=1SC(=CN=1)C(=O)NC=1N=CC(Cl)=C(C=1)C(F)(F)F)C(=O)C1=NC=NC(N)=C1Cl VWMJHAFYPMOMGF-ZCFIWIBFSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 101710168651 Thioredoxin 1 Proteins 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 206010044269 Toxocariasis Diseases 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical group [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 101710112793 Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 229940124674 VEGF-R inhibitor Drugs 0.000 description 1
- 241000244005 Wuchereria bancrofti Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- RBYICHYEXYRQFK-UHFFFAOYSA-N [1,2]oxazolo[4,5-c]pyridin-3-amine Chemical compound C1=NC=C2C(N)=NOC2=C1 RBYICHYEXYRQFK-UHFFFAOYSA-N 0.000 description 1
- GVPMWXBBOYRYAA-UHFFFAOYSA-N [3-methyl-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrazol-4-yl]boronic acid Chemical compound CC1=NN(C(=O)OC(C)(C)C)C=C1B(O)O GVPMWXBBOYRYAA-UHFFFAOYSA-N 0.000 description 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 1
- DSVGQVZAZSZEEX-UHFFFAOYSA-N [C].[Pt] Chemical compound [C].[Pt] DSVGQVZAZSZEEX-UHFFFAOYSA-N 0.000 description 1
- NWUFRZAXUSSXOR-UHFFFAOYSA-K [K+].[K+].[K+].[O-]P([O-])([O-])=O.CCN(CC)CC Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O.CCN(CC)CC NWUFRZAXUSSXOR-UHFFFAOYSA-K 0.000 description 1
- NFDFTBILUBCQDV-UHFFFAOYSA-N [K].P(=O)(ON1N=CC(=C1)C=1C2=C(C(=NC1)C1=C(C=C(C(=C1)C(C)=O)N)F)C(=NO2)N)(OC)O Chemical compound [K].P(=O)(ON1N=CC(=C1)C=1C2=C(C(=NC1)C1=C(C=C(C(=C1)C(C)=O)N)F)C(=NO2)N)(OC)O NFDFTBILUBCQDV-UHFFFAOYSA-N 0.000 description 1
- JLCHNBRGUPQWKF-UHFFFAOYSA-J [OH-].[C+4].[OH-].[OH-].[OH-] Chemical compound [OH-].[C+4].[OH-].[OH-].[OH-] JLCHNBRGUPQWKF-UHFFFAOYSA-J 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 229950001573 abemaciclib Drugs 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229950009821 acalabrutinib Drugs 0.000 description 1
- WDENQIQQYWYTPO-IBGZPJMESA-N acalabrutinib Chemical compound CC#CC(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C(=O)NC=2N=CC=CC=2)=C2N1C=CN=C2N WDENQIQQYWYTPO-IBGZPJMESA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 229950009557 adavosertib Drugs 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 201000005179 adrenal carcinoma Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229960001611 alectinib Drugs 0.000 description 1
- KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- QDWKGEFGLQMDAM-ULJHMMPZSA-N amcasertib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(=CC=C3NC\2=O)C=2N=C(SC=2)C=2C=CC=CC=2)=C1C QDWKGEFGLQMDAM-ULJHMMPZSA-N 0.000 description 1
- 229950003669 amcasertib Drugs 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- 229950004189 andecaliximab Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 208000020282 anthrax disease Diseases 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229960003982 apatinib Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229950009563 avadomide Drugs 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229950009568 bemcentinib Drugs 0.000 description 1
- 229940121413 bempegaldesleukin Drugs 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- MXMZCLLIUQEKSN-UHFFFAOYSA-N benzimidazoline Chemical compound C1=CC=C2NCNC2=C1 MXMZCLLIUQEKSN-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229950003054 binimetinib Drugs 0.000 description 1
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229950004237 birinapant Drugs 0.000 description 1
- 108010063132 birinapant Proteins 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052796 boron Chemical group 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000006015 bromomethoxy group Chemical group 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- YSHOWEKUVWPFNR-UHFFFAOYSA-N burgess reagent Chemical compound CC[N+](CC)(CC)S(=O)(=O)N=C([O-])OC YSHOWEKUVWPFNR-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- HGXJOXHYPGNVNK-UHFFFAOYSA-N butane;ethenoxyethane;tin Chemical compound CCCC[Sn](CCCC)(CCCC)C(=C)OCC HGXJOXHYPGNVNK-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- PKFDLKSEZWEFGL-MHARETSRSA-N c-di-GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=C(C(NC(N)=N5)=O)N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 PKFDLKSEZWEFGL-MHARETSRSA-N 0.000 description 1
- 229950010831 cabiralizumab Drugs 0.000 description 1
- 229960001292 cabozantinib Drugs 0.000 description 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 1
- 229960001838 canakinumab Drugs 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229950005852 capmatinib Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229950006754 cedelizumab Drugs 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- OHUHVTCQTUDPIJ-JYCIKRDWSA-N ceralasertib Chemical compound C[C@@H]1COCCN1C1=CC(C2(CC2)[S@](C)(=N)=O)=NC(C=2C=3C=CNC=3N=CC=2)=N1 OHUHVTCQTUDPIJ-JYCIKRDWSA-N 0.000 description 1
- 229950002256 cergutuzumab amunaleukin Drugs 0.000 description 1
- 229960001602 ceritinib Drugs 0.000 description 1
- WRXDGGCKOUEOPW-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)NS(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 WRXDGGCKOUEOPW-UHFFFAOYSA-N 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229950009221 chidamide Drugs 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000004651 chloromethoxy group Chemical group ClCO* 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229940069588 citarinostat Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 description 1
- 229950002334 clenoliximab Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960002271 cobimetinib Drugs 0.000 description 1
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 125000004976 cyclobutylene group Chemical group 0.000 description 1
- ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004977 cycloheptylene group Chemical group 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000004980 cyclopropylene group Chemical group 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 201000008167 cystoisosporiasis Diseases 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229950007409 dacetuzumab Drugs 0.000 description 1
- 229960002204 daratumumab Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229950008937 defactinib Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229950007998 demcizumab Drugs 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 150000001975 deuterium Chemical group 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 229950009859 dinaciclib Drugs 0.000 description 1
- 229950002854 dinutuximab beta Drugs 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- CBSJDBFVIHDOFO-UHFFFAOYSA-N ditert-butyl methyl phosphate Chemical compound CC(C)(C)OP(=O)(OC)OC(C)(C)C CBSJDBFVIHDOFO-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 208000006036 elephantiasis Diseases 0.000 description 1
- 229960004137 elotuzumab Drugs 0.000 description 1
- 229950004647 emactuzumab Drugs 0.000 description 1
- 229950001969 encorafenib Drugs 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229950004270 enoblituzumab Drugs 0.000 description 1
- 229950004126 ensartinib Drugs 0.000 description 1
- 206010014881 enterobiasis Diseases 0.000 description 1
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 1
- 229950005837 entinostat Drugs 0.000 description 1
- 229950006370 epacadostat Drugs 0.000 description 1
- 108060002566 ephrin Proteins 0.000 description 1
- 102000012803 ephrin Human genes 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 description 1
- 229960003649 eribulin Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- UPWRZNAVNWHRKP-UHFFFAOYSA-N ethyl 2-amino-5-[3-amino-7-(1H-pyrazol-4-yl)-[1,2]oxazolo[4,5-c]pyridin-4-yl]-4-fluorobenzoate hydrochloride Chemical compound Cl.NC1=C(C(=O)OCC)C=C(C(=C1)F)C1=NC=C(C2=C1C(=NO2)N)C=2C=NNC2 UPWRZNAVNWHRKP-UHFFFAOYSA-N 0.000 description 1
- VWVCBBKTVWJWLG-UHFFFAOYSA-N ethyl 2-amino-5-[3-amino-7-[1-[bis[(2-methylpropan-2-yl)oxy]phosphoryloxymethyl]pyrazol-4-yl]-[1,2]oxazolo[4,5-c]pyridin-4-yl]-4-fluorobenzoate Chemical compound NC1=C(C(=O)OCC)C=C(C(=C1)F)C1=NC=C(C2=C1C(=NO2)N)C=1C=NN(C=1)COP(=O)(OC(C)(C)C)OC(C)(C)C VWVCBBKTVWJWLG-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 229960004979 fampridine Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229950000456 galunisertib Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- 229950009672 glembatumumab vedotin Drugs 0.000 description 1
- 229950007540 glesatinib Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000029080 human African trypanosomiasis Diseases 0.000 description 1
- BNRNAKTVFSZAFA-UHFFFAOYSA-N hydrindane Chemical compound C1CCCC2CCCC21 BNRNAKTVFSZAFA-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 229960001507 ibrutinib Drugs 0.000 description 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229940121569 ieramilimab Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 229950009034 indoximod Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 201000006675 intestinal schistosomiasis Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 150000002537 isoquinolines Chemical class 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229950001890 itacitinib Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229950010828 keliximab Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960003784 lenvatinib Drugs 0.000 description 1
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- CMJCXYNUCSMDBY-ZDUSSCGKSA-N lgx818 Chemical compound COC(=O)N[C@@H](C)CNC1=NC=CC(C=2C(=NN(C=2)C(C)C)C=2C(=C(NS(C)(=O)=O)C=C(Cl)C=2)F)=N1 CMJCXYNUCSMDBY-ZDUSSCGKSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- KRTIYQIPSAGSBP-KLAILNCOSA-N linrodostat Chemical compound C1(CCC(CC1)C1=C2C=C(F)C=CC2=NC=C1)[C@@H](C)C(=O)NC1=CC=C(Cl)C=C1 KRTIYQIPSAGSBP-KLAILNCOSA-N 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229950011263 lirilumab Drugs 0.000 description 1
- 238000006138 lithiation reaction Methods 0.000 description 1
- LICLSCLTWYBIFP-UHFFFAOYSA-M lithium 2-chloro-4-fluoro-5-iodopyridine-3-carboxylate Chemical compound ClC1=C(C(=O)[O-])C(=C(C=N1)I)F.[Li+] LICLSCLTWYBIFP-UHFFFAOYSA-M 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- YIJGRCNSLDPVFT-UHFFFAOYSA-N lithium;di(propan-2-yl)azanide;n-propan-2-ylpropan-2-amine Chemical compound [Li+].CC(C)NC(C)C.CC(C)[N-]C(C)C YIJGRCNSLDPVFT-UHFFFAOYSA-N 0.000 description 1
- 229950001290 lorlatinib Drugs 0.000 description 1
- IIXWYSCJSQVBQM-LLVKDONJSA-N lorlatinib Chemical compound N=1N(C)C(C#N)=C2C=1CN(C)C(=O)C1=CC=C(F)C=C1[C@@H](C)OC1=CC2=CN=C1N IIXWYSCJSQVBQM-LLVKDONJSA-N 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 1
- 229950003135 margetuximab Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000010576 medium-pressure preparative liquid chromatography Methods 0.000 description 1
- 229950009580 merestinib Drugs 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- RPNNPZHFJPXFQS-UHFFFAOYSA-N methane;rhodium Chemical compound C.[Rh] RPNNPZHFJPXFQS-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 238000006063 methoxycarbonylation reaction Methods 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- OSCGIRVYKOIFGA-UHFFFAOYSA-N methyl 2-amino-5-[3-amino-7-[1-(oxan-2-yl)pyrazol-4-yl]-[1,2]oxazolo[4,5-c]pyridin-4-yl]-4-fluorobenzoate Chemical compound NC1=C(C(=O)OC)C=C(C(=C1)F)C1=NC=C(C2=C1C(=NO2)N)C=2C=NN(C2)C2OCCCC2 OSCGIRVYKOIFGA-UHFFFAOYSA-N 0.000 description 1
- RYXGOXBTMYCSMN-UHFFFAOYSA-N methyl 2-amino-5-[3-amino-7-[1-[bis[(2-methylpropan-2-yl)oxy]phosphoryloxymethyl]pyrazol-4-yl]-[1,2]oxazolo[4,5-c]pyridin-4-yl]-4-fluorobenzoate Chemical compound NC1=C(C(=O)OC)C=C(C(=C1)F)C1=NC=C(C2=C1C(=NO2)N)C=2C=NN(C2)COP(=O)(OC(C)(C)C)OC(C)(C)C RYXGOXBTMYCSMN-UHFFFAOYSA-N 0.000 description 1
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 1
- 229950010895 midostaurin Drugs 0.000 description 1
- 229950000035 mirvetuximab soravtansine Drugs 0.000 description 1
- 230000033607 mismatch repair Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- MJHOMTRKVMKCNE-NWDGAFQWSA-N mivavotinib Chemical compound C1=NN(C)C=C1C1=NC(N[C@H]2[C@H](CCCC2)N)=C(F)C2=C1C(=O)NC2 MJHOMTRKVMKCNE-NWDGAFQWSA-N 0.000 description 1
- 229950007812 mocetinostat Drugs 0.000 description 1
- 229950007699 mogamulizumab Drugs 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 229950001907 monalizumab Drugs 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229950007627 motolimod Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical class C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- WXHHICFWKXDFOW-BJMVGYQFSA-N n-(2-amino-5-fluorophenyl)-4-[[[(e)-3-pyridin-3-ylprop-2-enoyl]amino]methyl]benzamide Chemical compound NC1=CC=C(F)C=C1NC(=O)C(C=C1)=CC=C1CNC(=O)\C=C\C1=CC=CN=C1 WXHHICFWKXDFOW-BJMVGYQFSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- NSQSAUGJQHDYNO-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide Chemical compound C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 NSQSAUGJQHDYNO-UHFFFAOYSA-N 0.000 description 1
- RJCWBNBKOKFWNY-IDPLTSGASA-N n-[(4as,6ar,6bs,8ar,12as,14ar,14bs)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicen-4a-yl]-2,2-difluoropropanamide Chemical compound C([C@@]12C)=C(C#N)C(=O)C(C)(C)[C@@H]1CC[C@]1(C)C2=CC(=O)[C@@H]2[C@@H]3CC(C)(C)CC[C@]3(NC(=O)C(F)(F)C)CC[C@]21C RJCWBNBKOKFWNY-IDPLTSGASA-N 0.000 description 1
- UEPXBTCUIIGYCY-UHFFFAOYSA-N n-[3-[2-(2-hydroxyethoxy)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]-2-(trifluoromethyl)pyridine-4-carboxamide Chemical compound C1=C(C=2C=C(N=C(OCCO)C=2)N2CCOCC2)C(C)=CC=C1NC(=O)C1=CC=NC(C(F)(F)F)=C1 UEPXBTCUIIGYCY-UHFFFAOYSA-N 0.000 description 1
- HUFOZJXAKZVRNJ-UHFFFAOYSA-N n-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound COC1=CC(N2CCN(CC2)C(C)=O)=CC=C1NC(N=1)=NC=C(C(F)(F)F)C=1NC1=CC=CC(NC(=O)C=C)=C1 HUFOZJXAKZVRNJ-UHFFFAOYSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- JUPOTOIJLKDAPF-UHFFFAOYSA-N n-[3-cyclopropyl-1-[(6-methylpyridin-2-yl)methyl]indazol-4-yl]-7-[2-(4-methylpiperazin-1-yl)ethoxy]imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C1CN(C)CCN1CCOC1=CC2=NC=C(C(=O)NC=3C=4C(C5CC5)=NN(CC=5N=C(C)C=CC=5)C=4C=CC=3)N2C=C1 JUPOTOIJLKDAPF-UHFFFAOYSA-N 0.000 description 1
- QHADVLVFMKEIIP-UHFFFAOYSA-N n-[3-fluoro-4-[1-methyl-6-(1h-pyrazol-4-yl)indazol-5-yl]oxyphenyl]-1-(4-fluorophenyl)-6-methyl-2-oxopyridine-3-carboxamide Chemical compound O=C1N(C=2C=CC(F)=CC=2)C(C)=CC=C1C(=O)NC(C=C1F)=CC=C1OC1=CC=2C=NN(C)C=2C=C1C=1C=NNC=1 QHADVLVFMKEIIP-UHFFFAOYSA-N 0.000 description 1
- WPEWQEMJFLWMLV-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 description 1
- RRTPWQXEERTRRK-UHFFFAOYSA-N n-[4-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)oxybutyl]octadecanamide Chemical compound C1=CC=CC2=C3N(OCCCCNC(=O)CCCCCCCCCCCCCCCCC)C(CCCC)=NC3=C(N)N=C21 RRTPWQXEERTRRK-UHFFFAOYSA-N 0.000 description 1
- WHMMKPWGWNYYFE-UHFFFAOYSA-N n-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6h-quinoline-3-carboxamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=N1)=CC=C1NC(=O)C(C1=O)=CC=2C(=O)CCCC=2N1C1=CC=CC=C1 WHMMKPWGWNYYFE-UHFFFAOYSA-N 0.000 description 1
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 description 1
- YBGGBHCJSAEIAS-UHFFFAOYSA-N n-[5-[2-(2,6-dichlorophenyl)-5-(difluoromethyl)pyrazol-3-yl]-1,3-thiazol-2-yl]cyclopropanecarboxamide Chemical compound ClC=1C=CC=C(Cl)C=1N1N=C(C(F)F)C=C1C(S1)=CN=C1NC(=O)C1CC1 YBGGBHCJSAEIAS-UHFFFAOYSA-N 0.000 description 1
- YRCHYHRCBXNYNU-UHFFFAOYSA-N n-[[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-(4-fluorophenyl)acetamide Chemical compound N1=CC(CNCCOC)=CC=C1C1=CC2=NC=CC(OC=3C(=CC(NC(=S)NC(=O)CC=4C=CC(F)=CC=4)=CC=3)F)=C2S1 YRCHYHRCBXNYNU-UHFFFAOYSA-N 0.000 description 1
- YRNOSHBJMBLOSL-UHFFFAOYSA-N n-[tert-butylimino-bis(dimethylamino)-$l^{5}-phosphanyl]-n-methylmethanamine Chemical compound CN(C)P(N(C)C)(N(C)C)=NC(C)(C)C YRNOSHBJMBLOSL-UHFFFAOYSA-N 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- FWLMVFUGMHIOAA-UHFFFAOYSA-N n-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide Chemical compound C1=CC(C(=O)NC)=CC=C1NC1=NC=C(C(F)(F)F)C(NCC=2C(=NC=CN=2)N(C)S(C)(=O)=O)=N1 FWLMVFUGMHIOAA-UHFFFAOYSA-N 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- DPHUWDIXHNQOSY-UHFFFAOYSA-N napabucasin Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1OC(C(=O)C)=C2 DPHUWDIXHNQOSY-UHFFFAOYSA-N 0.000 description 1
- 229950011456 napabucasin Drugs 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 229960000513 necitumumab Drugs 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
- 229960000801 nelarabine Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229960004378 nintedanib Drugs 0.000 description 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 1
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 description 1
- 229950011068 niraparib Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 229960000572 olaparib Drugs 0.000 description 1
- FDLYAMZZIXQODN-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FDLYAMZZIXQODN-UHFFFAOYSA-N 0.000 description 1
- 229940059392 oleclumab Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229950008128 omaveloxolone Drugs 0.000 description 1
- 208000002042 onchocerciasis Diseases 0.000 description 1
- 229950007283 oregovomab Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 229960001638 osimertinib mesylate Drugs 0.000 description 1
- FUKSNUHSJBTCFJ-UHFFFAOYSA-N osimertinib mesylate Chemical compound CS(O)(=O)=O.COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 FUKSNUHSJBTCFJ-UHFFFAOYSA-N 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- UHHKSVZZTYJVEG-UHFFFAOYSA-N oxepane Chemical compound C1CCCOCC1 UHHKSVZZTYJVEG-UHFFFAOYSA-N 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229960004390 palbociclib Drugs 0.000 description 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 1
- JKDRQYIYVJVOPF-FDGPNNRMSA-L palladium(ii) acetylacetonate Chemical compound [Pd+2].C\C([O-])=C\C(C)=O.C\C([O-])=C\C(C)=O JKDRQYIYVJVOPF-FDGPNNRMSA-L 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- MXQOYLRVSVOCQT-UHFFFAOYSA-N palladium;tritert-butylphosphane Chemical compound [Pd].CC(C)(C)P(C(C)(C)C)C(C)(C)C.CC(C)(C)P(C(C)(C)C)C(C)(C)C MXQOYLRVSVOCQT-UHFFFAOYSA-N 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-L pemetrexed(2-) Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-L 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 150000004686 pentahydrates Chemical class 0.000 description 1
- GUVXZFRDPCKWEM-UHFFFAOYSA-N pentalene Chemical compound C1=CC2=CC=CC2=C1 GUVXZFRDPCKWEM-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- JGWRKYUXBBNENE-UHFFFAOYSA-N pexidartinib Chemical compound C1=NC(C(F)(F)F)=CC=C1CNC(N=C1)=CC=C1CC1=CNC2=NC=C(Cl)C=C12 JGWRKYUXBBNENE-UHFFFAOYSA-N 0.000 description 1
- 229950001457 pexidartinib Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- SFLGSKRGOWRGBR-UHFFFAOYSA-N phthalane Chemical compound C1=CC=C2COCC2=C1 SFLGSKRGOWRGBR-UHFFFAOYSA-N 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- LYKMMUBOEFYJQG-UHFFFAOYSA-N piperoxan Chemical compound C1OC2=CC=CC=C2OC1CN1CCCCC1 LYKMMUBOEFYJQG-UHFFFAOYSA-N 0.000 description 1
- 229950011498 plinabulin Drugs 0.000 description 1
- UNRCMCRRFYFGFX-TYPNBTCFSA-N plinabulin Chemical compound N1C=NC(\C=C/2C(NC(=C\C=3C=CC=CC=3)/C(=O)N\2)=O)=C1C(C)(C)C UNRCMCRRFYFGFX-TYPNBTCFSA-N 0.000 description 1
- 229950004423 plozalizumab Drugs 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- DTYWJKSSUANMHD-UHFFFAOYSA-N preladenant Chemical compound C1=CC(OCCOC)=CC=C1N1CCN(CCN2C3=C(C4=NC(=NN4C(N)=N3)C=3OC=CC=3)C=N2)CC1 DTYWJKSSUANMHD-UHFFFAOYSA-N 0.000 description 1
- 229950008939 preladenant Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229950003700 priliximab Drugs 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 229960002633 ramucirumab Drugs 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
- 229940121484 relatlimab Drugs 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229950009855 rociletinib Drugs 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- 229960003452 romidepsin Drugs 0.000 description 1
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 1
- 108010091666 romidepsin Proteins 0.000 description 1
- 229950006765 rovalpituzumab tesirine Drugs 0.000 description 1
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 description 1
- 229950004707 rucaparib Drugs 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229950003500 savolitinib Drugs 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 229950010746 selumetinib Drugs 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229950010611 sitravatinib Drugs 0.000 description 1
- 201000002612 sleeping sickness Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 1
- 239000012418 sodium perborate tetrahydrate Substances 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 235000019832 sodium triphosphate Nutrition 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- PVGBHEUCHKGFQP-UHFFFAOYSA-N sodium;n-[5-amino-2-(4-aminophenyl)sulfonylphenyl]sulfonylacetamide Chemical compound [Na+].CC(=O)NS(=O)(=O)C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 PVGBHEUCHKGFQP-UHFFFAOYSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 239000003447 supported reagent Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- ATFXVNUWQOXRRU-UHFFFAOYSA-N taminadenant Chemical compound BrC=1C(N)=NC(N2N=CC=C2)=NC=1N1C=CC=N1 ATFXVNUWQOXRRU-UHFFFAOYSA-N 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940126625 tavolimab Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229950004774 tazemetostat Drugs 0.000 description 1
- PRAAPINBUWJLGA-UHFFFAOYSA-N telaglenastat Chemical compound FC(F)(F)OC1=CC=CC(CC(=O)NC=2N=NC(CCCCC=3SC(NC(=O)CC=4N=CC=CC=4)=NN=3)=CC=2)=C1 PRAAPINBUWJLGA-UHFFFAOYSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000006209 tert-butylation Effects 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical class CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 238000002411 thermogravimetry Methods 0.000 description 1
- XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 1
- VOVUARRWDCVURC-UHFFFAOYSA-N thiirane Chemical compound C1CS1 VOVUARRWDCVURC-UHFFFAOYSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229950007133 tiragolumab Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 229940121514 toripalimab Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 description 1
- 229960000977 trabectedin Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960004066 trametinib Drugs 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960001612 trastuzumab emtansine Drugs 0.000 description 1
- 229950010086 tregalizumab Drugs 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 208000003982 trichinellosis Diseases 0.000 description 1
- 125000004784 trichloromethoxy group Chemical group ClC(O*)(Cl)Cl 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 229950007127 trilaciclib Drugs 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229950004593 ublituximab Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229950003520 utomilumab Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- 229950000449 vanucizumab Drugs 0.000 description 1
- 229950001067 varlilumab Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229950011257 veliparib Drugs 0.000 description 1
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- HHJUWIANJFBDHT-KOTLKJBCSA-N vindesine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 HHJUWIANJFBDHT-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- BPQMGSKTAYIVFO-UHFFFAOYSA-N vismodegib Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 description 1
- 229960004449 vismodegib Drugs 0.000 description 1
- 229950007259 vistusertib Drugs 0.000 description 1
- 229940121351 vopratelimab Drugs 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229950009002 zanolimumab Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/062—Organo-phosphoranes without P-C bonds
Definitions
- the present invention has the general formula (I)
- STING Stimulation of Interferon Genes
- cGAS cyclic GMP-AMP synthase
- cGAMP cyclic GMP-AMP
- Non-Patent Document 1 cyclic dinucleotides such as cyclic Di-GMP, which were first identified as a bacterial second messenger and were later confirmed to be present in mammals, are also known to bind directly to STING and activate them (Non-Patent Document 1). 1).
- STING is also known to be involved in autoimmune diseases and tumor immunity. For example, it has been shown that aberrant host DNA leaks from the nucleus to activate STING, inducing a proinflammatory response, indicating its involvement in autoimmune disease.
- the STING pathway also detects tumor-derived DNA and promotes T cell responses to tumors.
- STING agonist compounds administered to tumors of mice induce adaptive immune response to cause tumor regression (Non-Patent Document 2), and activating molecules of the STING pathway enhance IFN production and exhibit antiviral effects. (Non-patent document 3) is known.
- STING agonist compounds compounds of so-called cyclic dimerized nucleic acid as disclosed in Patent Documents 1 to 3 and acyclic dimerized nucleic acid compounds as disclosed in Patent Documents 4 to 7 have been used. Although reported, no STING agonist compound having a structure like the compound of the present invention has been reported.
- An object of the present invention is to provide a drug containing a compound having an agonistic activity against STING as an active ingredient.
- the present inventors have conducted extensive studies to find compounds having agonistic activity against STING, and as a result, found the following compounds and completed the present invention.
- Z represents an oxygen atom or a sulfur atom
- T represents Represents a carbon atom or a nitrogen atom
- ring A represents a 5 to 7 membered monocycle
- ring B represents a 5 to 7 membered monocycle or 8 to 10 membered bicycle
- L 1 represents a bond
- L 2 is a bond, a C1-3 alkylene group, a C3-7 cycloalkylene group Or a phenylene group
- R 1 is a hydrogen atom, a halogen atom, a hydroxyl group, a cyano group, N (R 1a ) 2 (wherein the two R 1a's are each independently a
- R 2 is a hydrogen atom, a halogen atom, a hydroxyl group, an oxo Group, nitro group, cyano group, C1-4 alkoxy group or —CH 2 NR 2a R 2b or NR 2a R 2b (wherein R 2a represents a hydrogen atom or a C1-4 alkyl group, and R 2b represents a hydrogen atom) Represents an integer of 0 or 1, R 3 represents a hydrogen atom, a halogen atom, a hydroxyl group, a C1-4 alkyl group, a C1-4 alkoxy group, a C1-4 haloalkyl group, C1-4.
- n represents an integer of 1 to 16 (in the case where n is 2 or more, the groups represented by plural R 3 may be the same or different), and R 4 is , Hydrogen atom, Represents 1-4 alkyl group or a carboxy group, R 5 represents a C1-C4 alkyl group, p is 0 to an integer of 5 (wherein, when p is 2 or more, groups represented by a plurality of R 5 May be the same or different.), R 6 represents a hydrogen atom or a C1-4 alkyl group, and R 7 represents a hydrogen atom.
- b represents the bonding position of ring B.
- Ring A is (a) C5-6 monocyclic carbocycle or (b) 5-6 membered monocyclic ring containing 1-4 heteroatoms selected from oxygen atom, nitrogen atom and sulfur atom
- Ring B is (a) C5-6 monocyclic carbocycle or (b) 5-6 membered monocyclic ring containing 1-4 heteroatoms selected from oxygen atom, nitrogen atom and sulfur atom
- Ring A is (a) a benzene ring or (b)
- Ring B is (a) a benzene ring or (b) a 5- to 6-membered monocyclic aromatic heterocycle containing 1 to 4 heteroatoms selected from oxygen atom, nitrogen atom and sulfur atom.
- Ring A is a 5- to 6-membered monocyclic aromatic nitrogen-containing heterocyclic ring containing 1 to 4 nitrogen atoms and containing no other heteroatoms, [1], [3] and [3] 5]
- the compound according to any one of 5] an N-oxide thereof, a prodrug thereof, a pharmaceutically acceptable salt thereof or a solvate thereof;
- Z is an oxygen atom, an N-oxide thereof, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a salt thereof.
- U represents a nitrogen atom or a carbon atom (here, when U represents a nitrogen atom, m represents 0, and when U represents a carbon atom, m represents 1)
- W represents- CR 3 ⁇ or a nitrogen atom
- V represents —CH ⁇ or a nitrogen atom
- the formula (Ib) has a plurality of R 3 , the groups represented by them may be the same or different, and other symbols are It has the same meaning as described above.
- L 1 in the general formula (I) or the like is —CONH— (however, the left side of the group is bonded to the ring B), —CO—, —CO 2 —, —S—, —SO 2 —.
- the compound represented by the general formula (I) is (1) 4- (4-amino-2-fluoro-5-methoxyphenyl) -7- (1H-pyrazol-4-yl) isoxazolo [5,4-c] pyridin-3-amine, (2) 4- (4-amino-2-fluoro-5-methoxyphenyl) -7- (1H-pyrazol-4-yl) isoxazolo [4,5-c] pyridin-3-amine, (3) 4- (4-amino-3-methoxyphenyl) -7- (1H-pyrazol-4-yl) isoxazolo [4,5-c] pyridin-3-amine, (4) 4- (4-amino-2-fluoro-5- (methylthio) phenyl) -7- (1H-pyrazol-4-yl) isoxazolo [4,5-c] pyridin-3-amine, (5) 4- (4-amino-2-fluoro-5- (methoxyphenyl) -7- (1
- Ring A is (a) a C5-6 monocyclic carbocycle or (b) a 5- to 6-membered monocyclic carbon ring containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom and a sulfur atom.
- Ring B is (a) a C5-6 monocyclic carbocycle or (b) a 5-6 membered single ring containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom and a sulfur atom.
- Ring A is (a) a benzene ring or (b) a 5 to 6 membered monocyclic aromatic heterocycle containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom and a sulfur atom.
- Ring B is (a) a benzene ring or (b) a 5- to 6-membered monocyclic aromatic heterocycle containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom and a sulfur atom.
- Ring A represents a 5- to 6-membered monocyclic aromatic nitrogen-containing heterocycle containing 1 to 4 nitrogen atoms and containing no other heteroatoms, [1-1], [ [1-3] and [1-5], the N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof; [1-7] The compound according to any one of the above-mentioned [1-1] to [1-6], wherein Z is an oxygen atom, an N-oxide thereof, a pharmaceutically acceptable salt thereof or a compound thereof.
- Ring A is pyrazole, triazole (eg, 1,2,3-triazole and 1,2,4-triazole), tetrazole, oxazole, isoxazole, imidazole, thiazole or isothiazole, 1-1], [1-3], [1-5] and the compound according to any one of [1-7] to [1-12], N-oxides thereof, and pharmaceutically acceptable thereof Salts or solvates thereof; [1-14]
- the compound represented by the general formula (I-1) is represented by the general formula (III-1)
- L 1 in the general formula (I-1) or the like is —O—, —CONH—, —CO—, —CO 2 —, —S—, —SO 2 — or —SO—.
- L 1 of the general formula (I-1) or the like is —CONH— (however, the left side of the group is bound to the ring B), —CO—, —CO 2 —, —S—,
- Acceptable salt is an alkali metal salt (eg, lithium salt, sodium salt or potassium salt), alkaline earth metal salt (eg, calcium salt), magnesium salt, zinc salt, ammonium salt formed with the same group, or A pharmaceutically acceptable salt of the compound according to any one of the above [1-1] to [1-28], which is an organic amine salt, or a solvate thereof; [1-31]
- the organic amine salt is an aliphatic amine salt (eg, methylamine salt, dimethylamine salt, cyclopentylamine salt, trimethylamine salt, triethylamine salt, dicyclohexylamine salt, monoethanolamine salt, diethanolamine salt, triethanolamine).
- Salt procaine salt, meglumine salt, diethanolamine salt, tris (hydroxymethyl) aminomethane salt, ethylenediamine salt, etc.), aralkylamine salt (eg, benzylamine salt, phenethylamine salt, N, N-dibenzylethylenediamine salt, benetamine salt, etc.) ), A heterocyclic aromatic amine salt (eg, piperidine salt, pyridine salt, picoline salt, quinoline salt or isoquinoline salt), a quaternary ammonium salt (eg, tetramethylammonium salt, tetraethyl salt) Ruamonium salt, benzyltrimethylammonium salt, benzyltriethylammonium salt, benzyltributylammonium salt, methyltrioctylammonium salt or tetrabutylammonium salt), basic amino acid salt (eg arginine salt or lysine salt) or N-methyl
- the compound represented by the general formula (I-1) is (1) 4- (4-amino-2-fluoro-5-methoxyphenyl) -7- (1H-pyrazol-4-yl) isoxazolo [5,4-c] pyridin-3-amine, (2) 4- (4-amino-2-fluoro-5-methoxyphenyl) -7- (1H-pyrazol-4-yl) isoxazolo [4,5-c] pyridin-3-amine, (3) 4- (4-amino-3-methoxyphenyl) -7- (1H-pyrazol-4-yl) isoxazolo [4,5-c] pyridin-3-amine, (4) 4- (4-amino-2-fluoro-5- (methylthio) phenyl) -7- (1H-pyrazol-4-yl) isoxazolo [4,5-c] pyridin-3-amine, (5) 4- (4-amino-2-fluoro-5-
- the pharmaceutically acceptable salt of the compound according to any one of the above [1-1] to [1-34] is an alkali metal salt (eg, lithium salt, sodium salt or potassium salt).
- [2-1] A compound represented by the general formula (I), the general formula (II) or the general formula (III), an N-oxide thereof, a prodrug thereof, a pharmaceutically acceptable salt thereof or a compound thereof A pharmaceutical composition containing a solvate and a pharmaceutically acceptable carrier; [2-2] A compound represented by the general formula (I-1), the general formula (II-1) or the general formula (III-1), an N-oxide thereof, a pharmaceutically acceptable salt thereof or a compound thereof. A pharmaceutical composition containing a solvate of the above and a pharmaceutically acceptable carrier; [2-3] The pharmaceutical composition according to the above [2-1] or [2-2], which further contains one or more kinds of active ingredients of other anticancer agents;
- [3-1] A compound represented by the general formula (I), the general formula (II) or the general formula (III), an N-oxide thereof, a prodrug thereof, a pharmaceutically acceptable salt thereof or a compound thereof An agent for suppressing the progression of cancer or infectious disease, suppressing recurrence and / or treating, which comprises a solvate as an active ingredient; [3-2] A compound represented by the general formula (I-1), the general formula (II-1) or the general formula (III-1), an N-oxide thereof, a pharmaceutically acceptable salt thereof or a compound thereof. Or a therapeutic agent for suppressing the progression of cancer or infectious disease, suppressing recurrence, and / or containing the solvate of E.
- Solid cancer is malignant melanoma (eg, malignant melanoma in skin, oral mucosal epithelium, or orbit etc.), non-small cell lung cancer (eg, squamous non-small cell lung cancer and non-squamous non-small cell lung cancer) ), Small cell lung cancer, head and neck cancer (eg, oral cancer, nasopharyngeal cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, salivary gland cancer and tongue cancer), renal cell cancer (eg clear cell renal cell cancer) ), Breast cancer, ovarian cancer (eg serous ovarian cancer and clear cell adenocarcinoma of the ovary), nasopharyngeal cancer, uterine cancer (eg cervical and endometrial cancer), anal cancer (eg anal melanoma (eg, malignant melanoma in skin, oral mucosal epithelium, or orbit etc.), non-small cell lung
- TPS Percentage of tumor cells expressing PD-L1 in the tumor cells
- CPS Percentage of tumor cells expressing PD-L1 in the tumor cells
- CPS Percentage of tumor cells expressing PD-L1 in the tumor cells
- CPS Percentage of tumor cells expressing PD-L1 in the tumor cells
- CPS Percentage of tumor cells expressing PD-L1 in the tumor cells
- CPS Percentage of tumor cells expressing PD-L1 in the tumor cells
- CPS Percentage of tumor cells expressing PD-L1 in the tumor cells
- CPS Percentage of tumor cells expressing PD-L1 in the tumor cells
- CPS Percentage of tumor cells expressing PD-L1 in the tumor cells
- CPS Percentage of tumor cells expressing PD-L1 in the tumor cells
- CPS Percentage of tumor cells expressing PD-L1 in the tumor cells
- CPS Percentage of tumor cells expressing PD-L1 in the tumor cells
- CPS
- TMB tumor mutation load of cancer
- the number of mutations is 10 or more per 10 6 bases is 10 or more
- [3-23] The agent according to any one of [3-1] to [3-22] above, which is further administered in combination with one or more other anticancer agents;
- [4-1] The agent according to the above [3-1] or [3-2], wherein the infectious disease is a symptom caused by viral infection, parasitic infection, bacterial infection or fungal infection;
- Virus infection is adenovirus, arenavirus, bunyavirus, calicivirus, coronavirus, filovirus, hepadnavirus, herpes virus, orthomyxovirus, papovavirus, paramyxovirus, parvovirus, picornavirus , Poxvirus, reovirus, retrovirus, rhabdovirus, togavirus, papillomavirus (eg human papillomavirus (HPV)), human immunodeficiency virus (HIV), poliovirus, hepatitis virus (eg hepatitis A) Virus (HAV), Hepatitis B virus (HBV), He
- An effective dose of a compound represented by the general formula (I), an N-oxide thereof, a prodrug thereof, a pharmaceutically acceptable salt thereof or a solvate thereof is A method for suppressing progression of cancer or infectious disease, suppressing recurrence, and / or treating, comprising administering to a patient in need thereof; [5-2] Patients who need to administer an effective dose of the compound represented by the general formula (I-1), an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. A method for suppressing progression of cancer or infectious disease, suppressing recurrence and / or treating the same;
- [6-1] A compound represented by the general formula (I), an N-oxide thereof, a prodrug thereof, or a pharmaceutical thereof for use in suppressing the progression of cancer or infectious disease, suppressing recurrence and / or treating. Acceptable salts or solvates thereof; [6-2] A compound represented by the general formula (I-1), its N-oxide, and a pharmaceutically acceptable compound thereof for use in suppressing the progression of cancer or infectious disease, suppressing the recurrence and / or treating Salts or solvates thereof;
- [7-1] Compounds represented by general formula (I), N-oxides thereof, prodrugs thereof, and pharmaceuticals thereof for suppressing the progression of cancer or infectious disease, suppressing recurrence and / or producing therapeutic agents Use of an acceptable salt or a solvate thereof;
- [7-2] A compound represented by the general formula (I-1), an N-oxide thereof, or a pharmaceutically acceptable compound thereof for suppressing the progression of cancer or infectious disease, suppressing recurrence and / or manufacturing a therapeutic agent. Salt or a solvate thereof;
- the other anticancer agent according to the above [2-3], [3-8] to [3-10], or [3-23] is an alkylating agent, a platinum preparation, or an antimetabolite.
- an antimetabolite for example, antifolate, pyridine, and purine metabolism inhibitors, ribonucleotide reductase inhibitors, nucleotide analogs, topoisomerase inhibitors, microtubule polymerization inhibitors, microtubule depolymerization inhibitors, antitumor antibiotics
- the pharmaceutical composition according to the above [2-3] or the composition according to the above [3-8] to [3-10] or [3-23] which is one or more agents selected from the group consisting of: a cytokine preparation and an antihormonal drug.
- the other anticancer agent according to the above [2-3], [3-8] to [3-10] or [3-23] is a molecular targeted drug, and the above [2-3 ]
- the molecular target drug is an ALK inhibitor, a BCR-ABL inhibitor, an EGFR inhibitor, a B-Raf inhibitor, a VEGFR inhibitor, an FGFR inhibitor, a c-Met inhibitor, an Axl inhibitor, a Mek inhibitor.
- CDK inhibitor CDK inhibitor, Btk inhibitor, PI3K- ⁇ / ⁇ inhibitor, JAK-1 / 2 inhibitor, TGFbR1 inhibitor, Cancer cell stemness kinase inhibitor, Syk / FLT3 dual inhibitor, ATR inhibitor, Wee1 kinase Inhibitors, multi-tyrosine kinase inhibitors, mTOR inhibitors, HDAC inhibitors, PARP inhibitors, aromatase inhibitors, EZH2 inhibitors, galectin-3 inhibitors, STAT3 inhibitors, DNMT inhibitors, SMO inhibitors, Hsp90 inhibitors , ⁇ -tubulin specific inhibitor, HIF2 ⁇ inhibitor, glutaminase inhibitor, E3 ligase inhibitor, Nrf2 Activator, arginase inhibitor, cell cycle inhibitor, IAP antagonist, anti-Her2 antibody, anti-EGFR antibody, anti-VEGF antibody, anti-VEGFR2 antibody, anti-CD20 antibody, anti-CD30 antibody, anti-CD38 antibody, anti-DR5 antibody
- Anti-PD-L1 antibody is Atezolizumab, Avelumab, Durvalumab, BMS-936559, STI-1014, KN035, LY3300054, HLX20, SHR-1316, CS1001, MSB2311, BGB-A333, KL-A167, CK-.
- [9-1] A compound represented by the general formula (I), the general formula (II) or the general formula (III), an N-oxide thereof, a prodrug thereof, a pharmaceutically acceptable salt thereof or a compound thereof A STING agonist containing a solvate as an active ingredient; [9-2] A compound represented by the general formula (I-1), the general formula (II-1) or the general formula (III-1), an N-oxide thereof, a pharmaceutically acceptable salt thereof or a compound thereof. A STING agonist containing as an active ingredient a solvate of
- [10-1] A compound represented by the general formula (I), the general formula (II) or the general formula (III), an N-oxide thereof, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a salt thereof: IFN- ⁇ production inducer containing a solvate as an active ingredient; and [10-2] a compound represented by the general formula (I-1), the general formula (II-1) or the general formula (III-1), An IFN- ⁇ production inducer containing an N-oxide, a pharmaceutically acceptable salt thereof or a solvate thereof as an active ingredient.
- the compound of the present invention has an agonistic activity against STING, it can be used as an active ingredient for suppressing the progression of cancer or infectious disease, suppressing recurrence and / or a therapeutic agent.
- halogen atom examples include a fluorine atom, a chlorine atom, a bromine atom and an iodine atom.
- examples of the “C1-4 alkyl group” include methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group and tert-butyl group.
- C1-5 alkyl group means methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group. , Isopentyl group and 2,3-dimethylpropyl group.
- C1-3 alkylene group is a methylene group, an ethylene group or a propylene group.
- examples of the “C1-4 alkoxy group” include methoxy group, ethoxy group, n-propoxy group, isopropoxy group, n-butoxy group, isobutoxy group, sec-butoxy group and tert-butoxy group. Can be mentioned.
- examples of the “C1-4 haloalkyl group” include, for example, fluoromethyl group, chloromethyl group, bromomethyl group, iodomethyl group, difluoromethyl group, trifluoromethyl group, 1-fluoroethyl group, 2-fluoro group.
- Ethyl group, 2-chloroethyl group, pentafluoroethyl group, 1-fluoropropyl group, 2-chloropropyl group, 3-fluoropropyl group, 3-chloropropyl group, 4,4,4-trifluorobutyl group and 4- Bromobutyl and the like can be mentioned.
- examples of the “C1-4 haloalkoxy group” include trifluoromethoxy group, trichloromethoxy group, chloromethoxy group, bromomethoxy group, fluoromethoxy group, iodomethoxy group, difluoromethoxy group, dibromomethoxy group.
- examples of the “C3-6 cycloalkyl group” include cyclopropyl group, cyclobutyl group, cyclopentyl group and cyclohexyl group.
- examples of the “C3-7 cycloalkyl group” include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group and a cycloheptyl group.
- examples of the “C3-7 cycloalkylene group” include cyclopropylene group, cyclobutylene group, cyclopentylene group, cyclohexylene group and cycloheptylene group.
- C1-4 alkoxycarbonyl group means methoxycarbonyl group, ethoxycarbonyl group, n-propoxycarbonyl group, isopropoxycarbonyl group, n-butoxycarbonyl group, isobutoxycarbonyl group, sec-butoxy group. Examples thereof include a carbonyl group and a tert-butoxycarbonyl group.
- examples of the “C5-6 monocyclic carbocycle” include cyclopentane, cyclohexane, cyclopentene, cyclohexene, cyclopentadiene, cyclohexadiene, benzene and the like.
- examples of the “5- to 7-membered monocycle” include, for example, cyclopentane, cyclohexane, cyclopentene, cyclohexene, cyclopentadiene, cyclohexadiene, benzene, cycloheptane, cycloheptene, cycloheptadiene, pyrrole, oxazole, isocycle.
- examples of the “8 to 10-membered bicycle” include pentalene, perhydropentalene, indene, perhydroindene, indane, azulene, perhydroazulene, naphthalene, dihydronaphthalene, tetrahydronaphthalene, perhydro.
- examples of the “5- to 6-membered monocyclic heterocycle containing 1 to 4 heteroatoms selected from oxygen atom, nitrogen atom and sulfur atom” include, for example, pyrrole, oxazole, isoxazole, Thiazole, isothiazole, pyrroline, pyrrolidine, dihydrooxazole, tetrahydrooxazole, dihydroisoxazole, tetrahydroisoxazole, dihydrothiazole, tetrahydrothiazole, dihydroisothiazole, tetrahydroisothiazole, imidazole, pyrazole, furazan, oxadiazole, thiadiazole, imidazoline , Imidazolidine, pyrazoline, pyrazolidine, dihydrofurazan, tetrahydrofurazan, dihydrooxadiazole, tetrahydrooxadiazole, dihydrothiadiaz
- examples of the "5- to 6-membered monocyclic aromatic heterocycle containing 1 to 4 heteroatoms selected from oxygen atom, nitrogen atom and sulfur atom” include, for example, pyrrole, imidazole and triazole. , Tetrazole, pyrazole, furan, thiophene, oxazole, isoxazole, thiazole, isothiazole, furazan, oxadiazole, thiadiazole, pyridine, pyrazine, pyrimidine and pyridazine.
- examples of the “5- to 6-membered monocyclic aromatic nitrogen-containing heterocycle containing 1 to 4 nitrogen atoms and other heteroatoms” include, for example, pyrrole, imidazole, triazole, Examples include tetrazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine and the like.
- examples of the “3- to 7-membered monocyclic non-aromatic heterocycle” include, for example, oxirane, aziridine, thiirane, azetidine, oxetane, thietane, pyrroline, pyrrolidine, imidazoline, imidazolidine, triazoline, Triazolidine, tetrazoline, tetrazolidine, pyrazoline, pyrazolidine, dihydrofuran, tetrahydrofuran, dihydrothiophene, tetrahydrothiophene, dihydrooxazole, tetrahydrooxazole, dihydroisoxazole, tetrahydroisoxazole, dihydrothiazole, tetrahydrothiazole, dihydroisothiazole, tetrahydroisothiazole, dihydro Frazane, tetrahydrofurazan, dihydro
- a compound which is decomposed in vivo to produce a compound represented by the general formula (I), an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof is free.
- groups include the group defined as R FR .
- the ring A in the general formula (I), (I-1), (II) or (II-1) of the present invention is preferably 1 to 4 heteroatoms selected from oxygen atom, nitrogen atom and sulfur atom.
- ring B of the general formula (I) or (I-1) of the present invention is preferably (i) C5-6 monocyclic carbocycle Or (ii) a 5- to 6-membered monocyclic heterocycle containing 1 to 4 heteroatoms selected from oxygen atom, nitrogen atom and sulfur atom, and more preferably benze It is a ring.
- Z in the general formula (I) or (I-1) of the present invention is preferably an oxygen atom
- Y is preferably —CH ⁇
- X is preferably a nitrogen atom
- L 2 in the general formula (I), the formula (Ib), the general formula (I-1) and the like or the formula (Ib-1) of the present invention is preferably a bond or a C1-3 alkylene group, and more preferably , A bond, and L 1 is preferably —O—, —CONH—, —CO—, —CO 2 —, —S—, —SO 2 — or —SO—, and more preferably —CONH.
- R 2 and R 2c is preferably nit B group and NR 2a R 2b and NR 2d R 2e , respectively, more preferably an amino group
- R 3 is preferably a hydrogen atom, a halogen atom or a hydroxyl group, and more preferably a halogen atom.
- n is preferably 2 or 1.
- R 2a , R 4 and R 6 in the general formula (I) and the like of the present invention are preferably hydrogen atoms
- R 2d , R 4a and R 6a in the general formula (I-1) and the like are preferably hydrogen atoms.
- a phosphonooxyalkyl group, and the phosphonooxyalkyl group is preferably —CH 2 OP ( ⁇ O) (OH) 2 , —CHCH 3 OP ( ⁇ O) (OH) 2 or —CH 2 OP ( ⁇ O) (OH) (OCH 2 OCO 2 CH (CH 3 ) 2 ), and more preferably —CH 2 OP ( ⁇ O) (OH) 2 .
- two or more of R 2d , R 4a and R 6a do not simultaneously represent a phosphonooxyalkyl group.
- W is preferably —CH ⁇
- V is preferably —CH ⁇
- U in formula (Ib), formula (Ib-1), general formula (II) or general formula (II-1) of the present invention is preferably a carbon atom.
- T in the general formula (I), (I-1), (II) or (II-1) of the present invention a nitrogen atom is preferable.
- the compound represented by the general formula (I) of the present invention an N-oxide thereof, a prodrug thereof, a pharmaceutically acceptable salt thereof or a solvate thereof is preferably represented by the general formula (II).
- the compound represented by the general formula (I), an N-oxide thereof, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a solvate thereof is preferable, for example, as described in the above item [26].
- examples thereof include compounds (1) to (35), N-oxides thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, and solvates thereof.
- the compound represented by the general formula (I-1) of the present invention, an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof is preferably the compound represented by the general formula (II-1):
- the compound represented by the general formula (I-1), an N-oxide thereof, a pharmaceutically acceptable salt thereof, or a solvate thereof is preferably, for example, the one described in the above item [1-33].
- Examples thereof include compounds 1) to 44, N-oxides thereof, pharmaceutically acceptable salts thereof, and solvates thereof.
- a solvate of the compound of (1) to (44) described in [1-33] above preferably, the compound of (1) to (44) described in [1-33] above or a pharmaceutically acceptable compound thereof. It is a hydrate of an acceptable salt (eg, an alkali metal salt (eg, lithium salt, sodium salt, potassium salt, etc.)).
- the isomers include all of them unless otherwise specified in the present invention.
- alkyl groups include straight and branched ones.
- geometric isomers E-form, Z-form, cis-form, trans-form
- optical isomers due to the presence of an asymmetric carbon atom R, S-form, ⁇ , ⁇ configuration, Enantiomers, diastereomers
- optically active substances with optical activity D, L, d, l isomers
- polar substances high polar substances, low polar substances by chromatographic separation, equilibrium compounds, rotamers, and these Mixtures in any proportion, racemic mixtures, are all included in the present invention.
- the present invention includes all isomers due to tautomers.
- optical isomer in the present invention is not limited to 100% pure one, and may contain less than 50% other optical isomer.
- N-oxide form The compound represented by the general formula (I) or the like or the general formula (I-1) or the like can be converted into an N-oxide by a known method.
- the N-oxide form means a compound represented by the general formula (I) or the general formula (I-1) in which the nitrogen atom is oxidized.
- these N-oxides can be used as described in the following [Prodrug], [Salt] and [Solvate] below, and their pharmaceutically acceptable pharmaceutically acceptable form. It may be a salt or a solvate thereof.
- the compound represented by the general formula (I) or the N-oxide thereof can be converted into a prodrug by a known method.
- the prodrug is a compound which is converted into, for example, a compound represented by the general formula (I) or the N-oxide form thereof by a reaction with an enzyme, gastric acid or the like in vivo.
- the compound represented by the general formula (I-1) or the N-oxide thereof in which any one of R 2d , R 4a and R 6a is the above R FR is represented by the general formula (I) and the like.
- the compound or its N-oxide form can be administered as a prodrug, and the prodrug is preferably, for example, (14), (18), (19), (32) described in the above item [1-33]. , (37) to (39), (41) and (42).
- the compounds represented by the general formula (I) or the N-oxide prodrugs thereof are as described in Hirokawa Shoten, 1990, "Development of Pharmaceuticals," Vol. 7, “Molecular Design,” pages 163-198. It may be changed to the corresponding compound represented by the general formula (I) or the N-oxide thereof under physiological conditions.
- Examples of other prodrugs of the compound represented by the general formula (I) or the N-oxide thereof include, for example, a compound represented by the general formula (I) or an N-oxide thereof having 1 to 4 nitrogen atoms.
- the nitrogen atom on the nitrogen-containing heterocycle is acylated, alkylated or phosphorylated.
- a compound represented by the general formula (I) or the like has an amino group, a compound in which the amino group is acylated, alkylated or phosphorylated (for example, a compound represented by the general formula (I) or the like) Amino group is eicosanoylated, alanylated, pentylaminocarbonylated, (5-methyl-2-oxo-1,3-dioxolen-4-yl) methoxycarbonylation, tetrahydrofuranylation, pyrrolidylmethylation, pivaloyloxymethylation, acetoxymethylation or tert-butylation Etc.), a compound represented by the general formula (I) or the like has an amino group, a compound in which the amino group is acylated, alkylated or phosphorylated (for example, a compound represented by the general formula (I) or the like) Amino group is eicosanoylated, alanylated, penty
- the hydroxyl group of the compound represented by the general formula (I) or the like is acetylated, palmitoylated, propanoylated, pivalloy.
- Compound, succinylated, fumarylated, alanylated or dimethylaminomethylcarbonylated compound) when the compound represented by the general formula (I) has a carboxy group, the carboxy group is esterified or amide.
- Compound for example, a compound represented by the general formula (I) or the like has a carboxy group converted to ethyl ester, phenyl ester, carboxymethyl ester, dimethylaminomethyl ester, pivaloyloxymethyl ester, 1- ⁇ (Ethoxycarbonyl) oxy ⁇ ethyl esterification, phthalidyl esterification, (5-methyl-2-oxo-1,3-dioxolen-4-yl) methyl esterification, 1- ⁇ [(cyclohexyloxy) carbonyl] oxy ⁇ Ethyl esterified or methyl amidated compound etc.) No.
- the prodrug of the compound represented by the general formula (I) or the like or its N-oxide form is pharmaceutically acceptable as described in the following [Salt] section and [Solvate] section below. It may be an acceptable salt or solvate.
- a compound represented by the general formula (I) or the like, an N-oxide thereof or a prodrug thereof and a compound represented by the general formula (I-1) or the N-oxide thereof can be prepared by a known method. It can be converted into an acceptable salt.
- an alkali metal salt eg, lithium salt, sodium salt, potassium salt, etc.
- alkaline earth metal salt eg, calcium salt, magnesium salt, barium salt, etc.
- Ammonium salt organic amine salt (eg, aliphatic amine salt (eg, methylamine salt, dimethylamine salt, cyclopentylamine salt, trimethylamine salt, triethylamine salt, dicyclohexylamine salt, monoethanolamine salt, diethanolamine salt, triethanolamine) Salt, procaine salt, meglumine salt, diethanolamine salt, tris (hydroxymethyl) aminomethane salt, ethylenediamine salt, etc.), aralkylamine salt (eg, benzylamine salt, phenethylamine salt, N, N-dibenzylethylenedia) Salt and benetamine salt, etc.), heterocyclic aromatic amine salt (eg, piperidine salt, pyridine salt, picoline salt,
- the pharmaceutically acceptable salt is preferably water-soluble.
- examples of the compound which forms a salt with the group include ,
- a preferred alkaline earth metal salt is a calcium salt
- a preferred organic amine salt is a basic amino acid salt (eg, arginine salt (eg, L-arginine salt)), lysine salt (eg, L-lysine salt), etc. ), Meglumine salt and tris (hydroxymethyl) aminomethane salt.
- Solvates Compounds represented by general formula (I), N-oxides thereof, prodrugs thereof or pharmaceutically acceptable salts thereof, and compounds represented by general formula (I-1), N-oxides thereof Alternatively, a pharmaceutically acceptable salt thereof can be converted into a solvate by a known method.
- Solvates are preferably low toxicity and water soluble. Suitable solvates include, for example, solvates with water and alcoholic solvents (eg ethanol).
- the hydrate may be in the form of, for example, polyhydrate such as monohydrate or pentahydrate, and low hydrate such as hemihydrate. Examples of the hydrate form include monohydrate, dihydrate, trihydrate and 2-3 hydrates.
- these hydrates includes clathrate hydrates.
- These hydrates include compounds represented by the general formula (I), N-oxides thereof, prodrugs thereof or pharmaceutically acceptable salts thereof, or compounds represented by the general formula (I-1).
- Its N-oxide or a pharmaceutically acceptable salt thereof can be obtained, for example, by precipitating it from a water-containing organic solvent.
- [Co-crystal] Compounds represented by general formula (I), N-oxides thereof, prodrugs thereof, pharmaceutically acceptable salts thereof or solvates thereof, and compounds represented by general formula (I-1) , Their N-oxides, their pharmaceutically acceptable salts or their solvates can form co-crystals with suitable co-crystal formers.
- the co-crystal is preferably a pharmaceutically acceptable co-crystal formed with a pharmaceutically acceptable co-crystal forming agent.
- a co-crystal is defined as a crystal in which two or more different molecules are formed by an intermolecular interaction different from an ionic bond. Further, the co-crystal may be a complex of a neutral molecule and a salt.
- Co-crystals can be prepared by known methods, for example by melt crystallization, recrystallization from solvent or by physically grinding the components together.
- Suitable co-crystal formers include those described in WO 2006/007448, such as 4-aminobenzoic acid, 4-aminopyridine, adenine, alanine, acetylsalicylic acid and the like.
- a compound in which all or part of hydrogen atoms constituting one or more groups of R 6a and R 7 are substituted with a deuterium atom or a tritium atom for example, 4- (4-amino- 2-fluoro-5- (methoxy-d 3 ) phenyl) -7- (1H-pyrazol-4-yl) isoxazolo [4,5-c] pyridin-3-amine and the like can be mentioned.
- “methyl-d 3 ” and “methoxy-d 3 ” represent a triduteriomethyl group and a triduteriomethoxy group, respectively.
- the compound of the present invention is a known method, for example, the method described in Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition (Richard C. Larock, John Wiley & Sons Inc, 1999), the method shown below or practice. It can be produced by appropriately improving the methods shown in the examples and using them in combination.
- Pg represents a protecting group for an amino group (for example, a tert-butoxycarbonyl group, a benzyloxycarbonyl group, a fluorenylcarbonyl group, a trityl group, an o-nitrobenzenesulfenyl group or an acetyl group), and R ′ are each independently a hydrogen atom, a C1-5 alkyl group, a C3-6 cycloalkyl group, a hydroxyl group or a halogen atom, and when R'represents a C1-5 alkyl group, two R's are It may form a dioxaborolane ring together with the adjacent oxygen atom and boron atom, and other symbols have the same meanings as described above. ]
- the coupling reaction 1 in the reaction process formula 1 can be carried out by a known Suzuki coupling reaction.
- a palladium catalyst eg, tetrakistriphenylphosphine palladium, bis (triphenylphosphine) can be used.
- the coupling reaction 1 can also be carried out by a known coupling reaction using an organometallic reagent, for example, a Negishi reaction using a zinc reagent instead of a boric acid reagent, a tin reagent instead of a boric acid reagent.
- an organometallic reagent for example, a Negishi reaction using a zinc reagent instead of a boric acid reagent, a tin reagent instead of a boric acid reagent.
- the Still reaction used, the Hiyama coupling using a silicon reagent instead of the boric acid reagent, the Grignard reagent instead of the boric acid reagent, and the Kumada reaction using a nickel catalyst instead of the palladium catalyst are also performed.
- the coupling reaction 2 in the reaction process formula 1 is also performed by the known Suzuki coupling reaction, Negishi reaction, Stille reaction, Hiyama coupling, Kumada reaction, etc.
- the deprotection reaction in Reaction Scheme 1 can be carried out by a known deprotection reaction under acidic conditions, and for example, an organic solvent (for example, dichloromethane, chloroform, dioxane, ethyl acetate, methanol, isopropyl alcohol, tetrahydrofuran or Organic acid (eg acetic acid, trifluoroacetic acid, methanesulfonic acid or p-tosylic acid etc.) or inorganic acid (eg hydrochloric acid or sulfuric acid etc.) or a mixture thereof (eg hydrogen bromide / acetic acid etc.) ) In the presence or absence of 2,2,2-trifluoroethanol at 0 to 100 ° C.
- an organic solvent for example, dichloromethane, chloroform, dioxane, ethyl acetate, methanol, isopropyl alcohol, tetrahydrofuran or Organic acid (eg acetic acid, triflu
- a compound represented by the general formula (I-1) or the like in which none of R 2d , R 4a and R 6a represents the above R FR may be produced by the method represented by the above reaction scheme 1. it can.
- R 4b represents — (CR Fb 2 ) q OP ( ⁇ O) (OR Fa ′) 2 and each R Fa ′ independently represents a hydrogen atom, a C1-4 alkyl group, a C3— 6 cycloalkyl group,-(CH 2 ) 2 OH or -CH 2 OCO 2 CH (CH 3 ) 2 and other symbols have the same meanings as described above.
- the compound represented by the formula] is produced by subjecting the compound represented by the general formula (IV) to the following alkylation reaction, and if R Fa 'is a protecting group, subjecting it to a deprotection reaction, if necessary. You can
- X 1 represents a halogen atom, and other symbols have the same meanings as described above.
- the alkylation reaction is known, and, for example, in an organic solvent (eg, dichloromethane, chloroform, dioxane, ethyl acetate, methanol, ethanol, isopropyl alcohol, tetrahydrofuran, dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, etc.).
- organic solvent eg, dichloromethane, chloroform, dioxane, ethyl acetate, methanol, ethanol, isopropyl alcohol, tetrahydrofuran, dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, etc.
- deprotection reaction of R Fa ′ when R Fa ′ is a protecting group is also known, and for example, known deprotection reaction under acidic conditions or hydrogenation reaction in the presence of palladium-carbon catalyst and the like. It can be carried out.
- R Fa ′ represents a protective group
- a protective group it corresponds to a protective group for a hydroxyl group, and examples thereof include a methyl group, a trityl group, a methoxymethyl group, a 1-ethoxyethyl group, a methoxyethoxymethyl group, a 2-tetrahydropyranyl group, Trimethylsilyl group, triethylsilyl group, tert-butyldimethylsilyl group, tert-butyldiphenylsilyl group, acetyl group, pivaloyl group, benzoyl group, benzyl group, p-methoxybenzyl group, allyloxycarbonyl group or 2,2,2- Examples thereof include trichloroethoxycarbonyl group.
- the hydrogenation reaction in the presence of a palladium-carbon catalyst or the like can be performed, for example, in a hydrogen gas atmosphere of 1 to 20 atm in an organic solvent (eg, methanol, ethanol, tetrahydrofuran, dioxane, ethyl acetate or isopropyl alcohol), It is carried out at room temperature to 120 ° C. in the presence of 0.01 to 100 mol% of a catalyst (eg, palladium-carbon, platinum-carbon, palladium hydroxide-carbon, rhodium-carbon, etc.).
- an organic solvent eg, methanol, ethanol, tetrahydrofuran, dioxane, ethyl acetate or isopropyl alcohol
- a catalyst eg, palladium-carbon, platinum-carbon, palladium hydroxide-carbon, rhodium-carbon, etc.
- the lithiation reaction in the reaction process formula 2 can be carried out by a known method, and for example, an organic solvent (eg, tetrahydrofuran, diethyl ether, dioxane, dichloromethane, dichloroethane, n-hexane or toluene, or a mixed solvent thereof or the like). ), A base (eg, lithium diisopropylamide, n-butyllithium or tert-butyllithium) is reacted at ⁇ 78 ° C. to room temperature, and then carbon dioxide (eg, carbon dioxide gas or dry ice) is added, It is carried out by reacting at 78 ° C to room temperature.
- an organic solvent eg, tetrahydrofuran, diethyl ether, dioxane, dichloromethane, dichloroethane, n-hexane or toluene, or a mixed solvent thereof or the like.
- a base e
- the amidation reaction in Reaction Scheme 2 can be carried out by a known method, for example, in an organic solvent (eg, chloroform, dichloromethane, diethyl ether, tetrahydrofuran, dimethoxyethane, etc.) or in the absence of a solvent.
- Reaction with an agent eg, oxalyl chloride or thionyl chloride
- a base eg, pyridine, triethylamine, dimethylaniline, dimethylaminopyridine or N, N-diisopropyl.
- Ammonia eg, ammonia gas, ammonia water or ammonia methanol solution
- the reaction is performed at ⁇ 78 ° C. to reflux temperature.
- the dehydration reaction in Reaction Scheme 2 can be carried out by a known method, for example, in an organic solvent (eg chloroform, dichloromethane, diethyl ether, tetrahydrofuran or dimethoxyethane etc.) or in the absence of a solvent, a base (eg , Pyridine, triethylamine, dimethylaniline, N, N-dimethylaminopyridine or N, N-diisopropylethylamine) in the presence or absence of a dehydrating agent (eg, thionyl chloride, trifluoroacetic anhydride, acetic anhydride, dipentoxide).
- a dehydrating agent eg, thionyl chloride, trifluoroacetic anhydride, acetic anhydride, dipentoxide.
- the reaction is carried out in the presence of phosphorus or (methoxycarbonylsulfamoyl) triethylammonium
- the aromatic nucleophilic substitution reaction in the reaction scheme 2 can be carried out by a known method.
- an organic solvent eg, N, N-dimethylacetamide, N, N-dimethylformamide, tetrahydrofuran, acetonitrile, 2 1 to 10 equivalents of acetoxime, a base (eg, tert-butoxy potassium, tert-butoxy sodium, potassium carbonate, cesium carbonate, sodium hydrogen carbonate or triphosphate) in propanol or dimethyl sulfoxide or a mixed solvent thereof. It is carried out by reacting at room temperature to 120 ° C. in the presence of potassium or the like).
- the deprotection reaction in Reaction Scheme 2 can be carried out by a known method, for example, the deprotection reaction under acidic conditions.
- an organic solvent eg, dichloromethane, chloroform, dioxane, ethyl acetate, methanol, isopropyl alcohol, tetrahydrofuran, anisole, etc.
- an organic acid eg, acetic acid, trifluoroacetic acid, methanesulfonic acid or p-tosylic acid
- It is carried out at 0-100 ° C. in an inorganic acid (eg hydrochloric acid or sulfuric acid etc.) or a mixture thereof (eg hydrogen bromide / acetic acid etc.) in the presence or absence of 2,2,2-trifluoroethanol.
- the bromination reaction in Reaction Scheme 2 can be carried out by a known method, for example, in an organic solvent (eg, dichloromethane, chloroform, tetrahydrofuran, acetonitrile, dioxane, ethyl acetate, acetic acid, etc.), 1-10, etc.
- an organic solvent eg, dichloromethane, chloroform, tetrahydrofuran, acetonitrile, dioxane, ethyl acetate, acetic acid, etc.
- Amount of brominating agent eg trimethylsilyl bromide (TMSBr), bromine, hydrobromic acid or phosphorus tribromide etc.
- catalyst eg copper (II) bromide or lithium bromide etc.
- a compound used as a starting material, a compound or a reagent to be added for example, a compound represented by the general formula (IV-3) or general formula (IV-5) and an alkylation reaction or reaction
- the compound used in step 2 is known or can be produced according to a known method or a method described in Examples.
- compounds having optical activity can be produced by using starting materials or reagents having optical activity, or by optically resolving a racemic intermediate, and then converting the compound to be used in the present invention. It can also be produced by derivatizing or optically resolving a racemic compound.
- This method of optical resolution is known, and for example, after forming a salt / complex with another optically active compound and performing recrystallization, the desired compound is isolated or directly using a chiral column or the like. Examples of the method of separation include the following.
- reaction involving heating can be carried out using a water bath, an oil bath, a sand bath or a microwave, as will be apparent to those skilled in the art.
- a solid-phase supported reagent supported on a high-molecular polymer for example, polystyrene, polyacrylamide, polypropylene, polyethylene glycol, etc.
- a high-molecular polymer for example, polystyrene, polyacrylamide, polypropylene, polyethylene glycol, etc.
- the reaction product is a conventional purification means, for example, distillation under normal pressure or reduced pressure, high performance liquid chromatography using silica gel or magnesium silicate, thin layer chromatography, ion exchange resin, It can be purified by a method such as scavenger resin or column chromatography, washing or recrystallization. Purification may be carried out for each reaction or may be carried out after the completion of some reactions.
- the compound of the present invention has a sufficiently low toxicity and can be safely used as a pharmaceutical.
- the compound of the present invention Since the compound of the present invention has an agonistic activity against STING, it can be formulated as an effective suppressive agent for cancer or infectious disease progression, suppressive recurrence or therapeutic agent.
- cancer treatment refers to, for example, (a) reduction of cancer cell proliferation, (b) reduction of symptoms caused by cancer, and quality of life of cancer patients. In order to (c) reduce the dose of other anti-cancer drug or cancer therapeutic adjuvant that has already been administered, and / or (d) to prolong the survival of cancer patients.
- Including treatment “suppressing cancer progression” means delaying the progression of cancer, stabilizing the symptoms associated with cancer, and slowing the progression of symptoms.
- the term “suppressing recurrence” means preventing cancer recurrence prophylactically in a patient whose cancer lesion has been completely or substantially eliminated or removed by cancer treatment or surgical resection of cancer.
- the compound of the present invention is (a) a cancer patient whose therapeutic effect by another anticancer agent is insufficient or insufficient, or a cancer patient who is exacerbated after treatment with another anticancer agent, (b) radical or unresectable , Metastatic, recurrent, refractory and / or distant metastatic cancer patients, (c) TPS or CPS is 50% or more, 25% or more, 10% or more, 5% or more or 1% or more, Cancer patients, (d) cancer patients with MSI-H or dMMR, (e) BRAF V600E mutation-positive malignant melanoma or non-small cell lung cancer patients, (f) EGFR gene mutation-positive or ALK fusion gene-positive Or (g) TMB is prevalent in cancer patients.
- the compound of the present invention is (a) a cancer patient who has no history of treatment with other anticancer agents, (b) TPS or CPS is less than 50%, less than 25%, less than 10%, less than 5%. Or less than 1% cancer patients, (c) cancer patients without MSI-H and / or dMMR, or with MSI-L, (d) BRAF V600 wild type malignant melanoma or non-small When more prescription is required for patients with cell lung cancer, (e) non-small cell lung cancer with EGFR mutation negative and / or ALK fusion gene negative, or (f) cancer with low TMB frequency There is also.
- it can be prescribed as postoperative adjuvant therapy to prevent recurrence or metastasis of cancer after surgical resection, or as preoperative adjuvant therapy performed before surgical resection.
- the “other anticancer agent” is an anticancer agent described in the section “combination or combination agent” below, that is, an alkylating agent, a platinum preparation, an antimetabolite (for example, folic acid metabolism).
- Antagonist for example, pyridine metabolism inhibitor and purine metabolism inhibitor
- ribonucleotide reductase inhibitor for example, nucleotide analogue
- topoisomerase inhibitor for example, folic acid metabolism
- microtubule polymerization inhibitor for example, microtubule depolymerization inhibitor
- antitumor antibiotic for example, cytokine preparation
- cytokine preparation anti The drugs exemplified as the hormonal drug, the molecular target drug and the cancer immunotherapeutic drug can be mentioned.
- Cancers targeted by the compound of the present invention for suppression of progression, suppression of recurrence and / or treatment include any solid cancers and hematological cancers.
- solid cancers epithelial cell cancers include, for example, malignant melanoma.
- non-small cell lung cancer e.g, squamous non-small cell lung cancer and non-squamous non-small cell lung cancer
- small cell lung cancer head and neck cancer (eg, oral cavity) Cancer, nasopharyngeal cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, salivary gland cancer and tongue cancer), renal cell carcinoma (eg clear cell renal cell carcinoma), breast cancer, ovarian cancer (eg serous ovarian cancer) And clear cell adenocarcinoma of the ovary), nasopharyngeal cancer, uterine cancer (eg cervical cancer and endometrial cancer), anal cancer (eg anal canal cancer), colon cancer (eg MSI-H and / or dMMR positive colon) Cancer), rectal cancer, colon cancer, hepatocellular carcinoma, esophageal cancer Gastric cancer, e
- sarcomas include bone and soft tissue sarcomas (eg, Ewing sarcoma, childhood rhabdomyosarcoma, leiomyosarcoma of the uterine body, chondrosarcoma, lung sarcoma, osteosarcoma, congenital fibrosarcoma) and Examples include Kaposi's sarcoma.
- hematological cancers include multiple myeloma, malignant lymphoma (for example, non-Hodgkin lymphoma (for example, follicular lymphoma, precursor B-cell lymphoblastic lymphoma, chronic B lymphocytic leukemia, nodal marginal zone).
- malignant lymphoma for example, non-Hodgkin lymphoma (for example, follicular lymphoma, precursor B-cell lymphoblastic lymphoma, chronic B lymphocytic leukemia, nodal marginal zone).
- B-cell lymphoma diffuse large B-cell lymphoma, MALT lymphoma, splenic primary marginal zone B-cell lymphoma, hairy cell leukemia, primary mediastinal large B-cell lymphoma, Burkitt lymphoma, mantle cells Lymphoma, mycosis fungoides, Sézary syndrome, chronic or acute lymphocytic leukemia, precursor T cell lymphoblastic lymphoma, chronic T lymphocytic leukemia, large granular T cell leukemia, large granular NK cell leukemia, peripheral T cell lymphoma, extranodal NK / T cell lymphoma, adult T cell leukemia, angiocentric lymphoma, intestinal T cell lymphoma, Hodgkin-like / Hodoki Related anaplastic large cell lymphoma, B cell lymphoblastic leukemia, T cell lymphoblastic leukemia and lymphoplasmacytoid lymphoma) and Hodgkin
- cancers targeted by the compound of the present invention for suppression of progression, suppression of recurrence and / or treatment include pediatric cancer and cancer of unknown primary origin.
- Infections targeted by the compound of the present invention for inhibition of progression, inhibition of recurrence and / or treatment include symptoms caused by viral infection, parasitic infection, bacterial infection or fungal infection.
- viral infections include adenovirus, arenavirus, bunyavirus, calicivirus, coronavirus, filovirus, hepadnavirus, herpesvirus, orthomyxovirus, papovavirus, paramyxovirus, parvovirus, picornavirus, Poxvirus, reovirus, retrovirus, rhabdovirus, togavirus, papillomavirus (eg human papillomavirus (HPV)), human immunodeficiency virus (HIV), poliovirus, hepatitis virus (eg hepatitis A virus) (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV), hepatitis E virus (HEV)), smallpox virus (eg, smallpox, smallpox), Vaccinia virus, Influenza virus, rhinovirus, dengue virus, equine encephalitis virus, rubella virus, yellow fever virus, nor
- Examples of parasitic infections include acanthamoeba keratitis, amebiasis, ascariasis, babesiosis, valantidiasis, raccoon roundworm, Chagas disease, hepatic dystomatosis, cochleomyia, cryptosporidia, cleft head streptococcal disease, and Medina.
- Insectosis echinococcosis, elephantiasis, pinworm, liver fluke, hypertrophic liver fluke, filariasis, giardiasis, jaw-and-mouth disease, tapeworm disease, isosporosis, katayama fever, leishmaniasis, lime.
- Examples of the bacterial infection include tubercle bacillus, anthrax, pathogenic bacterium, food poisoning bacterium, salmonella, staphylococcus, streptococcus, tetanus bacterium, mycobacteria, tetanus bacterium, plague bacterium, anthrax and methicillin-resistant Staphylococcus aureus Infectious diseases caused by infection with antibiotic-resistant bacteria such as MRSA), Clostridium difficile, and other infectious bacteria.
- fungal infections include Aspergillus spp., Blastomyces dermatitisdis, Candida yeast (eg Candida albicans), Coccidioides, Cryptococcus neoformans, Cryptococcus gatti, dermatophytes, Fusarium spp. Infectious diseases caused by infections of Kapsulatum, Phytophthora, Pneumocystis girobesi, Sporothrix schenky, Exerohyrum or Cladosporium.
- the compound of the present invention or a pharmaceutical composition containing the compound of the present invention as an active ingredient is (a) an effect of suppressing the progression of cancer or infectious disease, suppressing recurrence and / or a therapeutic effect. And / or (d) for reducing the dose of other drugs that are prescribed in combination, (c) for reducing the side effects of other drugs that are prescribed in combination, and / or (d). ) In order to enhance the immunopotentiating effect of the other drug to be prescribed in combination, that is, it may be prescribed in combination with one or more other drugs as an adjuvant.
- the dosage form in the case of prescribing in combination with other drug may be a combination drug form in which both components are mixed in one preparation, or a dosage form as separate preparations.
- Good. By the combined use, prevention, suppression of symptom progression, recurrence suppression and / or therapeutic effects of other drugs can be supplemented, and the dose or frequency of administration can be maintained or reduced.
- the compound of the present invention and the like and the other drug are separately prescribed, they may be simultaneously administered for a certain period of time, and then only the compound of the present invention or the other drug may be administered.
- the compound of the present invention or the like may be administered first, and then other drug may be administered after the administration, or the other drug may be administered first and the compound of the present invention or the like may be administered later, or In the above administration, there may be a certain period in which both drugs are administered simultaneously.
- the administration method of each drug may be the same or different. Depending on the nature of the drug, it can be provided as a kit of a drug product containing the compound of the present invention and a drug product containing another drug.
- the dose of the other drug can be appropriately selected based on the dose clinically used.
- other drugs may be administered in combination of any two or more kinds at an appropriate ratio. Further, the above-mentioned other drugs include not only those which have been found to date but those which will be found in the future.
- an anticancer agent that can be used in combination with the compound of the present invention, for example, an alkylating agent (for example, dacarbazine, Nimustine, Temozolomide, Fotemustine, bendamustine, Cyclophosphamide, Ifosfamide, Carmustine, Chlorambucil and Procarbazine etc.), platinum preparations (eg Cisplatin, Carboplatin, Nedaplatin and oxaliplatin etc.), antimetabolites (eg folate antimetabolites (eg Pemetrexed, leucovorin and Methotrexate etc.), pyridine metabolism inhibitors (eg TS-1) (Registered trademark), 5-fluorouracil, UFT, Carmofur, Doxifluridine, FdUrd, Cytarabine and Capecitabine etc.), purine metabolism inhibitors (eg Fludarabine, Cladribine and Nelarabine etc.), ribonucleotide reduct
- examples of the molecular target drug include ALK inhibitors (eg Crizotinib, Ceritinib, Ensartinib, Alectinib and Lorlatinib), BCR-ABL inhibitors (eg Imatinib and Dasatinib), EGFR inhibitors (eg Erlotinib, EGF816).
- ALK inhibitors eg Crizotinib, Ceritinib, Ensartinib, Alectinib and Lorlatinib
- BCR-ABL inhibitors eg Imatinib and Dasatinib
- EGFR inhibitors eg Erlotinib, EGF816).
- Mek inhibitors eg Cobimetinib, Binimetinib, Selumetinib and Trametinib
- CDK inhibition Eg Dinaciclib, Abemaciclib, Palbociclib and trilaciclib
- Btk inhibitors eg ONO-4059, Ibrutinib and Acalabrutinib
- PI3K- ⁇ / ⁇ inhibitors eg TGR-1202, INCB050465 and IPI-549
- JAK- JAK-.
- ERK inhibitor eg SCH900353
- TGFbR1 inhibitor eg Galunisertib
- Cancer cell stemness kinase inhibitor eg Amcasertib
- FAK inhibitor eg, Defactinib
- Syk / FLT3 dual inhibitor eg TAK-659
- ATR inhibitor eg AZD6738
- Wee1 kinase inhibitor eg AZD1775
- multi-tyrosine kinase inhibitor eg Sunitinib, Pazopanib, Cabozantinib, Regorafenib, Nintedanib, Sitravatinib and Midostaurin
- mTOR inhibitors eg Temsirolimus, Everolimus, Vistusertib, Irinotecan
- HDAC inhibitors eg Vorinostat, Romidepsin, Entinostat, Chidamide, Mocetinostat
- EZH2 inhibitors eg tazemetostat
- galectin-3 inhibitors eg GR-MD-02
- STAT3 inhibitors eg Napabucasin
- DNMT inhibitors eg Azacitidine
- SMO inhibitors eg For example, Vismodegib
- Hsp90 inhibitor eg, XL888
- ⁇ -tubulin specific inhibitor eg, Glaziovianin A, Plinabulin
- HIF2 ⁇ inhibitor eg, PT2385
- glutaminase inhibitor eg, CB-839)
- E3 ligase inhibitors eg Avadomide
- Nrf2 activators eg Omaveloxolone
- arginase inhibitors eg CB- 1158
- cell cycle inhibitors eg Trabectedin
- Ephrin B4 inhibitors eg sEphB4-HAS
- IAP antagonists eg Birinapant
- anti-CD38 antibody for example, Daratumumab
- anti-DR5 antibody for example, DS-8273a
- anti-CA125 antibody for example, Oregovomab
- anti-DLL4 antibody for example, Demcizumab
- anti-fucosyl GM1 antibody for example.
- BMS-986012 anti-gpNMB antibody (eg Glembatumumab vedotin), anti-Mesothelin antibody ( For example, BMS-986148), anti-MMP9 antibody (eg Andecaliximab), anti-GD2 antibody (eg Dinutuximab- ⁇ ), anti-c-Met antibody (eg ABT-399), anti-FOLR1 antibody (eg Mirvetuximab soravtansine), Anti-Ang2-VEGF bispecific antibody (eg Vanucizumab), anti-CD30-CD16A bispecific antibody (eg AFM13), anti-CD79b antibody (eg Polatumazumab Vedotin), anti-FAP antibody / IL-2 fusion protein (eg For example, RO6874281), anti-CEA antibody / IL-2 fusion protein (eg Cergutuzumab amunaleukin), anti-CEA-CD3 bispecific antibody (eg RO695868
- anti-PD-1 antibody eg, Nivolumab, Cemiplimab (REGN-2810), Pembrolizumab (MK-3475), Spartalizumab (PDR-001), Tislelizumab (BGB-A317), AMP-514 (MEDI0680), Dostarlimab (ANB011 / TSR-042), Tripalimab (JS001), Camrelizumab (SHR-1210), Genolimzumab (CBT-501), Sintilimab (IBI308), STI-A1110, ENUM 388D4, ENUM 244C8, GLS010, MGA012, AGEN2034, CS1003, HLX10, BAT-1306, AK105, AK103, BI754091, LZM009, CMAB819, Sym021, GB226, SSI-361, JY034, HX008, ABBV181, BCD
- anti-PD-1 antibody eg, Nivolum
- anti-PD-L1 antibody for example, Atezolizumab (RG7446 / MPDL3280A), Avelumab (PF-06834635 / MSB0010718C), Durvalumab (MEDI4736), BMS-936559, STI-1014, KN035, LY3300054, HLX20, SHR-1316, CS1001, MSB2311, BGB-A333, KL-A167, CK-301, AK106, AK104, ZKAB001, FAZ053, CBT-502, JS003 and CX-072, etc.), PD-1 overlay Agent (for example, each compound of AUNP-12, BMS-M1 to BMS-M10 (WO2014 / 151634, WO2016 / 039749, WO2016 / 057624, WO2016 / 077518, WO2016 / 100285, WO2016 / 100608, WO2016 / 126646,
- PD-L1 / VISTA antagonist for example, CA-170, etc.
- PD-L1 / TIM3 antagonist eg CA-327 etc.
- anti-PD-L2 antibody eg PD- 1 fusion protein, PD-L2 fusion protein (eg AMP-224 etc.)
- anti-CTLA-4 antibody eg Ipilimumab (MDX-010), AGEN1884 and Tremelimumab etc.
- anti-LAG-3 antibody eg Relatlimab (BMS -986016 / ONO-4482
- LAG525, REGN3767 and MK-4280 LAG-3 fusion protein
- anti-Tim3 antibody eg MBG453 and TSR-022 etc.
- anti-KIR antibody eg Lirilumab (BMS-986015 / ONO-4483
- CSF-1R inhibitor eg, Cabiralizumab (FPA008 / BMS-986227 / ON O-4687), Emactuzumab (RG7155 / RO5509554), LY3022855, MCS-110, IMC-CS4, AMG820, Pexidartinib, BLZ945 and ARRY-382, etc., anti-OX40 antibody (for example, MEDI6469, PF-04518600, MEDI0562, MEDI6383, MEDI6383, Efizonerimod, GSK3174998, BMS-986178, MOXR0916 etc.), anti-HVEM antibody, anti-CD27 antibody (eg Varlilumab (CDX-1127) etc.), anti-GITR antibody (eg MK-4166, INCAGN01876, GWN323 and TRX-518 etc.).
- anti-OX40 antibody for example, MEDI6469, PF-04518600, MEDI0562
- Anti-CD28 antibody, anti-CCR4 antibody eg Mogamulizumab etc.
- anti-B7-H3 antibody eg Enoblituzumab etc.
- anti-ICOS agonist antibody eg JTX-2011 and GSK3359609 etc.
- anti-CD4 antibody eg MTRX-antibody
- Anti-DEC-205 antibody / NY-ES O-1 fusion protein eg CDX-1401 etc.
- anti-SLAMF7 antibody eg Elotuzumab etc.
- anti-CD73 antibody eg Oleclumab and BMS-986179 etc.
- anti-CD122 antibody eg NKTR-214 etc.
- Anti-CD40 agonist antibody eg ABBV-428, APX005M and RO7009789 etc.
- IDO inhibitor eg Epacadostat, Indoximod and BMS-986205 etc.
- TLR agonist eg Motolimod, CMP-001, G100, IMO-2125, etc.
- adenosine A2A receptor antagonist eg Preladenant, AZD4635, PBF509 and CPI-444 etc.
- anti-NKG2A antibody eg Monalizumab etc.
- anti-CSF-1 antibody eg PD
- Nivolumab can be produced according to the method described in WO2006 / 121168
- Pembrolizumab can be produced according to the method described in WO2008 / 156712, BMS-936559, WO2007 / 005874 Can be produced according to the method described in
- Ipilimumab can be produced according to the method described in WO2001 / 014424.
- antibody drugs include, for example, anti-IL-1 ⁇ antibody (eg, Canakinumab etc.) and anti-CCR2 antibody (eg, Plozalizumab etc.) and the like.
- the compound of the present invention or the combination of the compound of the present invention and another drug is usually administered systemically or locally, orally or parenterally.
- the dose varies depending on the age, body weight, symptoms, therapeutic effect, administration method, treatment time, etc., but usually, it is orally administered once per adult in the range of 1 ng to 2,000 mg once a day. Or, it is parenterally administered once per adult in the range of 0.1 ng to 200 mg once to several times a day, or is continuously administered intravenously in the range of 30 minutes to 24 hours per day. To be done.
- a dose smaller than the above dose may be sufficient in some cases, or a dose exceeding the range may be required in some cases.
- solid preparations for oral administration include tablets, pills, capsules, powders and granules, and capsules include hard capsules and soft capsules.
- the solid preparation may be prepared, for example, by formulating the compound of the present invention together with a pharmaceutically acceptable carrier.
- a pharmaceutically acceptable carrier used for formulating the solid agent include excipients (eg, lactose, mannitol, glucose, microcrystalline cellulose and starch), binders (eg, hydroxy). Propylcellulose, polyvinylpyrrolidone and magnesium aluminometasilicate, etc.), disintegrants (eg, calcium fibrin glycolate), lubricants (eg, magnesium stearate), stabilizers, solubilizers (eg, glutamic acid, etc.) Aspartic acid, etc.) and the like.
- excipients eg, lactose, mannitol, glucose, microcrystalline cellulose and starch
- binders eg, hydroxy
- disintegrants eg, calcium
- a coating agent for example, sucrose, gelatin, hydroxypropylcellulose and hydroxypropylmethylcellulose phthalate
- it may be contained in a capsule containing gelatin.
- the liquid preparation for oral administration may be in any form such as aqueous solution, suspension, emulsion, syrup and elixir.
- the compound of the present invention may be diluted with a diluent (for example, purified water, ethanol or It may be dissolved, suspended or emulsified in a mixed solution thereof, etc. to prepare a preparation.
- the liquid preparation may contain a wetting agent, a suspending agent, an emulsifying agent, a sweetening agent, a flavoring agent, an aromatic agent, a preservative or a buffering agent.
- the sustained-release preparation for oral administration may include, for example, a gel-forming substance, and examples of the gel-forming substance include gum arabic, agar, polyvinylpyrrolidone, sodium alginate, propylene glycol alginate and carboxyvinyl polymer. , Carboxymethylcellulose, sodium carboxymethylcellulose, guar gum, gelatin, hydroxypropylmethylcellulose, hydroxypropylcellulose, polyvinyl alcohol, methylcellulose or hydroxyethylmethylcellulose.
- the injection or infusion for parenteral administration may be in the form of an aqueous solution, suspension or emulsion, and may be used as a solvent (for example, distilled water for injection, physiological saline, glucose solution and By adding an isotonic solution (for example, a solution of sodium chloride, potassium chloride, glycerin, mannitol, sorbitol, boric acid, borax, propylene glycol, etc.), it is dissolved, suspended or emulsified so that it can be used. It may be formulated as a solid formulation with a pharmaceutically acceptable carrier.
- a solvent for example, distilled water for injection, physiological saline, glucose solution
- an isotonic solution for example, a solution of sodium chloride, potassium chloride, glycerin, mannitol, sorbitol, boric acid, borax, propylene glycol, etc.
- an isotonic solution for example, a solution of sodium chloride, potassium chloride,
- examples of the “pharmaceutically acceptable carrier” include stabilizers (eg, various amino acids, albumin, globulin, gelatin, mannitol, glucose, dextran, ethylene glycol, propylene glycol, polyethylene glycol, ascorbic acid, and sulfite).
- stabilizers eg, various amino acids, albumin, globulin, gelatin, mannitol, glucose, dextran, ethylene glycol, propylene glycol, polyethylene glycol, ascorbic acid, and sulfite.
- solubilizers eg alcohol (eg ethanol)
- polyalcohols eg propylene glycol, polyethylene glycol etc.
- nonionic Surfactants eg, Polysorbate 20 (registered trademark), Polysorbate 80 (registered trademark), HCO-50, etc.
- suspending agents eg, glyceryl monostearate, monostea
- emulsifiers eg gum arabic, sodium alginate and tragacanth
- soothing agents eg benzyl alcohol, chlorobutanol and sorbitol
- buffers Formula example, phosphate buffer, acetate buffer, borate buffer, carbonate buffer, citrate buffer, Tris buffer, glutamate buffer and epsilon amino
- antioxidants for example, (1) water-soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite and sodium sulfite, (2) ascorbyl palmitate, butylated hydroxyanisole, Use of oil-soluble antioxidants such as butylated hydroxytoluene, lecithin, propyl gallate and ⁇ -tocopherol and (3) metal chelating agents such as citric acid, ethylenediaminetetraacetic acid, sorbitol, tartaric acid and phosphoric acid. You can
- the injection or infusion can be manufactured by sterilizing it in the final step or by aseptic operation method, for example, sterilizing by filtering with a filter or the like, and then filling in an aseptic container.
- the injectable solution or infusion solution can be used by dissolving a sterile powder obtained by vacuum drying and freeze-drying (which may include a powder of a pharmaceutically acceptable carrier) in an appropriate solvent before use. .
- the dosage form of the external preparation for parenteral administration includes, for example, sprays, inhalants, sprays, aerosols, ointments, gels, creams, poultices, patches, liniments and nasal drops. Can be mentioned.
- Such propellants, inhalants and sprays include buffers such as sodium chloride, sodium citrate or citric acid which are isotonic with stabilizers such as sodium bisulfite in addition to commonly used diluents. It may also contain isotonic agents such as The method for producing the spray agent is described in detail, for example, in U.S. Pat. Nos. 2,868,691 and 3,095,355.
- the inhalant includes an inhalation liquid or an inhalation powder, and the liquid may be in a form of being dissolved or suspended in water or another appropriate medium before use.
- These inhalants are manufactured according to known methods. For example, in the case of inhalation liquids, preservatives (such as benzalkonium chloride and paraben), coloring agents, buffers (such as sodium phosphate). And sodium acetate, etc.), an isotonicity agent (eg, sodium chloride and concentrated glycerin, etc.), a thickener (eg, carboxyvinyl polymer, etc.), and an absorption enhancer, etc. are appropriately mixed if necessary.
- preservatives such as benzalkonium chloride and paraben
- coloring agents such as sodium phosphate). And sodium acetate, etc.
- an isotonicity agent eg, sodium chloride and concentrated glycerin, etc.
- a thickener eg, carboxyvinyl polymer, etc.
- lubricants eg stearic acid and salts thereof
- binders eg starch and dextrin
- excipients eg lactose and cellulose
- colorants eg lactose and cellulose
- a preservative for example, benzalkonium chloride, paraben, etc.
- an absorption promoter for example, an absorption promoter, and the like
- a nebulizer for example, an atomizer and a nebulizer
- an inhaler administration device for powder medicine is usually used when administering a powder medicine for inhalation.
- the ointment is prepared by a known or normally used formulation, for example, by mixing or melting the compound of the present invention in an ointment base.
- the ointment base is selected from known or commonly used ones, for example, higher fatty acid or higher fatty acid ester (for example, adipic acid, myristic acid, palmitic acid, stearic acid, oleic acid, adipic acid ester, Myristic acid ester, palmitic acid ester, stearic acid ester, oleic acid ester, etc.), waxes (eg, beeswax, whale wax and ceresin, etc.), surfactants (eg, polyoxyethylene alkyl ether phosphate, etc.), higher grades Alcohols (eg cetanol, stearyl alcohol and cetostearyl alcohol etc.), silicone oils (eg dimethyl polysiloxane etc.), hydrocarbons (eg hydrophilic petrolatum, white petrolatum, purified
- ethylene glycol diethylene glycol, propylene glycol, polyethylene glycol and macrogol
- vegetable oils eg castor oil, olive oil, sesame oil and turpentine oil
- animal oils eg mink oil, egg yolk oil, squalane and squalene etc.
- water an absorption promoter and an anti-rash agent
- it may contain a moisturizing agent, a preservative, a stabilizer, an antioxidant or a flavoring agent.
- the gel is prepared by a known or commonly used formulation, for example, by melting the compound of the present invention in a gel base.
- the gel base is selected from known or commonly used ones, and examples thereof include lower alcohols (eg, ethanol and isopropyl alcohol), gelling agents (eg, carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose and Ethyl cellulose and the like), a neutralizing agent (for example, triethanolamine and diisopropanolamine and the like), a surfactant (for example, polyethylene glycol monostearate and the like), gums, water, an absorption promoter and an anti-rash agent 1 It is used as a mixture of two or more species. Furthermore, a preservative, an antioxidant or a flavoring agent may be included.
- the cream is prepared by a known or commonly used formulation, and is produced, for example, by melting or emulsifying the compound of the present invention in a cream base.
- the cream base is selected from known or commonly used ones, for example, higher fatty acid ester, lower alcohol, hydrocarbons, polyhydric alcohol (eg, propylene glycol and 1,3-butylene glycol).
- a higher alcohol eg, 2-hexyldecanol and cetanol
- an emulsifier eg, polyoxyethylene alkyl ethers and fatty acid esters
- water an absorption promoter and an anti-rash agent Used.
- a preservative, an antioxidant or a flavoring agent may be included.
- the poultice is prepared by a known or commonly used formulation, for example, the compound of the present invention is melted in a poultice base, and a kneaded product is spread and applied on a support.
- the poultice base is selected from known or commonly used ones, and examples thereof include thickeners (for example, polyacrylic acid, polyvinylpyrrolidone, gum arabic, starch, gelatin and methylcellulose), wetting agents (for example, , Urea, glycerin, propylene glycol, etc.), a filler (for example, kaolin, zinc oxide, talc, calcium and magnesium, etc.), water, a solubilizing agent, a tackifier, and an antifoggant Used. Furthermore, a preservative, an antioxidant or a flavoring agent may be included.
- the patch is prepared by a known or commonly used formulation, for example, the compound of the present invention is melted in a patch base and spread-coated on a support.
- the patch base is selected from known or commonly used bases, for example, one or more selected from polymer bases, fats and oils, higher fatty acids, tackifiers and anti-rash agents are mixed. Used. Furthermore, a preservative, an antioxidant or a flavoring agent may be included.
- the liniment is prepared by a known or commonly used formulation.
- the compound of the present invention may be prepared by adding the compound of the present invention to water, alcohol (eg, ethanol and polyethylene glycol), higher fatty acid, glycerin, soap, emulsifier and suspending agent. It is prepared by dissolving, suspending or emulsifying at least one selected from Furthermore, a preservative, an antioxidant or a flavoring agent may be included.
- Hi-flash SI silica gel (manufactured by Yamazen Co., Ltd.)
- Hi-flash NH Aminopropyl group-supporting silica gel (manufactured by Yamazen Co., Ltd.)
- the compound names used in the present specification are generally computer programs for naming according to IUPAC rules, ACD / Name (registered trademark) (version 6.00, manufactured by Advanced Chemistry Development Inc.), Chemdraw Ultra (version 12.0, manufactured by CambridgeSoft) or Lexichem Toolkit (version 1.4.2, manufactured by OpenEye Scientific Software), or named according to IUPAC nomenclature.
- Sodium tert-butoxide (9.02 g) was added to a solution of propan-2-one oxime (6.86 g) in THF (100 mL) at room temperature and stirred for 1 hour (hereinafter, this solution is referred to as an oxime solution).
- the oxime solution was added dropwise to a solution of the compound (26.5 g) produced in Reference Example 2 in THF (90 mL) over 15 minutes under ice cooling. After the temperature of the reaction solution was raised to room temperature, it was further stirred for 30 minutes. A saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate.
- Metachloroperbenzoic acid (containing about 30% water) (1.41 g) was added to a dichloromethane solution (8.0 mL) of the compound (500 mg) produced in Reference Example 8 under ice cooling. After stirring under ice-cooling for 1 hour, 10% sodium thiosulfate aqueous solution and saturated sodium hydrogencarbonate aqueous solution were added to stop the reaction. The solution was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over sodium sulfate, and concentrated.
- Example 2 4- (4-Amino-2-fluoro-5-methoxyphenyl) -7- (1H-pyrazol-4-yl) isoxazolo [4,5-c] pyridin-3-amine hydrochloride under nitrogen atmosphere A solution of the compound (235 mg) produced in Reference Example 6 in 1,4-dioxane (7.1 mL) was added to 5-fluoro-2-methoxy-4- (4,4,5,5-tetramethyl-1,3).
- Example 3 1- (2-amino-5- (3-amino-7- (1H-pyrazol-4-yl) isoxazolo [4,5-c] pyridin-4-yl) -4-fluorophenyl) ethane
- NMP 1-methyl-2-pyrrolidone
- Example 4 4- (4-Amino-2-fluoro-5- (methylthio) phenyl) -7- (1H-pyrazol-4-yl) isoxazolo [4,5-c] pyridin-3-amine hydrochloride Reference Instead of the methyl 2-amino-4-fluoro-5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzoate prepared in Example 12 (1), Reference Example 12 Using the boronic acid ester prepared in (2) and performing the same operation as in Reference Example 13, the obtained 4- (4-amino-2-fluoro-5- (methylthio) phenyl) -7- (1 -(Tetrahydro-2H-pyran-2-yl) -1H-pyrazol-4-yl) isoxazolo [4,5-c] pyridin-3-amine (76.6 mg) in THF solution (1.5 mL) at room temperature Under hydrochloric acid (10% Nord solution, 1.1 mL) was added and stirred
- Example 4 4- (4-amino-2-chloro-5- (methylthio) phenyl) -7- (1H-pyrazol-4-yl) isoxazolo [4,5-c] pyridin-3-amine Hydrochloride LCMS retention time (min): 0.63; MS (ESI, Pos.): 373 (M + H) + ; 1 H-NMR (DMSO-d 6 ): ⁇ 9.08 (s, 1H), 8.43 (s, 2H), 7.40 (s, 1H), 6.93 (s, 1H), 2.37 (s, 3H).
- Example 4 4- (2-Fluoro-5-methoxy-4-nitrophenyl) -7- (1H-pyrazol-4-yl) isoxazolo [4,5-c] pyridin-3-amine trifluoro Acetate LCMS retention time (min): 0.92; MS (ESI, Pos.): 371 (M + H) + .
- Example 5 4- (4-Amino-2-fluoro-5- (methylsulfinyl) phenyl) -7- (1H-pyrazol-4-yl) isoxazolo [4,5-c] pyridin-3-amine trifluoro Acetate
- sodium perborate tetrahydrate (6.16 mg)
- acetic acid 0.5 mL
- methanol 0.2 mL
- the present compound (5.0 mg) was obtained.
- Example 6 2-Amino-5- (3-amino-7- (1H-pyrazol-4-yl) isoxazolo [4,5-c] pyridin-4-yl) -4-fluorobenzoic acid
- THF 0.2 mL
- methanol 0.1 mL
- sodium hydroxide aqueous solution 81 ⁇ L was added dropwise at room temperature, and the mixture was stirred for 3 hours.
- Example 7 4- (4-Amino-2-fluoro-5-methoxyphenyl) -7- (3-methyl-1H-pyrazol-4-yl) isoxazolo [4,5-c] pyridin-3-amine tri Fluoroacetate 1- (Tetrahydro-2H-pyran-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -1H-pyrazole instead of Using (1- (tert-butoxycarbonyl) -3-methyl-1H-pyrazol-4-yl) boronic acid, the same operation as in Reference Example 6 ⁇ Reference Example 13 ⁇ Example 2 was carried out, and the following physical property values were obtained. To obtain the compound of the present invention. LCMS retention time (min): 0.56; MS (ESI, Pos.): 355 (M + H) + .
- Example 8 1- (2-amino-5- (3-amino-7- (1H-pyrazol-4-yl) isoxazolo [4,5-c] pyridin-4-yl) -4-hydroxyphenyl) ethane 1-one trifluoroacetate 1- (2-amino-5- (3-amino-7- (1- (tetrahydro-2H-pyran-2-yl) -1H-) prepared in the process described in Example 3 Pyrazol-4-yl) isoxazolo [4,5-c] pyridin-4-yl) -4-fluorophenyl) ethan-1-one (150 mg) in 1,3-dimethyl-2-imidazolidinone (3 mL) solution Acetohydroxamic acid (258 mg) and potassium carbonate (618 mg) were added to and the mixture was stirred at 80 ° C.
- Example 10 (1) to 10 (12) Substitute for the methyl 2-amino-5- (3-amino-7- (1H-pyrazol-4-yl) isoxazolo [4,5-c] pyridin-4-yl) -4-fluorobenzoate prepared in Example 1. Using a compound corresponding to, the same operation as in Reference Example 18 ⁇ Example 10 was carried out to obtain a compound of the present invention having the following physical properties.
- Example 10 (4- (4- (5-acetyl-4-amino-2-fluorophenyl) -3-aminoisoxazolo [4,5-c] pyridin-7-yl) -1H- Pyrazol-1-yl) methyl dihydrogen phosphate
- a compound of the present invention (3.9 mg) having the following physical data was obtained.
- Example 10 Ethyl 2-amino-5- (3-amino-7- (1-((phosphonooxy) methyl) -1H-pyrazol-4-yl) isoxazolo [4,5-c] pyridine-4 -Yl) -4-fluorobenzoate
- a compound of the present invention (15.0 mg) having the following physical data was obtained.
- Example 10 (4- (3-Amino-4- (4-amino-5- (ethylcarbamoyl) -2-fluorophenyl) isoxazolo [4,5-c] pyridin-7-yl) -1H -Pyrazol-1-yl) methyl dihydrogen phosphate
- Example 10 (4- (3-amino-4- (4-amino-2-fluoro-5- (methylthio) phenyl) isoxazolo [4,5-c] pyridin-7-yl) -1H- Pyrazol-1-yl) methyl dihydrogen phosphate
- Example 10 (4- (3-amino-4- (4-amino-2-fluoro-5-propionylphenyl) isoxazolo [4,5-c] pyridin-7-yl) -1H-pyrazole- 1-yl) methyl dihydrogen phosphate
- Example 10 (4- (3-Amino-4- (4-amino-2-fluoro-5- (methylsulfonyl) phenyl) isoxazolo [4,5-c] pyridin-7-yl) -1H -Pyrazol-1-yl) methyl dihydrogen phosphate
- Example 10 (4- (3-amino-4- (4-amino-5- (ethylcarbamoyl) -2-chlorophenyl) isoxazolo [4,5-c] pyridin-7-yl) -1H- Pyrazol-1-yl) methyl dihydrogen phosphate acetate or acetate
- Example 10 (4- (4- (5-acetyl-4-amino-2-fluorophenyl) -3-aminoisoxazolo [4,5-c] pyridin-7-yl) -1H- Pyrazol-1-yl) methyl dihydrogen phosphate hydrate
- the compound (100 mg) produced in Example 3 was subjected to the same operation as in Reference Example 18 to give (4- (4- (5-acetyl-4- Amino-2-fluorophenyl) -3-aminoisoxazolo [4,5-c] pyridin-7-yl) -1H-pyrazol-1-yl) methyl di-tert-butyl phosphate (112 mg) was obtained.
- Example 10 Example 10 (1) having the following physical properties and in the form of a hydrate. In addition, it was confirmed from the DSC and TG analysis of the compound of the present invention that it was a hydrate.
- Example 10 (4- (4- (5-acetyl-4-amino-2-fluorophenyl) -3-aminoisoxazolo [4,5-c] pyridin-7-yl) -1H- Pyrazol-1-yl) methyl monohydrogen phosphate monopotassium salt
- acetic acid (1.25 mL)
- a 0.25M aqueous potassium acetate solution (0.43 mL, 1 equivalent). was added and the mixture was stirred at room temperature for 8 hours.
- the obtained suspension was collected by filtration and dried under reduced pressure to obtain the compound of the present invention (43.5 mg) having the following physical properties.
- Example 10 Ethyl 2-amino-5- (3-amino-7- (1-((phosphonooxy) methyl) -1H-pyrazol-4-yl) isoxazolo [4,5-c] pyridine-4 -Yl) -4-fluorobenzoate trifluoroacetate salt or trifluoroacetic acid solvate
- a solution of the compound prepared in Example 4 (6) (2.00 g) in DMF (0.5 mL) was added with cesium carbonate (128 mg) and Di-tert-butyl-chloromethyl phosphate (27 ⁇ L) was added, and the mixture was stirred at room temperature overnight. City water was added to the reaction solution, and the mixture was extracted with ethyl acetate.
- purified water (30 mL) and acetic acid (20 mL) were added, and the mixture was stirred at 60 ° C for 4 hours. It was stirred. The solvent was distilled off under reduced pressure and diluted with ethanol (30 mL).
- Example 11 1- (2-amino-5- (3-amino-7- (1H-pyrazol-4-yl) isothiazolo [4,5-c] pyridin-4-yl) -4-fluorophenyl) ethane 1-one trifluoroacetate
- Example 12 Action on THP1-Dual cells
- THP1-Dual cells (Invivogen) were suspended in RPMI medium to prepare a cell suspension of 2 ⁇ 10 6 cells / mL. 50 ⁇ L of each cell suspension was dispensed into a 96-well plate, and 50 ⁇ L of each 6-20,000 nmol / L compound solution was added. After adding the compound, the mixture was incubated at 37 ° C. for about 24 hours. After the incubation, 10 ⁇ L of cell suspension was collected from each well and mixed with 50 ⁇ L of Quanti-luc (Invivogen). Then, activation of the IRF (Interferon regulatory factor) pathway was measured by detecting luminescence using a microplate reader (Molcular Devices).
- IRF Interferon regulatory factor
- Example 13 Action on THP1-Dual-STING KO cells
- THP1-Dual cells homozygous for the STING gene THP1-Dual-STING KO cells (Invivogen)
- THP1-Dual-STING KO cells Invivogen
- 50 ⁇ L of the cell suspension was dispensed into a 96-well plate, and 50 ⁇ L of a compound solution of 6 to 20,000 nM was further added to the 96-well plate, and the mixture was added at 37 ° C. for about 24 hours.
- 10 ⁇ L of the cell suspension was collected from each well and mixed with 50 ⁇ L of Quanti-luc (Invivogen), after which the activity of the IRF pathway was detected by detecting luminescence using a microplate reader. was measured.
- Example 1 The compound of the present invention shown in Example 1 did not show an IRF activating effect. Therefore, it was shown that the IRF activating action of the compound of the present invention exemplified in Example 1 is based on the agonistic activity on STING by the compound of the present invention.
- Example 14 Evaluation of IDO1 inhibitory activity The evaluation of IDO1 inhibitory activity was carried out using an IDO1 Fluorogenic Inhibitor Screening Assay Kit (BPS Bioscience). Specifically, IDO1 Fluorogenic Reaction Solution was dissolved and 180 ⁇ L was added to each well. Then, 10 ⁇ L of each compound having a concentration of 0.6, 2, 6, 20, 60 and 200 ⁇ mol / L was added. Furthermore, after adding 10 ⁇ L of IDO1 His-Tag solution, the mixture was incubated at room temperature for 1 hour. Next, 20 ⁇ L of Fluorescence Solutioon was added and incubated at 37 ° C. for 4 hours. After standing at room temperature for 10 minutes, fluorescence was measured using a microplate reader (excitation: 400 nm, emission: 510 nm).
- the compound of the present invention shown in Example 1 did not show IDO1 inhibitory activity.
- Example 15 Evaluation of inhibitory activity against various kinases 4 ⁇ mol / L test substance (the compound of the present invention shown in Example 1) solution (4 times the final concentration) was added to assay buffer (20 mmol / L HEPES, 0.01% Triton X). -100, 1 mmol / L DTT, pH 7.5). A 4 ⁇ mol / L substrate / ATP / metal solution (4 times the final concentration) was prepared with a kit buffer (20 mmol / L HEPES, 0.01% Triton X-100, 5 mmol / L DTT, pH 7.5). Various kinase solutions having twice the final concentration were prepared in assay buffer.
- the various kinases used for evaluation are as follows. BTK, KDR, each subtype of PKC ⁇ ⁇ ⁇ , each CDK of CDK2 ⁇ 9, FAK, TIE2, RAF1 and BRAF
- the compound of the present invention shown in Example 1 did not show significant inhibitory activity against any of the evaluated kinases.
- Example 1 The compound shown in Example 1 almost completely suppressed tumor growth at a dose of 3 mg / kg.
- Formulation example 1 The following components are admixed in a conventional method and punched out to obtain 10,000 tablets each containing 5 mg of the active ingredient.
- the solution is sterilized by a conventional method, 5 mL each is filled in an ampoule, and lyophilized by a conventional method to obtain 10,000 ampoule containing 20 mg of active ingredient per ampoule.
- a drug containing the compound as an active ingredient is useful as an agent for suppressing progression of cancer or infectious disease, suppressing recurrence and / or a therapeutic agent.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
一般式(I-1)
[1] 一般式(I)
[2] 環Aが、(a)C5~6単環式炭素環もしくは(b)酸素原子、窒素原子および硫黄原子から選択される1~4個のヘテロ原子を含む5~6員単環式複素環である、前項[1]記載の化合物、そのN-オキシド体、それらのプロドラッグ、それらの薬学的に許容される塩またはそれらの溶媒和物;
[3] 環Bが、(a)C5~6単環式炭素環もしくは(b)酸素原子、窒素原子および硫黄原子から選択される1~4個のヘテロ原子を含む5~6員単環式複素環である、前項[1]もしくは[2]記載の化合物、そのN-オキシド体、それらのプロドラッグ、それらの薬学的に許容される塩またはそれらの溶媒和物;
[4] 環Aが、(a)ベンゼン環もしくは(b)酸素原子、窒素原子および硫黄原子から選択される1~4個のヘテロ原子を含む5~6員単環式芳香族複素環である、前項[1]もしくは[3]記載の化合物、そのN-オキシド体、それらのプロドラッグ、それらの薬学的に許容される塩またはそれらの溶媒和物;
[5] 環Bが、(a)ベンゼン環もしくは(b)酸素原子、窒素原子および硫黄原子から選択される1~4個のヘテロ原子を含む5~6員単環式芳香族複素環である、前項[1]、[2]および[4]の何れか一項記載の化合物、そのN-オキシド体、それらのプロドラッグ、それらの薬学的に許容される塩またはそれらの溶媒和物;
[6] 環Aが、1~4個の窒素原子を含み、その他のヘテロ原子を含まない5~6員単環式芳香族含窒素複素環である、前項[1]、[3]および[5]の何れか一項記載の化合物、そのN-オキシド体、それらのプロドラッグ、それらの薬学的に許容される塩またはそれらの溶媒和物;
[7] Zが酸素原子である、前項[1]~[6]の何れか一項記載の化合物、そのN-オキシド体、それらのプロドラッグ、それらの薬学的に許容される塩またはそれらの溶媒和物;
[8] Xが窒素原子であり、Yが-CH=である、前項[1]~[7]の何れか一項記載の化合物、そのN-オキシド体、それらのプロドラッグ、それらの薬学的に許容される塩またはそれらの溶媒和物;
[9]一般式(I)の
[10] 一般式(I)で示される化合物が、一般式(II)
[11] Tが窒素原子である、前項[1]~[10]の何れか一項記載の化合物、そのN-オキシド体、それらのプロドラッグ、それらの薬学的に許容される塩またはそれらの溶媒和物;
[12] Uが炭素原子である、前項[9]~[11]の何れか一項記載の化合物、そのN-オキシド体、それらのプロドラッグ、それらの薬学的に許容される塩またはそれらの溶媒和物;
[13] 環Aが、ピラゾール、トリアゾール(例えば、1,2,3-トリアゾールおよび1,2,4-トリアゾール)、テトラゾール、オキサゾール、イソオキサゾール、イミダゾール、チアゾールまたはイソチアゾールである、前項[1]、[3]、[5]および[7]~[12]の何れか一項記載の化合物、そのN-オキシド体、それらのプロドラッグ、それらの薬学的に許容される塩またはそれらの溶媒和物;
[14] 一般式(I)で示される化合物が、一般式(III)
[15] 一般式(I)、一般式(II)および一般式(III)(以下、「一般式(I)等」と略記することがある。)のL2が、結合手またはC1~3アルキレン基である、前項[1]~[14]の何れか一項記載の化合物、そのN-オキシド体、それらのプロドラッグ、それらの薬学的に許容される塩またはそれらの溶媒和物;
[16] 一般式(I)等のL1が、-O-、-CONH-、-CO-、-CO2-、-S-、-SO2-または-SO-である、前項[1]~[15]の何れか一項記載の化合物、そのN-オキシド体、それらのプロドラッグ、それらの薬学的に許容される塩またはそれらの溶媒和物;
[17] 一般式(I)等のL1が、-CONH-(但し、当該基の左側が環Bに結合する。)、-CO-、-CO2-、-S-、-SO2-または-SO-である、前項[1]~[15]の何れか一項記載の化合物、そのN-オキシド体、それらのプロドラッグ、それらの薬学的に許容される塩またはそれらの溶媒和物;
[18] R1が、水素原子、水酸基、C1~4アルキル基またはカルボキシ基である、前項[1]~[17]の何れか一項記載の化合物、そのN-オキシド体、それらのプロドラッグ、それらの薬学的に許容される塩またはそれらの溶媒和物;
[19] R1が、水素原子またはC1~4アルキル基である、前項[1]~[17]の何れか一項記載の化合物、そのN-オキシド体、それらのプロドラッグ、それらの薬学的に許容される塩またはそれらの溶媒和物;
[20] R2が、ニトロ基またはNR2aR2bである、前項[1]~[19]の何れか一項記載の化合物、そのN-オキシド体、それらのプロドラッグ、それらの薬学的に許容される塩またはそれらの溶媒和物;
[21] R2aおよびR2bがともに水素原子である、前項[1]~[20]の何れか一項記載の化合物、そのN-オキシド体、それらのプロドラッグ、それらの薬学的に許容される塩またはそれらの溶媒和物;
[22] R3が、水素原子、ハロゲン原子または水酸基である、前項[1]~[21]の何れか一項記載の化合物、そのN-オキシド体、それらのプロドラッグ、それらの薬学的に許容される塩またはそれらの溶媒和物;
[23] R4が、水素原子である、前項[1]~[22]の何れか一項記載の化合物、そのN-オキシド体、それらのプロドラッグ、それらの薬学的に許容される塩またはそれらの溶媒和物;
[24] R6が、水素原子である、前項[1]~[23]の何れか一項記載の化合物、そのN-オキシド体、それらのプロドラッグ、それらの薬学的に許容される塩またはそれらの溶媒和物;
[25] pおよびpaが、ゼロまたは1である、前項[1]~[24]の何れか一項記載の化合物、そのN-オキシド体、それらのプロドラッグ、それらの薬学的に許容される塩またはそれらの溶媒和物;
[26] 一般式(I)で示される化合物が、
(1) 4-(4-アミノ-2-フルオロ-5-メトキシフェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[5,4-c]ピリジン-3-アミン、
(2) 4-(4-アミノ-2-フルオロ-5-メトキシフェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(3) 4-(4-アミノ-3-メトキシフェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(4) 4-(4-アミノ-2-フルオロ-5-(メチルチオ)フェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(5) 4-(4-アミノ-2-フルオロ-5-(メトキシ-d3)フェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(6) 4-(4-アミノ-2-フルオロ-5-(メチルスルホニル)フェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(7) 4-(4-アミノ-5-(エチルチオ)-2-フルオロフェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(8) 4-(4-アミノ-2-フルオロ-5-(メチルスルフィニル)フェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(9) 4-(4-アミノ-2-フルオロ-3-メトキシフェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(10) メチル 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロベンゾエート、
(11) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロ安息香酸、
(12) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロベンズアミド、
(13) 4-(4-アミノ-2-フルオロ-5-メトキシフェニル)-7-(3-メチル-1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(14) 1-(2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロフェニル)エタン-1-オン、
(15) 4-(4-アミノ-2-クロロ-5-(メチルチオ)フェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(16) エチル 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロベンゾエート、
(17) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロ-N-メチルベンズアミド、
(18) 1-(2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロフェニル)プロパン-1-オン、
(19) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-N-エチル-4-フルオロベンズアミド、
(20) 1-(2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)フェニル)エタン-1-オン、
(21) メチル 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)ベンゾエート、
(22) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-N-プロピルベンズアミド、
(23) 1-(2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロフェニル)ブタン-1-オン、
(24) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロ-N-プロピルベンズアミド、
(25) 1-(2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)フェニル)ブタン-1-オン、
(26) 2-ヒドロキシエチル 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロベンゾエート、
(27) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)ベンズアミド、
(28) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-N-メチルベンズアミド、
(29) 1-(2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-ヒドロキシフェニル)エタン-1-オン、
(30) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-N-エチルベンズアミド、
(31) 1-(2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)フェニル)プロパン-1-オン、
(32) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-クロロ-N-エチルベンズアミド、
(33) 4-(2-フルオロ-5-メトキシ-4-ニトロフェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(34) 1-(2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソチアゾロ[4,5-c]ピリジン-4-イル)-4-フルオロフェニル)エタン-1-オン、および
(35) 4-(4-アミノ-2-フルオロ-5-(トリフルオロメチル)フェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミンからなる群から選択される化合物である、前項[1]記載の化合物、そのN-オキシド体、それらのプロドラッグ、それらの薬学的に許容される塩またはそれらの溶媒和物;
(i)-(CRFb 2)qOP(=O)(ORFa)2[式中、RFaは、各々独立して、水素原子、C1~4アルキル基、C3~6シクロアルキル基、-(CH2)2OHまたは-CH2OCO2CH(CH3)2を表し、RFbは、水素原子またはメチル基を表し、qは1または2の整数を表す(ここで、複数のRFbが表す基は同じでも異なっていてもよい。)。](以下、当該-(CRFb 2)qOP(=O)(ORFa)2基を総称して「ホスホノオキシアルキル基」と略記することがある。)、または
(ii)生体内において分解された結果、一般式(I)で示される化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物を生成する遊離基を表し、その他の記号は前記と同じ意味を表す。但し、R2d、R4aおよびR6aのうちの二つ以上は、同時にRFRを表さない。]で示される化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-2] 環Aが、(a)C5~6単環式炭素環もしくは(b)酸素原子、窒素原子および硫黄原子から選択される1~4個のヘテロ原子を含む5~6員単環式複素環である、前項[1-1]記載の化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-3] 環Bが、(a)C5~6単環式炭素環もしくは(b)酸素原子、窒素原子および硫黄原子から選択される1~4個のヘテロ原子を含む5~6員単環式複素環である、前項[1-1]もしくは[1-2]記載の化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-4] 環Aが、(a)ベンゼン環もしくは(b)酸素原子、窒素原子および硫黄原子から選択される1~4個のヘテロ原子を含む5~6員単環式芳香族複素環である、前項[1-1]もしくは[1-3]記載の化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-5] 環Bが、(a)ベンゼン環もしくは(b)酸素原子、窒素原子および硫黄原子から選択される1~4個のヘテロ原子を含む5~6員単環式芳香族複素環である、前項[1-1]、[1-2]および[1-4]の何れか一項記載の化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-6] 環Aが、1~4個の窒素原子を含み、その他のヘテロ原子を含まない5~6員単環式芳香族含窒素複素環を表す、前項[1-1]、[1-3]および[1-5]の何れか一項記載の化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-7] Zが酸素原子である、前項[1-1]~[1-6]の何れか一項記載の化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-8] Xが窒素原子であり、Yが-CH=である、前項[1-1]~[1-7]の何れか一項記載の化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-9] 一般式(I-1)の
[1-10] 一般式(I-1)で示される化合物が、一般式(II-1)
[1-11] Tが窒素原子である、前項[1-1]~[1-10]の何れか一項記載の化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-12] Uが炭素原子である、前項[1-9]~[1-11]の何れか一項記載の化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-13] 環Aが、ピラゾール、トリアゾール(例えば、1,2,3-トリアゾールおよび1,2,4-トリアゾール)、テトラゾール、オキサゾール、イソオキサゾール、イミダゾール、チアゾールまたはイソチアゾールである、前項[1-1]、[1-3]、[1-5]および[1-7]~[1-12]の何れか一項記載の化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-14] 一般式(I-1)で示される化合物が、一般式(III-1)
[1-15] 一般式(I-1)、一般式(II-1)および一般式(III-1)(以下、「一般式(I-1)等」と略記することがある。)のL2が結合手またはC1~3アルキレン基である、前項[1-1]~[1-14]の何れか一項記載の化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-16] 一般式(I-1)等のL1が、-O-、-CONH-、-CO-、-CO2-、-S-、-SO2-または-SO-である、前項[1-1]~[1-15]の何れか一項記載の化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-17] 一般式(I-1)等のL1が、-CONH-(但し、当該基の左側が環Bに結合する。)、-CO-、-CO2-、-S-、-SO2-または-SO-である、前項[1-1]~[1-15]の何れか一項記載の化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-18] R1が、水素原子、水酸基、C1~4アルキル基またはカルボキシ基である、前項[1-1]~[1-17]の何れか一項記載の化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-19] R1が、水素原子またはC1~4アルキル基である、前項[1-1]~[1-17]の何れか一項記載の化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-20] R2cが、ニトロ基またはNR2dR2eである、前項[1-1]~[1-19]の何れか一項記載の化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-21] R3が、水素原子、ハロゲン原子または水酸基である、前項[1-1]~[1-20]の何れか一項記載の化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-22] R2dが水素原子またはRFRである前項[1-1]~[1-21]の何れか一項記載の化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-23] R4aおよびR6aがともに水素原子である、前項[1-1]~[1-22]の何れか一項記載の化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-24] R4aが水素原子またはRFRである前項[1-1]~[1-21]の何れか一項記載の化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-25] R2dおよびR6aがともに水素原子である、前項[1-1]~[1-21]および[1-24]の何れか一項記載の化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-26] R6aが水素原子またはRFRである前項[1-1]~[1-21]の何れか一項記載の化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-27] R2dおよびR4aがともに水素原子である、前項[1-1]~[1-21]および[1-26]の何れか一項記載の化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-28] RFRが、-(CRFb 2)qOP(=O)(ORFa)2[式中、すべての記号は前記と同じ意味を表す。]である、前項[1-1]~[1-27]の何れか一項記載の化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-29] RFRが表す-(CRFb 2)qOP(=O)(ORFa)2が、-CH2OP(=O)(OH)2、-CH(CH3)OP(=O)(OH)2または-CH2OP(=O)(OH)(OCH2OCO2CH(CH3)2)である前項[1-28]記載の化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-30] RFRが、-(CRFb 2)qOP(=O)(ORFa)2であり、前項[1-1]~[1-28]の何れか一項記載の薬学的に許容される塩が、同基とともに形成されるアルカリ金属塩(例えば、リチウム塩、ナトリウム塩またはカリウム塩)、アルカリ土類金属塩(例えば、カルシウム塩)、マグネシウム塩、亜鉛塩、アンモニウム塩または有機アミン塩である、前項[1-1]~[1-28]の何れか一項記載の化合物の薬学的に許容される塩またはそれらの溶媒和物;
[1-31] 有機アミン塩が、脂肪族アミン塩(例えば、メチルアミン塩、ジメチルアミン塩、シクロペンチルアミン塩、トリメチルアミン塩、トリエチルアミン塩、ジシクロヘキシルアミン塩、モノエタノールアミン塩、ジエタノールアミン塩、トリエタノールアミン塩、プロカイン塩、メグルミン塩、ジエタノールアミン塩、トリス(ヒドロキシメチル)アミノメタン塩またはエチレンジアミン塩等)、アラルキルアミン塩(例えば、ベンジルアミン塩、フェネチルアミン塩、N,N-ジベンジルエチレンジアミン塩またはベネタミン塩等)、ヘテロ環芳香族アミン塩(例えば、ピペリジン塩、ピリジン塩、ピコリン塩、キノリン塩またはイソキノリン塩等)、第四級アンモニウム塩(例えば、テトラメチルアンモニウム塩、テトラエチルアモニウム塩、ベンジルトリメチルアンモニウム塩、ベンジルトリエチルアンモニウム塩、ベンジルトリブチルアンモニウム塩、メチルトリオクチルアンモニウム塩またはテトラブチルアンモニウム塩等)、塩基性アミノ酸塩(例えば、アルギニン塩またはリシン塩等)またはN-メチル-D-グルカミン塩である、前項[1-30]記載の化合物の薬学的に許容される塩またはそれらの溶媒和物;
[1-32] pおよびpaが、ゼロまたは1である、前項[1-1]~[1-31]の何れか一項記載の化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-33] 一般式(I-1)で示される化合物が、
(1) 4-(4-アミノ-2-フルオロ-5-メトキシフェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[5,4-c]ピリジン-3-アミン、
(2) 4-(4-アミノ-2-フルオロ-5-メトキシフェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(3) 4-(4-アミノ-3-メトキシフェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(4) 4-(4-アミノ-2-フルオロ-5-(メチルチオ)フェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(5) 4-(4-アミノ-2-フルオロ-5-(メトキシ-d3)フェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(6) 4-(4-アミノ-2-フルオロ-5-(メチルスルホニル)フェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(7) 4-(4-アミノ-5-(エチルチオ)-2-フルオロフェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(8) 4-(4-アミノ-2-フルオロ-5-(メチルスルフィニル)フェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(9) 4-(4-アミノ-2-フルオロ-3-メトキシフェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(10) メチル 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロベンゾエート、
(11) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロ安息香酸、
(12) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロベンズアミド、
(13) 4-(4-アミノ-2-フルオロ-5-メトキシフェニル)-7-(3-メチル-1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(14) メチル 2-アミノ-5-(3-アミノ-7-(1-((ホスホノオキシ)メチル)-1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロベンゾエート、
(15) 1-(2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロフェニル)エタン-1-オン、
(16) 4-(4-アミノ-2-クロロ-5-(メチルチオ)フェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(17) エチル 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロベンゾエート、
(18) (4-(4-(5-アセチル-4-アミノ-2-フルオロフェニル)-3-アミノイソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル 二水素ホスフェート、
(19) エチル 2-アミノ-5-(3-アミノ-7-(1-((ホスホノオキシ)メチル)-1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロベンゾエート、
(20) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロ-N-メチルベンズアミド、
(21) 1-(2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロフェニル)プロパン-1-オン、
(22) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-N-エチル-4-フルオロベンズアミド、
(23) 1-(2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)フェニル)エタン-1-オン、
(24) メチル 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)ベンゾエート、
(25) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-N-プロピルベンズアミド、
(26) 1-(2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロフェニル)ブタン-1-オン、
(27) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロ-N-プロピルベンズアミド、
(28) 1-(2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)フェニル)ブタン-1-オン、
(29) 2-ヒドロキシエチル 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロベンゾエート、
(30) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)ベンズアミド、
(31) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-N-メチルベンズアミド、
(32) (4-(3-アミノ-4-(4-アミノ-5-(エチルカルバモイル)-2-フルオロフェニル)イソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル 二水素ホスフェート、
(33) 1-(2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-ヒドロキシフェニル)エタン-1-オン、
(34) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-N-エチルベンズアミド、
(35) 1-(2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)フェニル)プロパン-1-オン、
(36) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-クロロ-N-エチルベンズアミド、
(37) (4-(3-アミノ-4-(4-アミノ-2-フルオロ-5-(メチルチオ)フェニル)イソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル 二水素ホスフェート、
(38) (4-(3-アミノ-4-(4-アミノ-2-フルオロ-5-プロピオニルフェニル)イソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル 二水素ホスフェート、
(39) (4-(4-(3-アセチル-4-アミノフェニル)-3-アミノイソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル 二水素ホスフェート、
(40) 4-(2-フルオロ-5-メトキシ-4-ニトロフェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(41) (4-(3-アミノ-4-(4-アミノ-2-フルオロ-5-(メチルスルホニル)フェニル)イソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル 二水素ホスフェート、
(42) (4-(3-アミノ-4-(4-アミノ-5-(エチルカルバモイル)-2-クロロフェニル)イソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル 二水素ホスフェート、
(43) 1-(2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソチアゾロ[4,5-c]ピリジン-4-イル)-4-フルオロフェニル)エタン-1-オン、および
(44) 4-(4-アミノ-2-フルオロ-5-(トリフルオロメチル)フェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミンからなる群から選択される化合物である、前項[1-1]記載の化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-34] 一般式(I-1)で示される化合物が、
(1) メチル 2-アミノ-5-(3-アミノ-7-(1-((ホスホノオキシ)メチル)-1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロベンゾエート、
(2) (4-(4-(5-アセチル-4-アミノ-2-フルオロフェニル)-3-アミノイソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル 二水素ホスフェート、
(3) エチル 2-アミノ-5-(3-アミノ-7-(1-((ホスホノオキシ)メチル)-1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロベンゾエート、
(4) (4-(3-アミノ-4-(4-アミノ-5-(エチルカルバモイル)-2-フルオロフェニル)イソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル 二水素ホスフェート、
(5) (4-(3-アミノ-4-(4-アミノ-2-フルオロ-5-(メチルチオ)フェニル)イソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル 二水素ホスフェート、
(6) (4-(3-アミノ-4-(4-アミノ-2-フルオロ-5-プロピオニルフェニル)イソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル 二水素ホスフェート、
(7) (4-(4-(3-アセチル-4-アミノフェニル)-3-アミノイソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル 二水素ホスフェート、
(8) (4-(3-アミノ-4-(4-アミノ-2-フルオロ-5-(メチルスルホニル)フェニル)イソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル 二水素ホスフェート、および
(9) (4-(3-アミノ-4-(4-アミノ-5-(エチルカルバモイル)-2-クロロフェニル)イソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル 二水素ホスフェートからなる群から選択される化合物である、前項[1-1]記載の化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[1-35] 前項[1-1]~[1-34]の何れか一項記載の化合物の薬学的に許容される塩が、アルカリ金属塩(例えば、リチウム塩、ナトリウム塩またはカリウム塩)である、前項[1-1]~[1-34]の何れか一項記載の化合物の薬学的に許容される塩またはその溶媒和物;
[1-36] 前項[1-1]~[1-35]の何れか一項記載の化合物またはその許容される塩の溶媒和物が水和物である、前項[1-1]~[1-35]の何れか一項記載の化合物またはその薬学的に許容される塩の溶媒和物;
[2-2] 一般式(I-1)、一般式(II-1)もしくは一般式(III-1)で示される化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物および薬学的に許容される担体を含有する医薬組成物;
[2-3] さらに1種以上の他の抗がん剤の有効成分を含む、前項[2-1]または[2-2]記載の医薬組成物;
[3-2] 一般式(I-1)、一般式(II-1)もしくは一般式(III-1)で示される化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物を有効成分として含む、がんもしくは感染症の進行抑制、再発抑制および/または治療剤;
[3-3] がんが、固形がんまたは血液がんである、前項[3-1]または[3-2]記載の剤;
[3-4] 固形がんが、悪性黒色腫(例えば、皮膚、口腔粘膜上皮または眼窩内等における悪性黒色腫)、非小細胞肺癌(例えば、扁平非小細胞肺癌および非扁平非小細胞肺癌)、小細胞肺癌、頭頸部癌(例えば、口腔癌、上咽頭癌、中咽頭癌、下咽頭癌、喉頭癌、唾液腺癌および舌癌)、腎細胞癌(例えば、淡明細胞型腎細胞癌)、乳癌、卵巣癌(例えば、漿液性卵巣癌および卵巣明細胞腺癌)、鼻咽頭癌、子宮癌(例えば、子宮頸癌および子宮体癌)、肛門癌(例えば、肛門管癌)、大腸癌(例えば、高頻度マイクロサテライト不安定性(以下、「MSI-H」と略記する。)および/またはミスマッチ修復欠損(以下、「dMMR」と略記する。)陽性大腸癌)、直腸癌、結腸癌、肝細胞癌、食道癌、胃癌、食道胃接合部癌、膵癌、尿路上皮癌(例えば、膀胱癌、上部尿路癌、尿管癌、腎盂癌および尿道癌)、前立腺癌、卵管癌、原発性腹膜癌、悪性胸膜中皮腫、胆嚢癌、胆管癌、胆道癌、皮膚癌(例えば、ブドウ膜悪性黒色腫およびメルケル細胞癌)、精巣癌(胚細胞腫瘍)、膣癌、外陰部癌、陰茎癌、小腸癌、内分泌系癌、甲状腺癌、副甲状腺癌、副腎癌、脊椎腫瘍、神経芽細胞腫、髄芽腫、眼網膜芽細胞腫、神経内分泌腫瘍、脳腫瘍(例えば、神経膠腫(例えば、神経膠芽腫および神経膠肉腫)および髄膜腫)および扁平上皮癌から選択される1以上の癌である、前項[3-3]記載の剤;
[3-5] 固形がんが、骨・軟部肉腫(例えば、ユーイング肉腫、小児横紋筋肉腫、子宮体部平滑筋肉腫、軟骨肉腫、肺肉腫、骨肉腫および先天性繊維肉腫)またはカポジ肉腫である、前項[3-3]記載の剤;
[3-6] 血液がんが、多発性骨髄腫、悪性リンパ腫(例えば、非ホジキンリンパ腫(例えば、濾胞性リンパ腫、前駆B細胞リンパ芽球性リンパ腫、慢性Bリンパ性白血病、節性辺縁帯B細胞性リンパ腫、びまん性大細胞型B細胞性リンパ腫、MALTリンパ腫、脾原発辺縁帯B細胞性リンパ腫、ヘアリーセル白血病、原発性縦隔大細胞型B細胞性リンパ腫、バーキットリンパ腫、マントル細胞リンパ腫、菌状息肉症、セザリー症候群、慢性もしくは急性リンパ球性白血病、前駆T細胞リンパ芽球性リンパ腫、慢性Tリンパ球性白血病、大顆粒T細胞性白血病、大顆粒NK細胞性白血病、末梢性T細胞リンパ腫、節外性NK/T細胞リンパ腫、成人T細胞白血病、血管中心性リンパ腫、腸管T細胞性リンパ腫、ホジキン様/ホジキン関連未分化大細胞リンパ腫、B細胞リンパ芽球性白血病、T細胞リンパ芽球性白血病およびリンパ形質細胞性リンパ腫)およびホジキンリンパ腫(例えば、古典的ホジキンリンパ腫および結節性リンパ球優位型ホジキンリンパ腫))、白血病(例えば、急性骨髄性白血病および慢性骨髄性白血病)、中枢神経系原発悪性リンパ腫、骨髄異形成症候群および骨髄増殖症候群から選択される1以上のがんである、前項[3-3]記載の剤;
[3-7] がんが、小児がんまたは原発不明がんである、前項[3-1]または[3-2]記載の剤;
[3-8] がんが、他の抗がん剤による治療効果が不十分あるいは十分ではないがんである、前項[3-1]~[3-7]の何れか一項記載の剤;
[3-9] がんが、他の抗がん剤治療後に増悪したがんである、前項[3-1]~[3-8]の何れか一項記載の剤;
[3-10] がん患者が、他の抗がん剤による治療歴のない患者である、前項[3-1]~[3-7]の何れか一項記載の剤;
[3-11] 術後補助療法または術前補助療法において処方される、前項[3-1]~[3-10]の何れか一項記載の剤;
[3-12] がんが、根治もしくは切除不能、転移性、再発性、難治性および/または遠隔転移性である、前項[3-1]~[3-11]の何れか一項記載の剤;
[3-13] 腫瘍組織内の腫瘍細胞のうち、PD-L1を発現した腫瘍細胞が占める割合(以下、「TPS」と略記する。)またはPD-L1陽性細胞数(腫瘍細胞、リンパ球およびマクロファージ)を総腫瘍細胞数で除し、100を乗じた数値(以下、「CPS」と略記する。)が、50%以上、25%以上、10%以上、5%以上または1%以上である、前項[3-1]~[3-12]の何れか一項記載の剤;
[3-14] TPSが、50%未満、25%未満、10%未満、5%未満または1%未満である、前項[3-1]~[3-12]の何れか一項記載の剤;
[3-15] がんが、MSI-Hおよび/またはdMMRを有する、前項[3-1]~[3-14]の何れか一項記載の剤;
[3-16] がんが、MSI-Hおよび/またはdMMRを有しない、もしくは低頻度マイクロサテライト不安定性(以下、「MSI-L」と略記する。)を有する、前項[3-1]~[3-14]の何れか一項記載の剤;
[3-17] 悪性黒色腫または非小細胞肺癌が、BRAF V600E変異陽性である、前項[3-4]~[3-16]の何れか一項記載の剤;
[3-18] 悪性黒色腫または非小細胞肺癌が、BRAF V600野生型である、前項[3-4]~[3-16]の何れか一項記載の剤;
[3-19] 非小細胞肺癌が、EGFR遺伝子変異陽性および/またはALK融合遺伝子陽性である、前項[3-4]~[3-18]の何れか一項記載の剤;
[3-20] 非小細胞肺癌が、EGFR遺伝子変異陰性および/またはALK融合遺伝子陰性である、前項[3-4]~[3-18]の何れか一項記載の剤;
[3-21] がんの腫瘍変異負荷(以下、「TMB」と略記する。)が高頻度(106塩基当たりの変異数が10個以上)である、前項[3-1]~[3-20]の何れか一項記載の剤;
[3-22] がんのTMBが低頻度(106塩基当たりの変異数が10個未満)である、前項[3-1]~[3-20]の何れか一項記載の剤;
[3-23] さらに1種以上の他の抗がん剤と併用して投与されることを特徴とする、前項[3-1]~[3-22]の何れか一項記載の剤;
[4-1] 感染症が、ウイルス感染、寄生虫感染、細菌感染または真菌感染に起因する症状である、前項[3-1]または[3-2]記載の剤;
[4-2] ウイルス感染が、アデノウイルス、アレナウイルス、ブンヤウイルス、カリチウイルス、コロナウイルス、フィロウイルス、ヘパドナウイルス、ヘルペスウイルス、オルソミクソウイルス、パポバウイルス、パラミクソウイルス、パルボウイルス、ピコルナウイルス、ポックスウイルス、レオウイルス、レトロウイルス、ラブドウイルス、トガウイルス、乳頭腫ウイルス(例えば、ヒト乳頭腫ウイルス(HPV))、ヒト免疫不全ウイルス(HIV)、ポリオウイルス、肝炎ウイルス(例えば、A型肝炎ウイルス(HAV)、B型肝炎ウイルス(HBV)、C型肝炎ウイルス(HCV)、D型肝炎ウイルス(HDV)およびE型肝炎ウイルス(HEV))、天然痘ウイルス(例えば、大痘瘡および小痘瘡)、ワクシニアウイルス、インフルエンザウイルス、ライノウイルス、デング熱ウイルス、ウマ脳炎ウイルス、風疹ウイルス、黄熱病ウイルス、ノーウォークウイルス、ヒトT細胞白血病ウイルス(HTLV-I)、ヘアリーセル白血病ウイルス(HTLV-II)、カリフォルニア脳炎ウイルス、ハンタウイルス(出血性熱)、狂犬病ウイルス、エボラ熱ウイルス、マールブルグウイルス、麻疹ウイルス、流行性耳下腺炎ウイルス、呼吸系発疹ウイルス(RSV)、単純ヘルペス1型(口腔ヘルペス)、単純ヘルペス2型(陰部ヘルペス)、帯状ヘルペス(水痘・帯状疱疹ウイルス)、サイトメガロウイルス(CMV)、エプスタイン-バーウイルス(EBV)、フラビウイルス、口蹄疫ウイルス、チクングニヤウイルス、ラッサウイルス、アレナウイルスまたは発癌性ウイルスによる感染症である、前項[4-1]記載の剤;
[5-2] 一般式(I-1)で示される化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物の有効投与量を、その投与が必要な患者に対して投与することからなる、がんもしくは感染症の進行抑制、再発抑制および/または治療方法;
[6-2] がんもしくは感染症の進行抑制、再発抑制および/または治療において使用するための、一般式(I-1)で示される化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物;
[7-2] がんもしくは感染症の進行抑制、再発抑制および/または治療剤の製造における、一般式(I-1)で示される化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物の使用;
[8-2] 前項[2-3]、[3-8]~[3-10]または[3-23]記載の他の抗がん剤が、分子標的薬である、前項[2-3]記載の医薬組成物または前項[3-8]~[3-10]もしくは[3-23]記載の剤;
[8-3] 分子標的薬が、ALK阻害剤、BCR-ABL阻害剤、EGFR阻害剤、B-Raf阻害剤、VEGFR阻害剤、FGFR阻害剤、c-Met阻害剤、Axl阻害剤、Mek阻害剤、CDK阻害剤、Btk阻害剤、PI3K-δ/γ阻害剤、JAK-1/2阻害剤、TGFbR1阻害剤、Cancer cell stemness キナーゼ阻害剤、Syk/FLT3 dual阻害剤、ATR阻害剤、Wee1キナーゼ阻害剤、マルチチロシンキナーゼ阻害剤、mTOR阻害剤、HDAC阻害剤、PARP阻害剤、アロマターゼ阻害剤、EZH2阻害剤、ガレクチン-3阻害剤、STAT3阻害剤、DNMT阻害剤、SMO阻害剤、Hsp90阻害剤、γ-チューブリン特異的阻害剤、HIF2α阻害剤、グルタミナーゼ阻害剤、E3リガーゼ阻害剤、Nrf2活性化剤、アルギナーゼ阻害剤、細胞周期阻害剤、IAP拮抗剤、抗Her2抗体、抗EGFR抗体、抗VEGF抗体、抗VEGFR2抗体、抗CD20抗体、抗CD30抗体、抗CD38抗体、抗DR5抗体、抗CA125抗体、抗DLL4抗体、抗フコシルGM1抗体、抗gpNMB抗体、抗Mesothelin抗体、抗MMP9抗体、抗GD2抗体、抗c-Met抗体、抗FOLR1抗体、抗Ang2-VEGF二重特異性抗体、抗CD30-CD16A二重特異性抗体、抗CD79b抗体、抗FAP抗体/IL-2融合蛋白質、抗CEA抗体/IL-2融合蛋白質、抗CEA-CD3二重特異性抗体、抗DLL3抗体、抗CD3-CD19二重特異性抗体および抗CD20-CD3二重特異性抗体から選択される一種以上の剤である、前項[8-2]記載の医薬組成物または前項[8-2]記載の剤;
[8-4] 前項[2-3]、[3-8]~[3-10]または[3-23]記載の他の抗がん剤が、がん免疫治療薬である、前項[2-3]記載の医薬組成物または前項[3-8]~[3-10]もしくは[3-23]記載の剤;
[8-5] がん免疫治療薬が、抗PD-1抗体、抗PD-L1抗体、PD-1拮抗剤、PD-L1/VISTA拮抗剤、PD-L1/TIM3拮抗剤、抗PD-L2抗体、PD-L1融合タンパク質、PD-L2融合タンパク質、抗CTLA-4抗体、抗LAG-3抗体、LAG-3融合蛋白質、抗Tim3抗体、抗KIR抗体、抗BTLA抗体、抗TIGIT抗体、抗VISTA抗体、抗CD137抗体、抗CSF-1R抗体・CSF-1R阻害剤、抗OX40抗体、抗HVEM抗体、抗CD27抗体、抗GITR抗体、抗CD28抗体、抗CCR4抗体、抗B7-H3抗体、抗ICOSアゴニスト抗体、抗CD4抗体、抗DEC-205抗体/NY-ESO-1融合蛋白質、抗SLAMF7抗体、抗CD73抗体、抗CD122抗体、抗CD40アゴニスト抗体、IDO阻害剤、TLRアゴニスト、アデノシンA2A受容体拮抗剤、抗NKG2A抗体、抗CSF-1抗体、免疫増強剤、IL-15スーパーアゴニスト、可溶性LAG3、CD47拮抗剤およびIL-12拮抗剤から選択される一種以上の剤である、前項[8-4]記載の医薬組成物または前項[8-4]記載の剤;
[8-6] 抗PD-1抗体が、Nivolumab、Cemiplimab、Pembrolizumab、Spartalizumab、Tislelizumab、AMP-514、Dostarlimab、Toripalimab、Camrelizumab、Genolimzumab、Sintilimab、STI-A1110、ENUM 388D4、ENUM 244C8、GLS010、MGA012、AGEN2034、CS1003、HLX10、BAT-1306、AK105、AK103、BI 754091、LZM009、CMAB819、Sym021、GB226、SSI-361、JY034、HX008、ABBV181、BCD-100、ISU106、PF-06801591、CX-188、JNJ-63723283およびAB122から選択される抗体である、前項[8-5]記載の医薬組成物または前項[8-5]記載の剤;
[8-7] 抗PD-L1抗体が、Atezolizumab、Avelumab、Durvalumab、BMS-936559、STI-1014、KN035、LY3300054、HLX20、SHR-1316、CS1001、MSB2311、BGB-A333、KL-A167、CK-301、AK106、AK104、ZKAB001、FAZ053、CBT-502、JS003およびCX-072から選択される抗体である、前項[8-5]記載の医薬組成物または前項[8-5]記載の剤;
[9-2] 一般式(I-1)、一般式(II-1)もしくは一般式(III-1)で示される化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物を有効成分として含むSTING作動剤;
[10-2] 一般式(I-1)、一般式(II-1)もしくは一般式(III-1)で示される化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物を有効成分として含むIFN-β産生誘導剤。
本発明において特に指示しない限り、異性体はこれをすべて包含する。例えば、アルキル基には直鎖のものおよび分枝鎖のものが含まれる。さらに、二重結合、環、縮合環における幾何異性体(E体、Z体、シス体、トランス体)、不斉炭素原子の存在等による光学異性体(R、S体、α、β配置、エナンチオマー、ジアステレオマー)、旋光性を有する光学活性体(D、L、d、l体)、クロマトグラフ分離による極性体(高極性体、低極性体)、平衡化合物、回転異性体、これらの任意の割合の混合物、ラセミ混合物は、すべて本発明に含まれる。また、本発明においては、互変異性体による異性体をもすべて包含する。
一般式(I)等または一般式(I-1)等で示される化合物は、公知の方法でN-オキシド体にすることができる。N-オキシド体とは、一般式(I)等あるいは一般式(I-1)等で示される化合物の窒素原子が、酸化されたものを表す。また、これらN-オキシド体は、さらに下記[プロドラッグ]の項目、下記[塩]の項目および下記[溶媒和物]の項目に記載のように、そのプロドラッグ、その薬学的に許容される塩またはその溶媒和物となっていてもよい。
一般式(I)等で示される化合物またはそのN-オキシド体は、公知の方法により、プロドラッグにすることもできる。当該プロドラッグは、生体内において酵素や胃酸等による反応により、例えば、一般式(I)等で示される化合物またはそのN-オキシド体に変換される化合物をいう。例えば、R2d、R4aおよびR6aの何れか一つが前記のRFRである一般式(I-1)等で示される化合物またはそのN-オキシド体は、一般式(I)等で示される化合物またはそのN-オキシド体のプロドラッグとして投与することができ、そのプロドラッグとして好ましくは、例えば、前項[1-33]に記載の(14)、(18)、(19)、(32)、(37)~(39)、(41)および(42)の化合物が挙げられる。なお、一般式(I)等で示される化合物またはそのN-オキシド体のプロドラッグは、廣川書店1990年刊「医薬品の開発」第7巻「分子設計」163~198頁に記載されているような生理的条件で、対応する一般式(I)等で示される化合物またはそのN-オキシド体に変化するものであってもよい。
一般式(I)等で示される化合物、そのN-オキシド体もしくはそれらのプロドラッグおよび一般式(I-1)等で示される化合物またはそのN-オキシド体は、公知の方法で相当する薬学的に許容される塩に変換することができる。ここで、薬学的に許容される塩としては、例えば、アルカリ金属塩(例えば、リチウム塩、ナトリウム塩およびカリウム塩等)、アルカリ土類金属塩(例えば、カルシウム塩、マグネシウム塩およびバリウム塩等)、アンモニウム塩、有機アミン塩(例えば、脂肪族アミン塩(例えば、メチルアミン塩、ジメチルアミン塩、シクロペンチルアミン塩、トリメチルアミン塩、トリエチルアミン塩、ジシクロヘキシルアミン塩、モノエタノールアミン塩、ジエタノールアミン塩、トリエタノールアミン塩、プロカイン塩、メグルミン塩、ジエタノールアミン塩、トリス(ヒドロキシメチル)アミノメタン塩およびエチレンジアミン塩等)、アラルキルアミン塩(例えば、ベンジルアミン塩、フェネチルアミン塩、N,N-ジベンジルエチレンジアミン塩およびベネタミン塩等)、ヘテロ環芳香族アミン塩(例えば、ピペリジン塩、ピリジン塩、ピコリン塩、キノリン塩およびイソキノリン塩等)、第四級アンモニウム塩(例えば、テトラメチルアンモニウム塩、テトラエチルアモニウム塩、ベンジルトリメチルアンモニウム塩、ベンジルトリエチルアンモニウム塩、ベンジルトリブチルアンモニウム塩、メチルトリオクチルアンモニウム塩およびテトラブチルアンモニウム塩等)、塩基性アミノ酸塩(例えば、アルギニン塩、リシン塩等)およびN-メチル-D-グルカミン塩等)、酸付加物塩(例えば、無機酸塩(例えば、塩酸塩、臭化水素酸塩、ヨウ化水素酸塩、硫酸塩、リン酸塩および硝酸塩等)および有機酸塩(例えば、酢酸塩、トリフルオロ酢酸塩、乳酸塩、酒石酸塩、シュウ酸塩、フマル酸塩、マレイン酸塩、安息香酸塩、クエン酸塩、メタンスルホン酸塩、エタンスルホン酸塩、ベンゼンスルホン酸塩、トルエンスルホン酸塩、イセチオン酸塩、グルクロン酸塩およびグルコン酸塩等)等)等が挙げられる。薬学的に許容される塩は、水溶性のものが好ましい。
一般式(I)等で示される化合物、そのN-オキシド体、それらのプロドラッグまたはそれらの薬学的に許容される塩および一般式(I-1)等で示される化合物、そのN-オキシド体またはそれらの薬学的に許容される塩は、公知の方法で溶媒和物に変換することもできる。溶媒和物は低毒性かつ水溶性であることが好ましい。適当な溶媒和物としては、例えば、水、アルコール系の溶媒(例えば、エタノール等)との溶媒和物が挙げられる。ここで、水和物としては、例えば、1水和物ないし5水和物などのポリ水和物や、半水和物などの低水和物などの形態を取り得るが、本発明化合物の水和物の形態としては、例えば、1水和物、2水和物、3水和物および2~3水和物が挙げられる。また、これら水和物の形態には、包接水和物が含まれる。これら水和物は、一般式(I)等で示される化合物、そのN-オキシド体、それらのプロドラッグもしくはそれらの薬学的に許容される塩または一般式(I-1)等で示される化合物、そのN-オキシド体もしくはそれらの薬学的に許容される塩を、例えば、含水有機溶媒から析出させることで得ることができる。
一般式(I)等で示される化合物、そのN-オキシド体、それらのプロドラッグ、それらの薬学的に許容される塩またはそれらの溶媒和物および一般式(I-1)等で示される化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物は、適切な共結晶形成剤と共結晶を形成することができる。共結晶としては、薬学的に許容される共結晶形成剤と形成される、薬学的に許容されるものが好ましい。共結晶は、2種以上の異なる分子がイオン結合とは異なる分子間相互作用で形成される結晶として定義される。また、共結晶は中性分子と塩の複合体であってもよい。共結晶は、公知の方法、例えば、融解結晶化、溶媒からの再結晶または成分を一緒に物理的に粉砕することにより、調製することができる。適当な共結晶形成剤としては、国際公開第2006/007448号パンフレットに記載のもの、例えば、4-アミノ安息香酸、4-アミノピリジン、アデニン、アラニン、アセチルサリチル酸等が挙げられる。
一般式(I)等で示される化合物、そのN-オキシド体、それらのプロドラッグ、それらの薬学的に許容される塩またはそれらの溶媒和物および一般式(I-1)等で示される化合物、そのN-オキシド体、それらの薬学的に許容される塩またはそれらの溶媒和物は、同位元素(例えば、2H、3H、11C、13C、14C、13N、15N、15O、17O、18O、35S、18F、36Cl、123I、125I等)等で標識されていてもよい。例えば、一般式(I)におけるR1、R2、R3、R4、R5、R6およびR7あるいは一般式(I-1)におけるR1、R2c、R3、R4a、R5、R6aおよびR7のうちの一以上の基を構成する水素原子の全部または一部が、重水原子または三重水素原子に置換された化合物が挙げられ、例えば、4-(4-アミノ-2-フルオロ-5-(メトキシ-d3)フェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン等が挙げられる。なお、本明細書において、「メチル-d3」および「メトキシ-d3」は、各々トリデューテリオメチル基およびトリデューテリオメトキシ基を表す。
本発明化合物は、公知の方法、例えば、Comprehensive Organic Transformations : A Guide to Functional Group Preparations, 2nd Edition (Richard C. Larock, John Wiley & Sons Inc, 1999)に記載された方法、以下に示す方法または実施例に示す方法等を適宜改良し、組み合わせて用いることで製造することができる。
本発明化合物の毒性は十分に低いものであり、医薬品として安全に使用することができる。
本発明化合物は、STINGに対する作動活性を有するため、がんまたは感染症の有効な進行抑制、再発抑制または治療剤として処方することができる。
本発明化合物または本発明化合物を有効成分として含む医薬組成物(以下、「本発明化合物等」と略記する。)は、(a)がんもしくは感染症の進行抑制、再発抑制および/または治療効果の増強のために、(b)組み合わせて処方される他の薬剤の投与量の低減のために、(c)組み合わせて処方される他の薬剤の副作用の軽減のために、および/または(d)組み合わせて処方される他の薬剤の免疫増強作用を高めるために、すなわち、アジュバンドとして、一種以上の他の薬剤とともに組み合わせて処方してもよい。本発明において、他の薬剤とともに組み合わせて処方する場合の投与形態には、1つの製剤中に両成分を配合した配合剤の形態であっても、また別々の製剤としての投与形態であってもよい。その併用により、その他の薬剤の予防、症状進展抑制、再発抑制および/または治療効果を補完したり、投与量あるいは投与回数を維持ないし低減することができる。本発明化合物等と他の薬剤を別々に処方する場合には、一定期間同時投与し、その後、本発明化合物等のみあるいは他の薬剤のみを投与してもよい。また、本発明化合物等を先に投与し、その投与の後に他の薬剤を投与してもよいし、他の薬剤を先に投与し、本発明化合物等を後に投与してもよく、また、上記投与において、一定期間、両薬剤が同時に投与される期間があってもよい。また、各々の薬剤の投与方法は同じでも異なっていてもよい。薬剤の性質により、本発明化合物を含む製剤と他の薬剤を含む製剤のキットとして提供することもできる。ここで、他の薬剤の投与量は、臨床上用いられている用量を基準として適宜選択することができる。また、他の薬剤は任意の2種以上を適宜の割合で組み合わせて投与してもよい。また、前記他の薬剤には、現在までに見出されているものだけでなく今後見出されるものも含まれる。
本発明化合物等または本発明化合物と他の薬剤の併用剤を上記の目的で用いるには、通常、全身的または局所的に、経口または非経口の形で投与される。投与量は、年齢、体重、症状、治療効果、投与方法、処理時間等により異なるが、通常、成人一人当たり、一回につき、1ngから2,000mgの範囲で一日一回から数回経口投与されるか、または成人一人当たり、一回につき、0.1ngから200mgの範囲で一日一回から数回非経口投与されるか、または一日30分から24時間の範囲で静脈内に持続投与される。もちろん前記したように、投与量は種々の条件により変動するため、上記投与量より少ない量で十分な場合もあるし、また範囲を越えて投与の必要な場合もある。
本発明化合物等または本発明化合物と他の薬剤の併用剤を投与する際には、経口投与用固形剤もしくは液剤、経口投与用の徐放性製剤もしくは放出制御製剤または非経口投与用の注射剤、輸液、外用剤、吸入剤もしくは坐剤等として用いられる。
中圧分取液体クロマトグラフィーの箇所に示されている括弧内のHi-flash SIまたはHi-flash NHの記載は、各々用いたカラムの種別(Hi-flash SI:シリカゲル(山善株式会社製)、Hi-flash NH:アミノプロピル基担持型シリカゲル(山善株式会社製))を表す。
[カラム:YMC Triart C18(粒子径:1.9 x 10-6 m;カラム長:30 x 2.0 mm I.D.);流速:1.0mL/分;カラム温度:40℃;移動相(A):0.1%トリフルオロ酢酸水溶液;移動相(B):0.1%トリフルオロ酢酸-アセトニトリル溶液;グラジエント(移動相(A):移動相(B)の比率を記載):[0分]95:5;[0.1分]95:5;[1.2分]5:95;[1.4分]5:95;[1.41分]95:5;[1.5分]95:5;および検出器:UV(PDA)、ELSD、MS]
NMRの箇所に示した数値は、その括弧内に記載した測定溶媒を用いた時の1H-NMRの測定値(化学シフト値)である。
LCMS保持時間(分):0.63;
MS(ESI, Pos.):302(M+H)+;
1H-NMR(DMSO-d6):δ 8.44(d, J=9.0Hz, 1H)。
LCMS保持時間(分):0.92;
MS(ESI, Pos.):283(M+H)+;
1H-NMR(CDCl3):δ 8.83(d, J=7.7Hz, 1H)。
LCMS保持時間(分):1.02;
1H-NMR(CDCl3):δ 8.67(s, 1H), 2.21(s, 3H), 2.13(s, 3H)。
LCMS保持時間(分):0.76;
MS(ESI, Pos.):296(M+H)+;
1H-NMR(DMSO-d6):δ 8.65(s, 1H), 6.59(s, 2H)。
LCMS保持時間(分):0.81;
MS(ESI, Pos.):340 (M+H)+;
1H-NMR(CDCl3):δ 8.64(s, 1H), 6.48(s, 2H)。
LCMS保持時間(分):0.80;
MS(ESI, Pos.):364(M+H)+;
LCMS保持時間(分):1.05;
1H-NMR(CDCl3):δ 8.06(d, J=8.0Hz, 1H), 7.52(d, J=6.0Hz, 1H), 2.52(s, 3H)。
LCMS保持時間(分):1.01;
MS(ESI, Pos.):236(M+H)+。
1H-NMR(CDCl3):δ 7.52(d, J=7.5Hz, 1H), 6.50(d, J=10.5Hz, 1H), 4.45(brs, 2H), 2.31(s, 3H)。
LCMS保持時間(分):0.82;
MS(ESI, Pos.):268(M+H)+。
LCMS保持時間(分):0.91;
MS(ESI, Pos.):232(M+H)+。
LCMS保持時間(分):0.84;
MS(ESI, Pos.):261(M+H)+。
LCMS保持時間(分):0.91;
MS(ESI, Pos.):316(M+H)+。
参考例9の4-ブロモ-5-フルオロ-2-(メチルスルホニル)アニリンの代わりに相当するブロモアリール化合物を用い、参考例12と同様の操作を行い、以下の物性値を有する標題化合物を得た。
MS(ESI, Pos.):296(M+H)+。
MS(ESI, Pos.):284(M+H)+。
MS(ESI, Pos.):280(M+H)+。
MS(ESI, Pos.):309(M+H)+。
MS(ESI, Pos.):325(M+H)+。
LCMS保持時間(分):0.75;
MS(ESI, Pos.):453(M+H)+。
LCMS保持時間(分):0.59;
MS(ESI, Pos.):369(M+H)+;
1H-NMR(CD3OD):δ 8.86(s, 1H), 8.34(s, 2H), 8.05(d, J=8.5Hz, 1H), 6.66(d, J=12.5Hz, 1H), 3,85(s, 3H)。
窒素雰囲気下、参考例6で製造した化合物(235mg)の1,4-ジオキサン(7.1mL)溶液に、5-フルオロ-2-メトキシ-4-(4,4,5,5-テトラメチル-1,3,2-ジオキサボロラン-2-イル)アニリン(CAS No.1326283-60-6)(224mg)、ビス[トリ-tert-ブチルホスフィン]パラジウム(65.9mg)、および2mol/Lリン酸三カリウム水溶液(1.1mL)を加え、110℃で3時間撹拌した。反応液を直接シリカゲルカラムクロマトグラフィー(Hi-flash SI)(ヘキサン:酢酸エチル=100:0~0:100)で精製し、4-(4-アミノ-2-フルオロ-5-メトキシフェニル)-7-(1-(テトラヒドロ-2H-ピラン-2-イル)-1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン(108mg)を得た。
LCMS保持時間(分):0.54;
MS(ESI, Pos.):341(M+H)+;
1H-NMR(CD3OD):δ 8.96(s, 1H), 8.44(s, 2H), 7.11(d, J=6.5Hz, 1H), 6.70(d, J=12.0Hz, 1H), 3.93(s, 3H)。
窒素雰囲気下、参考例6で製造した化合物(10.0g)の1-メチル-2-ピロリドン(以下、NMPと略記する。)(100mL)溶液に、参考例12(3)で製造したボロン酸エステル(10.7g)、ブチルジ-1-アダマンチルホスフィン(984mg)、酢酸パラジウム(308mg)、ヨウ化カリウム(456mg)および2mol/Lリン酸三カリウム水溶液(28mL)を加え、50~60℃で45時間撹拌した。反応液を放冷後、不溶物をNMPで洗浄しながら濾過により取り除いた。ろ液に市水(240mL)を少しずつ加え40分撹拌し、析出した固体をろ取した。固体を順次アセトニトリル(80mL,2回)、メチルtert-ブチルエーテル(80mL,2回)でスラリー洗浄し、ろ取、乾燥することで、1-(2-アミノ-5-(3-アミノ-7-(1-(テトラヒドロ-2H-ピラン-2-イル)-1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロフェニル)エタン-1-オン(8.52g)を得た。
LCMS保持時間(分):0.56;
MS(ESI, Pos.):353(M+H)+;
1H-NMR(DMSO-d6):δ 13.3(s, 1H), 8.97(s, 1H), 8.47(s, 1H), 8.23(s, 1H), 7.98(d, J=8.5Hz, 1H), 7.71(brs, 2H), 6.67(d, J=13.0Hz, 1H), 5.73(s, 2H), 2.52(s, 3H)。
参考例12(1)で製造したメチル 2-アミノ-4-フルオロ-5-(4,4,5,5-テトラメチル-1,3,2-ジオキサボロラン-2-イル)ベンゾエートの代わりに参考例12(2)で製造したボロン酸エステルを用い、参考例13と同様の操作を行うことで、得られた4-(4-アミノ-2-フルオロ-5-(メチルチオ)フェニル)-7-(1-(テトラヒドロ-2H-ピラン-2-イル)-1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン(76.6mg)のTHF溶液(1.5mL)に、室温下で塩酸(10%メタノール溶液,1.1mL)を加え、1時間撹拌した。反応後、生じた沈殿をろ取することで、下記の物性値を有する本発明化合物(76.1mg)を得た。
LCMS保持時間(分):0.60;
MS(ESI, Pos.):357(M+H)+;
1H-NMR(CD3OD):δ 9.05(s, 1H), 8.53(s, 2H), 7.76(d,J=8.0Hz, 1H), 6.78(d, J=13.0Hz, 1H), 2.41(s, 3H)。
4-(4-アミノ-2-フルオロ-5-(メチルチオ)フェニル)-7-(1-(テトラヒドロ-2H-ピラン-2-イル)-1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミンの代わりに相当する化合物を、実施例4記載の操作と同様の操作により製造し、続く実施例4記載と同様の操作に付して、以下の物性値を有する本発明化合物を得た。
LCMS保持時間(分):0.51;
MS(ESI, Pos.):323(M+H)+;
1H-NMR(CD3OD):δ 8.99(s, 1H), 8.49(s, 2H), 7.52(s, 1H), 7.42(d, J=7.0Hz, 1H), 7.30(d, J=8.5Hz, 1H), 4.05(s, 3H)。
LCMS保持時間(分):0.55;
MS(ESI, Pos.):344(M+H)+;
1H-NMR(CD3OD):δ 9.09(s, 1H), 8.56(s, 2H), 7.29(d, J=5.5, 1H), 6.95(d, J=9.0Hz, 1H)。
LCMS保持時間(分):0.55;
MS(ESI, Pos.):389(M+H)+;
1H-NMR(CD3OD):δ 9.10(s, 1H), 8.50(s, 2H), 8.12(d, J=8.0, 1H), 6.90(d, J=12.5Hz, 1H), 3.17(s, 3H)。
HPLC保持時間(分):0.55;
MS(ESI, Pos.):341(M+H)+;
1H-NMR(CD3OD):δ 9.04(s, 1H), 8.49(s, 2H), 7.24(dd, J=8.5,7.5, 1H), 6.84(d, J=8.5Hz, 1H), 3.99(s, 3H)。
LCMS保持時間(分):0.50;
MS(ESI, Pos.):354(M+H)+;
1H-NMR(DMSO-d6):δ 9.03(s, 1H), 8.40(s, 2H),7.92(d, J=9.0, 1H), 7.79(br s, 1H), 7.23(br s, 1H), 6.64(d, J=12.0Hz, 1H), 5.98(br s, 2H)。
LCMS保持時間(分):0.69;
MS(ESI, Pos.):383(M+H)+;
1H-NMR(DMSO-d6):δ 9.01(s, 1H), 8.38 (s, 2H), 7.99(d, J=8.5, 1H), 7.30(br s, 1H), 6.72(d, J=13.0Hz, 1H), 5.83(br s, 2H), 4.28(q, J=7.0Hz, 2H), 1.29(t, J=7.0Hz, 3H)。
LCMS保持時間(分):0.77;
MS(ESI, Pos.):367(M+H)+;
1H-NMR(CD3OD):δ 8.94(s, 1H), 8.38(s, 2H), 8.20(d, J=8.5Hz, 1H), 6.66(d, J=13.0Hz, 1H), 2.94(q, J=7.0Hz, 2H), 1.09(t, J=7.0Hz, 3H)。
LCMS保持時間(分):0.70;
MS(ESI, Pos.):382(M+H)+;
1H-NMR(CD3OD):δ 8.98(s, 1H), 8.41(s, 2H), 7.85 (d, J=8.0Hz, 1H), 6.65(d, J=13.0Hz, 1H), 3.29(q, J=7.0Hz, 2H), 1.11(t, J=7.0Hz, 3H)。
LCMS保持時間(分):0.67;
MS(ESI, Pos.):335(M+H)+;
1H-NMR(CD3OD):δ 8.86(s, 1H), 8.37(s, 2H), 8.29(d, J=2.0Hz, 1H), 7.64(dd, J=9.0, 2.0Hz, 1H), 6.95(d, J=9.0Hz, 1H), 2.56(s, 3H)。
LCMS保持時間(分):0.71;
MS(ESI, Pos.):351(M+H)+;
1H-NMR(DMSO-d6):δ 9.00(s, 1H), 8.45(s, 2H), 8.21(s, 1H), 7.71(d, J=9.0Hz, 1H), 7.01(d, J=9.0Hz, 1H), 6.02(br s, 2H), 3.84(s, 3H)。
LCMS保持時間(分):0.70;
MS(ESI, Pos.):378(M+H)+;
1H-NMR(CD3OD):δ 8.86(s, 1H), 8.38(s, 2H), 7.95(d, J=2.0Hz, 1H), 7.60(dd, J=8.5, 2.0Hz, 1H), 6.94(d, J=8.5Hz, 1H), 3.26-3.13(m, 2H), 1.54(q, J=7.0Hz, 2H), 0.90(t, J=7.0Hz, 3H)。
LCMS保持時間(分):0.90;
MS(ESI, Pos.):381(M+H)+;
1H-NMR(CD3OD):δ 8.94(s, 1H), 8.37(s, 2H), 8.20(d, J=8.0Hz, 1H), 6.65(d, J=13.0Hz, 1H), 2.88(t, J=7.0Hz, 2H), 1.65(q, J=7.5Hz, 2H), 0.90(t, J=7.5Hz, 3H)。
LCMS保持時間(分):0.87;
MS(ESI, Pos.):363(M+H)+;
1H-NMR(CD3OD):δ 8.86(s, 1H), 8.38(s, 2H), 8.33(d, J=2.0Hz, 1H), 7.63(dd, J=9.0,2.0Hz, 1H), 6.96(d, J=9.0Hz, 1H), 2.96(t, J=7.5Hz, 2H), 1.70-1.64(m, 2H), 0.92(t, J=7.0Hz, 3H)。
LCMS保持時間(分):0.76;
MS(ESI, Pos.):399(M+H)+;
1H-NMR(CD3OD):δ 8.97(s, 1H), 8.39 (s, 2H), 8.30 (d, J= 8.5 Hz, 1H), 6.69 (d, J = 13.0 Hz, 1H), 4.26 (t, J = 5.0 Hz, 2H), 3.74 (t, J = 5.0 Hz, 2H)。
LCMS保持時間(分):0.69;
MS(ESI, Pos.):350(M+H)+;
1H-NMR(DMSO-d6):δ 9.04 (s, 1H), 8.56 (d, J=4.5 Hz, 1H), 8.52(s, 2H), 8.18 (d, J=2.0Hz, 1H), 7.64(dd, J = 8.5, 2.0Hz, 1H), 6.94(d, J=8.5Hz, 1H), 6.22(s, 2H), 2.78(d, J=4.5Hz, 3H)。
LCMS保持時間(分):0.63;
MS(ESI, Pos.):373(M+H)+;
1H-NMR(DMSO-d6):δ 9.08 (s, 1H), 8.43 (s, 2H), 7.40 (s, 1H), 6.93 (s, 1H), 2.37(s, 3H)。
4-(4-アミノ-2-フルオロ-5-(メチルチオ)フェニル)-7-(1-(テトラヒドロ-2H-ピラン-2-イル)-1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミンの代わりに相当する化合物を、実施例4記載の操作と同様の操作により製造した後、逆相HPLC(使用カラム:YMC Triart C18(30mm×75mm);移動相:0.1%TFA/水/アセトニトリル=95:5~60:40)で精製し、以下の物性値を有する本発明化合物を得た。
LCMS保持時間(分):0.66;
MS(ESI, Pos.):368(M+H)+;
1H-NMR(DMSO-d6):δ (ロータマー混合物)8.98(s, 1H), 8.35(s, 2H), 8.27-8.21(m, 1H), 7.76(d, J=8.5Hz, 1H), 6.61(d, J=12.5Hz, 1H), 5.69(br s, 2H), 2.71(s, 1.5H), 2.69(s, 1.5H)。
LCMS保持時間(分):0.64;
MS(ESI, Pos.):371(M+H)+;
1H-NMR(CD3OD):δ 8.97(s, 1H), 8.43(s, 2H), 7.69(d, J=8.0Hz, 1H), 6.73(d, J=12.5Hz, 1H), 2.81(q, J=7.0Hz, 2H), 1.25(t, J=7.0Hz, 3H)。
LCMS保持時間(分):0.84;
MS(ESI, Pos.):396(M+H)+;
1H-NMR(CD3OD):δ 8.82(s, 1H), 8.31(s, 2H), 7.67(d, J=8.0 Hz, 1H), 7.56(d, J=12.5 Hz, 1H), 3.26-3.13(m, 2H), 1.53-1.48(m, 2H), 0.86(t, J=7.0 Hz, 3H)。
LCMS保持時間(分):0.67;
MS(ESI, Pos.):336(M+H)+;
1H-NMR(CD3OD):δ 8.79 (s, 1H), 8.29(s, 2H), 7.95(d, J=2.0Hz, 1H), 7.55(dd, J=8.5, 2.0Hz, 1H), 6.88(d, J=8.5 Hz, 1H)。
LCMS保持時間(分):0.55;
MS(ESI, Pos.):364(M+H)+;
1H-NMR(DMSO-d6):δ 8.96(s, 1H), 8.37(s, 2H), 8.30(t, J=6.0Hz, 1H), 7.96(d, J=2.5Hz, 1H), 7.57(dd, J=11.5, 2.5Hz, 1H), 6.88(d, J=11.5Hz, 1H), 5.84(brs, 2H), 3.25(qd, J=9.0 ,6.0Hz, 2H), 1.10(t, J=9.0Hz, 3H)。
HPLC保持時間(分):0.62;
MS(ESI, Pos.):349(M+H)+;
1H-NMR(DMSO-d6):δ 8.97(s, 1H), 8.37(s, 2H), 8.33(s, 1H), 8.25(d, J=2.0Hz, 1H), 7.76(dd, J=9.0, 2.0Hz, 1H), 6.96(d, J=9.0Hz, 1H), 6.46(br s, 2H), 5.94(brs, 2H), 3.06(q, J=7.0Hz, 2H), 1.10(t, J=7.0Hz, 3H)。
LCMS保持時間(分):0.59;
MS(ESI, Pos.):398(M+H)+;
1H-NMR(DMSO-d6):δ 9.00(s, 1H), 8.38(s, 2H), 8.32(t, J=6.5Hz, 1H), 7.71(s, 1H), 6.95(s, 1H), 5.54(brs, 2H), 3.23(qd, J=10.0 ,6.5Hz, 2H), 1.08(t, J=10.0Hz, 3H)。
LCMS保持時間(分):0.92;
MS(ESI, Pos.):371(M+H)+。
4-(4-アミノ-2-フルオロ-5-(メチルチオ)フェニル)-7-(1-(テトラヒドロ-2H-ピラン-2-イル)-1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミンの代わりに相当する化合物を、実施例4記載の操作と同様の操作により製造した後、逆相HPLC(使用カラム:Xtimate C18(25mm×150mm);移動相:0.225%ギ酸/水/アセトニトリル=75:25~45:55)で精製し、以下の物性値を有する本発明化合物を得た。
LCMS保持時間(分):0.90;
MS(ESI, Pos.):379(M+H)+;
1H-NMR(DMSO-d6):δ 8.93(s, 1H), 8.39(s, 2H), 7.69(d, J=7.5Hz, 1H), 6.78(d, J=12.5Hz, 1H)。
実施例4で製造した化合物(17.2mg)、過ほう酸ナトリウム四水和物(6.16mg)、酢酸(0.5mL)およびメタノール(0.2mL)を混合し、50℃で6時間撹拌した。反応液を逆相HPLC(使用カラム:YMC Triart C18(30mm×75mm);移動相:0.1%TFA/水/アセトニトリル=95:5~60:40)で精製し、下記の物性値を有する本発明化合物(5.0mg)を得た。
LCMS保持時間(分):0.50;
MS(ESI, Pos.):373(M+H)+;
1H-NMR(DMSO-d6):δ 8.99 (s, 1H), 8.37(s, 2H), 7.56 (d, J=8.0Hz, 1H), 6.66(d, J=12.5Hz, 1H), 2.79(s, 3H)。
実施例1で製造した化合物(20mg)に、THF(0.2mL)およびメタノール(0.1mL)を加え、室温下で2.0mol/L水酸化ナトリウム水溶液(81μL)を滴下し、3時間撹拌した。反応液を中和し、逆相HPLC(使用カラム:YMC Triart C18(30mm×75mm);移動相:0.1%TFA/水/アセトニトリル=95:5~60:40)で精製し、以下の物性値を有する本発明化合物(12.1mg)を得た。
LCMS保持時間(分):0.53;
MS(ESI, Pos.):355(M+H)+;
1H-NMR(DMSO-d6):δ 8.97(s, 1H), 8.35(s, 2H), 7.93(d, J=8.5Hz, 1H), 7.23(br s, 1H), 6.67(d, J=12.5Hz, 1H), 5.72(br s, 2H)。
1-(テトラヒドロ-2H-ピラン-2-イル)-4-(4,4,5,5-テトラメチル-1,3,2-ジオキサボロラン-2-イル)-1H-ピラゾールの代わりに(1-(tert-ブトキシカルボニル)-3-メチル-1H-ピラゾール-4-イル)ボロン酸を用い、参考例6→参考例13→実施例2と同様の操作を行い、以下の物性値を有する本発明化合物を得た。
LCMS保持時間(分):0.56;
MS(ESI, Pos.):355(M+H)+。
実施例3記載の工程において製造した1-(2-アミノ-5-(3-アミノ-7-(1-(テトラヒドロ-2H-ピラン-2-イル)-1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロフェニル)エタン-1-オン(150mg)の1,3-ジメチル-2-イミダゾリジノン(3mL)溶液に、アセトヒドロキサム酸(258mg)および炭酸カリウム(618mg)を加え、80℃で5時間撹拌した。室温に冷却後、市水(15mL)を加え、酢酸エチル(20mL)で抽出した。飽和食塩水で洗浄後、濃縮した。残渣をシリカゲルカラムクロマトグラフィー(Hi-flash NH)(酢酸エチル:メタノール=100:0~50:50)で精製し、1-(2-アミノ-5-(3-アミノ-7-(1-(テトラヒドロ-2H-ピラン-2-イル)-1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-ヒドロキシフェニル)エタン-1-オン(50mg)を得た。
LCMS保持時間(分):0.55;
MS(ESI, Pos.):351(M+H)+。
1H-NMR(DMSO-d6):δ 8.81 (s, 1H)。
MS(ESI, Pos.):296(M+H)+;
1H-NMR(CDCl3):δ8.41(s, 1H), 6.76(d, J = 6.5Hz, 1H), 6.55(d, J= 11.5Hz, 1H), 4.25(s, 2H), 3.88(s, 3H)。
MS(ESI, Pos.):412(M+H)+;
1H-NMR(CDCl3):δ 8.57(dd, J=1.5, 0.5Hz, 1H), 8.30(d, J=2.0Hz, 1H), 8.23(d, J=1.0 Hz, 1H), 6.81(d, J=6.5Hz, 1H), 6.56(d, J=11.0Hz, 1H), 5.49-5.44(m, 1H), 4.19(s, 2H), 4.13-4.07(m, 1H), 3.89(s, 3H), 3.79-3.71(m, 1H), 2.17-2.05(m, 3H), 1.80-1.62 (m, 3H)。
MS(ESI, Pos.):425(M+H)+;
1H-NMR(CDCl3):δ 8.56(s, 1H), 8.42(s, 1H), 8.31(d, J=0.5Hz, 1H), 6.76(d, J=6.5Hz, 1H), 6.59(d, J=10.5Hz, 1H), 5.52-5.47(m, 1H), 4.14-4.08(m, 1H), 4.33(s, 2H), 4.15(s, 2H), 3.87(s, 3H), 3.79-3.70(m, 1H), 2.16-2.04(m, 3H), 1.75-1.50(m, 3H)。
LCMS保持時間(分):0.66;
MS(ESI, Pos.):341(M+H)+;
1H-NMR(CD3OD):δ 8.45(s, 2H), 8.24(d, J=1.0Hz, 1H), 6.92(d, J=7.0 Hz, 1H), 6.70(d, J = 11.5Hz, 1H), 3.89(s, 3H)。
LCMS保持時間(分):0.84;
MS(ESI, Pos.):591(M+H)+。
LCMS保持時間(分):0.51;
MS(ESI, Pos.):479(M+H)+;
1H-NMR(DMSO-d6):δ 8.99(s, 1H), 8.63(s, 1H), 8.35(s, 1H), 7.94(d, J=8.5Hz, 1H), 7.21(brs, 2H), 6.71(d, J=12.5Hz, 1H), 5.91(d, J=10.0Hz, 2H), 5.75(brs, 2H), 3.82(s, 3H)。
実施例1で製造したメチル 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロベンゾエートの代わりに相当する化合物を用い、参考例18→実施例10と同様の操作を行い、以下の物性値を有する本発明化合物を得た。
LCMS保持時間(分):0.50;
MS(ESI, Pos.):463(M+H)+;
1H-NMR(DMSO-d6):δ8.98(s, 1H), 8.61(s, 1H), 8.33(s, 1H), 7.97(d, J=8.5Hz, 1H), 7.70(brs, 2H), 6.65(d, J=13.0Hz, 1H), 5.89 (d, J=10.0Hz, 2H), 5.76(brs, 2H), 2.51(s, 3H)。
LCMS保持時間(分):0.55;
MS(ESI, Pos.):493(M+H)+;
1H-NMR(DMSO-d6):δ 8.97(s, 1H), 8.60(s, 1H), 8.31(s, 1H), 7.93(d, J=8.5Hz, 1H), 7.19(br s, 2H), 6.67(d, J=12.5Hz, 1H), 5.87(d, J=10.0Hz, 2H), 5.73(brs, 2H), 4.26(q, J=7.0Hz, 2H), 1.27(t, J=7.0Hz, 3H)。
MS(ESI, Pos.):492(M+H)+。
1H-NMR(DMSO-d6):δ 8.99(s, 1H), 8.61(s, 1H), 8.33(s, 1H), 8.27(t, J=5.5Hz, 1H), 7.78(d, J=8.5Hz, 1H), 7.13(brs, 2H), 6.60(d, J=12.5Hz, 1H), 5.88(d, J=10.0Hz, 2H), 5.65(brs, 2H), 3.26-3.18(m, 2H), 1.07(t, J=7.0Hz, 3H)。
MS(ESI, Pos.):467(M+H)+;
1H-NMR(DMSO-d6):δ8.96(s, 1H), 8.60(s, 1H), 8.32(s, 1H), 7.40(d, J=8.5Hz, 1H), 6.62(d, J=12.5Hz, 1H), 5.95(brs, 2H), 5.88 (d, J=10.0Hz, 2H), 5.64(s, 2H), 2.32(s, 3H)。
MS(ESI, Pos.):477(M+H)+;
1H-NMR(DMSO-d6):δ8.98(s, 1H), 8.61(s, 1H), 8.33(s, 1H), 7.99(d, J=8.5Hz, 1H), 7.70(brs, 2H), 6.66(d, J=12.0Hz, 1H), 5.88(d, J=10.0Hz, 2H), 5.75(brs, 2H), 2.96(q, J=7.5Hz, 2H), 1.05(t, J=7.5Hz, 3H)。
MS(ESI, Pos.):445(M+H)+;
1H-NMR(DMSO-d6):δ8.95(s, 1H), 8.58(s, 1H), 8.31(s, 1H), 8.19(d, J=2.0Hz, 1H), 7.77(dd, J=8.5, 2.0Hz, 1H), 7.58(brs, 2H), 6.92(d, J=8.5Hz, 1H), 5.92-5.85(m, 4H), 2.54(s, 3H)。
MS(ESI, Pos.):499(M+H)+;
1H-NMR(DMSO-d6):δ9.00(s, 1H), 8.63(s, 1H), 8.35(s, 1H), 7.74(d, J=8.0Hz, 1H), 6.79(d, J=12.0Hz, 1H), 6.64(brs, 2H), 5.91(d, J=12.0Hz, 2H), 5.83(brs, 2H), 3.18(s, 3H)。
LCMS保持時間(分):0.706;
MS(ESI, Pos.):508(M+H)+;
1H-NMR(DMSO-d6):δ9.01(s, 1H), 8.64(s, 1H), 8.36(s, 1H), 8.33-8.29(m, 1H), 7.70(s, 1H), 7.01(brs, 2H), 6.94(s, 1H), 5.90(d, J=10.0Hz, 2H), 5.53(brs, 2H), 3.24-3.18(m, 2H), 1.91(s, 3H), 1.07(t, J=7.0Hz, 3H)。
実施例3で製造した化合物(100mg)を参考例18と同様の操作に付すことによって、(4-(4-(5-アセチル-4-アミノ-2-フルオロフェニル)-3-アミノイソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル ジ-tert-ブチル ホスフェート(112mg)を得た。この化合物(25mg)に酢酸(0.20mL)および精製水(0.05mL)を加え、60℃で終夜撹拌した。得られた沈殿物をろ取し、乾燥することで下記の物性値を有し、水和物の形態である実施例10(1)の本発明化合物(18.0mg)を得た。なお、本発明化合物のDSCおよびTG分析から、水和物であることが確認できた。
LCMS保持時間(分):0.50;
MS(ESI, Pos.):463(M+H)+;
1H-NMR(DMSO-d6):δ8.98(s, 1H), 8.61(s, 1H), 8.33(s, 1H), 7.97(d, J=8.5Hz, 1H), 7.70(brs, 2H), 6.65(d, J=13.0Hz, 1H), 5.89 (d, J=10.0Hz, 2H), 5.76(brs, 2H), 2.51(s, 3H)。
実施例10(1)で製造した化合物(50mg)の酢酸(1.25mL)溶液に、0.25M 酢酸カリウム水溶液(0.43mL、1当量)を加え、室温で8時間撹拌した。得られた懸濁液をろ取し、減圧乾燥し、下記物性値を有する本発明化合物(43.5mg)を得た。
LCMS保持時間(分):0.49;
MS(ESI, Pos.):463(M+H)+;
1H-NMR(DMSO-d6+CD3OD):δ8.94(s, 1H), 8.60(s, 1H), 8.21(s, 1H), 7.99(d, J=8.5Hz, 1H), 7.70(brs, 2H), 6.66(d, J=13.0Hz, 1H), 5.69 (d, J=9.5Hz, 2H), 2.52(s, 3H)。
実施例4(6)で製造した化合物(2.00g)のDMF(0.5mL)溶液に、炭酸セシウム(128mg)およびジ-tert-ブチル-クロロメチルホスフェート(27μL)を加え、室温で終夜撹拌した。反応液に市水を加え、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、硫酸ナトリウムで乾燥後、濃縮した。残渣をシリカゲルカラムクロマトグラフィー(Hi-flash SI)(ヘキサン:酢酸エチル=90:10~0:100)で精製し、エチル 2-アミノ-5-(3-アミノ-7-(1-(((ジ-tert-ブトキシホスホリル)オキシ)メチル)-1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロベンゾエート(2.12g)を得た。これに精製水(10mL)、エタノール(10mL)およびトリフルオロ酢酸(5.3mL)を順次加え、40℃で撹拌した。2時間後、エタノール(5mL)を加え室温に冷却した。得られた沈殿物をエタノールで洗浄しながらろ取し、減圧乾燥することで下記物性値を有する本発明化合物(1.81g)を得た。
LCMS保持時間(分):0.55;
MS(ESI, Pos.):493(M+H)+;
1H-NMR(DMSO-d6):δ 9.02(s, 1H), 8.65(s, 1H), 8.36(s, 1H), 7.98 (d, J=8.5Hz, 1H), 7.32 (brs, 2H), 6.70(d, J=12.5Hz, 1H), 5.91(d, J=10.0Hz, 2H), 5.79(brs, 2H), 4.28(q, J=7.0Hz, 2H), 1.29(t, J=7.0Hz, 3H)。
実施例10(2)で製造した化合物(2.13g)に、精製水(30mL)、酢酸(20mL)を加え、60℃で4時間撹拌した。溶媒を減圧留去し、エタノール(30mL)で希釈した。反応液を終夜撹拌し、ろ取することで下記物性値を有する本発明化合物(1.50g)を得た。
LCMS保持時間(分):0.55;
MS(ESI, Pos.):493(M+H)+;
1H-NMR(DMSO-d6):δ8.99(s, 1H), 8.62(s, 1H), 8.34(s, 1H), 7.96(d, J=8.5Hz, 1H), 7.21(brs, 2H), 6.69(d, J=13.0Hz, 1H), 5.91(d, J=10.0Hz, 2H), 5.74(brs, 2H), 4.27(q, J=7.0Hz, 2H), 1.92(s, 3H), 1.29(t, J=7.0Hz, 3H)。
LCMS保持時間(分):0.88;
MS(ESI, Pos.):312(M+H)+;
LCMS保持時間(分):0.91;
MS(ESI, Pos.):356(M+H)+;
LCMS保持時間(分):0.86;
MS(ESI, Pos.):380(M+H)+;
LCMS保持時間(分):0.60;
MS(ESI, Pos.):369(M+H)+;
1H-NMR(DMSO-d6):δ8.83(s, 1H), 8.32(brs, 1H), 8.10(brs, 1H), 7.94(d, J=8.5Hz, 1H), 7.69(brs, 2H), 6.67(d, J=13.0Hz, 1H), 5.87(s, 2H), 2.49(s, 3H)。
実施例12:THP1-Dual細胞に対する作用
THP1-Dual細胞(Invivogen社)をRPMI培地に懸濁し、2×106細胞/mLの細胞懸濁液を調製した。96穴プレートに50μLずつ細胞懸濁液を分注し、さらに6~20,000nmol/Lの化合物溶液を50μLずつ添加した。化合物添加後、37℃にて約24時間インキュベートした。インキュベート後、各ウェルから10μLの細胞懸濁液を回収し、Quanti-luc(Invivogen社)50μLと混和した。その後、マイクロプレートリーダー(Molcular Devices社)を用いて発光を検出することで、IRF(Interferon regulatory factor)経路の活性化を測定した。
STING遺伝子をホモ欠損させたTHP1-Dual細胞(THP1-Dual-STING KO細胞(Invivogen社)をRPMI培地に懸濁し、2×106細胞/mLの細胞懸濁液を調製した。96穴プレートに50μLずつ細胞懸濁液を分注し、さらに6~20,000nMの化合物溶液を50μLずつ添加した。化合物添加後、37℃にて約24時間インキュベートした.インキュベート後、各ウェルから10μLの細胞懸濁液を回収し、Quanti-luc(Invivogen社)50μLと混和した。その後、マイクロプレートリーダーを用いて発光を検出することで、IRF経路の活性化を測定した。
IDO1阻害活性の評価はIDO1 Fluorogenic Inhibitor Screening Assay Kit(BPS Bioscience社)を用いて実施した。具体的には、IDO1 Fluorogenic Reaction Solutionを溶解させ、各ウェルに180μLずつ添加した。次に0.6、2、6、20、60および200μmol/Lの濃度の化合物を10μLずつ添加した。さらに、IDO1 His-Tag溶液を10μLずつ添加した後、室温で1時間インキュベートした。次に、Fluorescence Solutioonを20μLずつ添加し、37℃にて4時間インキュベートした。室温で10分静置した後、マイクロプレートリーダーを用いて蛍光を測定した(excitation:400nm,emission:510nm)。
4μmol/L被験物質(実施例1で示される本発明化合物)溶液(最終濃度の4倍濃度)をアッセイバッファー(20mmol/L HEPES,0.01% Triton X-100,1mmol/L DTT,pH7.5)にて調製した。4μmol/L基質/ATP/金属溶液(最終濃度の4倍濃度)をキットバッファー(20mmol/L HEPES,0.01% Triton X-100,5mmol/L DTT,pH7.5)にて調製した。最終濃度の2倍濃度の各種キナーゼ溶液をアッセイバッファーにて調製した。5μLの当該被験物質溶液、5μLの当該基質/ATP/金属溶液および10μLの当該キナーゼ溶液をポリプロピレン製384ウェルプレートのウェル内で混合し、室温にて1ないし5時間反応させた。70μLのターミネーションバッファー(QuickScout Screening Assist MSA; Carna Biosciences社)を添加して反応を停止させた。反応溶液中の基質ペプチドとリン酸化ペプチドをLabChip system(Perkin Elmer社)にて分離、定量した。キナーゼ反応は基質ペプチドピーク高さ(S)とリン酸化ペプチドピーク高さ(P)から計算される生成物比(P/(P+S))にて評価した。なお、評価に用いた各種キナーゼは以下のとおりである。
BTK、KDR、PKCα~ιの各サブタイプ、CDK2~9の各CDK、FAK、TIE2、RAF1およびBRAF
実施例1で示される本発明化合物は、評価した何れのキナーゼに対しても、有意な阻害活性を示さなかった。
C57/BL6マウス由来大腸癌細胞株MC38を同種同系マウス(C57/BL6、雌、6週齢(日本チャールズリバー社))の右側腹部に皮下移植し(ここで、移植日をDay0とした。)、MC38皮下担癌マウスを作製した。移植7日後に、腫瘍体積に基づき群分けを実施し、MC38皮下担癌マウスに対して、Vehicle群(n=8)ならびに実施例1に示される化合物投与群(3mg/kg、n=6)を設定した。腫瘍体積の変化を継時的に移植26日後(Day26)まで測定した。腫瘍体積は以下の式より算出した。
[腫瘍体積(mm3)]=[長径(mm)]×[短径(mm)]2×0.5
その結果を図1に示す。
C57/BL6マウス由来大腸癌細胞株MC38を同種同系マウス(C57/BL6、雌、6週齢(日本チャールズリバー社))の右側腹部に皮下移植し(ここで、移植日をDay0とした。)、MC38皮下担癌マウスを作製した。移植7または8日後に、腫瘍体積に基づき群分けを実施し、MC38皮下担癌マウスに対して、Vehicle(n=8または6)ならびに実施例10および10(1)~10(6)に示される各化合物(各々1、1、1、10、3、1および1mg/kg、n=8または6)を投与した。腫瘍体積の変化を継時的に移植28または30日後(Day28または30)まで測定した。腫瘍体積は実施例16で示した式より算出した。
製剤例1
以下の各成分を常法により混合した後打錠して、一錠中に5mgの活性成分を含有する錠剤1万錠を得ることができる。
・メチル 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロベンゾエート 50g
・カルボキシメチルセルロースカルシウム 20g
・ステアリン酸マグネシウム 10g
・微結晶セルロース 920g
製剤例2
以下の各成分を常法により混合した後、溶液を常法により滅菌し、5mLずつアンプルに充填し、常法により凍結乾燥し、1アンプル中20mgの活性成分を含有するアンプル1万本を得ることができる。
・メチル 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロベンゾエート 200g
・マンニトール 20g
・蒸留水 50L
Claims (36)
- 一般式(I-1)
- 環Aが、(a)C5~6単環式炭素環もしくは(b)酸素原子、窒素原子および硫黄原子から選択される1~4個のヘテロ原子を含む5~6員単環式複素環である、請求項1記載の化合物、その薬学的に許容される塩またはそれらの溶媒和物。
- 環Bが、(a)C5~6単環式炭素環もしくは(b)酸素原子、窒素原子および硫黄原子から選択される1~4個のヘテロ原子を含む5~6員単環式複素環である、請求項1もしくは2記載の化合物、その薬学的に許容される塩またはそれらの溶媒和物。
- 環Aが、(a)ベンゼン環もしくは(b)酸素原子、窒素原子および硫黄原子から選択される1~4個のヘテロ原子を含む5~6員単環式芳香族複素環である、請求項1もしくは3記載の化合物、その薬学的に許容される塩またはそれらの溶媒和物。
- 環Bが、(a)ベンゼン環もしくは(b)酸素原子、窒素原子および硫黄原子から選択される1~4個のヘテロ原子を含む5~6員単環式芳香族複素環である、請求項1、2および4の何れか一項記載の化合物、その薬学的に許容される塩またはそれらの溶媒和物。
- 環Aが、1~4個の窒素原子を含み、その他のヘテロ原子を含まない5~6員単環式芳香族含窒素複素環を表す、請求項1、3および5の何れか一項記載の化合物、その薬学的に許容される塩またはそれらの溶媒和物。
- Zが酸素原子である、請求項1~6の何れか一項記載の化合物、その薬学的に許容される塩またはそれらの溶媒和物。
- Xが窒素原子であり、Yが-CH=である、請求項1~7の何れか一項記載の化合物、その薬学的に許容される塩またはそれらの溶媒和物。
- Tが窒素原子である、請求項1~10の何れか一項記載の化合物、その薬学的に許容される塩またはそれらの溶媒和物。
- Uが炭素原子である、請求項9~11の何れか一項記載の化合物、その薬学的に許容される塩またはそれらの溶媒和物。
- 環Aが、ピラゾール、トリアゾール、テトラゾール、オキサゾール、イソオキサゾール、イミダゾール、チアゾールまたはイソチアゾールである、請求項1、3、5および7~12の何れか一項記載の化合物、その薬学的に許容される塩またはそれらの溶媒和物。
- L2が、結合手またはC1~3アルキレン基である、請求項1~14の何れか一項記載の化合物、その薬学的に許容される塩またはそれらの溶媒和物。
- L1が、-CONH-(但し、当該基の左側が環Bに結合する。)、-CO-、-CO2-、-S-、-SO2-または-SO-である、請求項1~15の何れか一項記載の化合物、その薬学的に許容される塩またはそれらの溶媒和物。
- R1が、水素原子またはC1~4アルキル基である、請求項1~16の何れか一項記載の化合物、その薬学的に許容される塩またはそれらの溶媒和物。
- R2cが、ニトロ基またはNR2dR2eである、請求項1~17の何れか一項記載の化合物、その薬学的に許容される塩またはそれらの溶媒和物。
- R3が、水素原子、ハロゲン原子または水酸基である、請求項1~18の何れか一項記載の化合物、その薬学的に許容される塩またはそれらの溶媒和物。
- R4aが水素原子またはRFRであり、R2dおよびR6aがともに水素原子である、請求項1~19の何れか一項記載の化合物、その薬学的に許容される塩またはそれらの溶媒和物。
- RFRが表す-(CRFb 2)qOP(=O)(ORFa)2が、-CH2OP(=O)(OH)2、-CH(CH3)OP(=O)(OH)2または-CH2OP(=O)(OH)(OCH2OCO2CH(CH3)2)である請求項1~20の何れか一項記載の化合物、その薬学的に許容される塩またはそれらの溶媒和物。
- pおよびpaが、ゼロまたは1である、請求項1~21の何れか一項記載の化合物、その薬学的に許容される塩またはそれらの溶媒和物。
- 一般式(I-1)で示される化合物が、
(1) 4-(4-アミノ-2-フルオロ-5-メトキシフェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[5,4-c]ピリジン-3-アミン、
(2) 4-(4-アミノ-2-フルオロ-5-メトキシフェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(3) 4-(4-アミノ-3-メトキシフェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(4) 4-(4-アミノ-2-フルオロ-5-(メチルチオ)フェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(5) 4-(4-アミノ-2-フルオロ-5-(メトキシ-d3)フェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(6) 4-(4-アミノ-2-フルオロ-5-(メチルスルホニル)フェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(7) 4-(4-アミノ-5-(エチルチオ)-2-フルオロフェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(8) 4-(4-アミノ-2-フルオロ-5-(メチルスルフィニル)フェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(9) 4-(4-アミノ-2-フルオロ-3-メトキシフェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(10) メチル 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロベンゾエート、
(11) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロ安息香酸、
(12) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロベンズアミド、
(13) 4-(4-アミノ-2-フルオロ-5-メトキシフェニル)-7-(3-メチル-1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(14) メチル 2-アミノ-5-(3-アミノ-7-(1-((ホスホノオキシ)メチル)-1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロベンゾエート、
(15) 1-(2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロフェニル)エタン-1-オン、
(16) 4-(4-アミノ-2-クロロ-5-(メチルチオ)フェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(17) エチル 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロベンゾエート、
(18) (4-(4-(5-アセチル-4-アミノ-2-フルオロフェニル)-3-アミノイソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル 二水素ホスフェート、
(19) エチル 2-アミノ-5-(3-アミノ-7-(1-((ホスホノオキシ)メチル)-1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロベンゾエート、
(20) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロ-N-メチルベンズアミド、
(21) 1-(2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロフェニル)プロパン-1-オン、
(22) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-N-エチル-4-フルオロベンズアミド、
(23) 1-(2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)フェニル)エタン-1-オン、
(24) メチル 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)ベンゾエート、
(25) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-N-プロピルベンズアミド、
(26) 1-(2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロフェニル)ブタン-1-オン、
(27) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロ-N-プロピルベンズアミド、
(28) 1-(2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)フェニル)ブタン-1-オン、
(29) 2-ヒドロキシエチル 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロベンゾエート、
(30) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)ベンズアミド、
(31) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-N-メチルベンズアミド、
(32) (4-(3-アミノ-4-(4-アミノ-5-(エチルカルバモイル)-2-フルオロフェニル)イソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル 二水素ホスフェート、
(33) 1-(2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-ヒドロキシフェニル)エタン-1-オン、
(34) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-N-エチルベンズアミド、
(35) 1-(2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)フェニル)プロパン-1-オン、
(36) 2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-クロロ-N-エチルベンズアミド、
(37) (4-(3-アミノ-4-(4-アミノ-2-フルオロ-5-(メチルチオ)フェニル)イソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル 二水素ホスフェート、
(38) (4-(3-アミノ-4-(4-アミノ-2-フルオロ-5-プロピオニルフェニル)イソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル 二水素ホスフェート、
(39) (4-(4-(3-アセチル-4-アミノフェニル)-3-アミノイソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル 二水素ホスフェート、
(40) 4-(2-フルオロ-5-メトキシ-4-ニトロフェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミン、
(41) (4-(3-アミノ-4-(4-アミノ-2-フルオロ-5-(メチルスルホニル)フェニル)イソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル 二水素ホスフェート、
(42) (4-(3-アミノ-4-(4-アミノ-5-(エチルカルバモイル)-2-クロロフェニル)イソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル 二水素ホスフェート、
(43) 1-(2-アミノ-5-(3-アミノ-7-(1H-ピラゾール-4-イル)イソチアゾロ[4,5-c]ピリジン-4-イル)-4-フルオロフェニル)エタン-1-オン、および
(44) 4-(4-アミノ-2-フルオロ-5-(トリフルオロメチル)フェニル)-7-(1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-3-アミンからなる群から選択される化合物である、請求項1記載の化合物、その薬学的に許容される塩またはそれらの溶媒和物。 - 一般式(I-1)で示される化合物が、
(1) メチル 2-アミノ-5-(3-アミノ-7-(1-((ホスホノオキシ)メチル)-1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロベンゾエート、
(2) (4-(4-(5-アセチル-4-アミノ-2-フルオロフェニル)-3-アミノイソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル 二水素ホスフェート、
(3) エチル 2-アミノ-5-(3-アミノ-7-(1-((ホスホノオキシ)メチル)-1H-ピラゾール-4-イル)イソキサゾロ[4,5-c]ピリジン-4-イル)-4-フルオロベンゾエート、
(4) (4-(3-アミノ-4-(4-アミノ-5-(エチルカルバモイル)-2-フルオロフェニル)イソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル 二水素ホスフェート、
(5) (4-(3-アミノ-4-(4-アミノ-2-フルオロ-5-(メチルチオ)フェニル)イソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル 二水素ホスフェート、
(6) (4-(3-アミノ-4-(4-アミノ-2-フルオロ-5-プロピオニルフェニル)イソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル 二水素ホスフェート、
(7) (4-(4-(3-アセチル-4-アミノフェニル)-3-アミノイソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル 二水素ホスフェート、
(8) (4-(3-アミノ-4-(4-アミノ-2-フルオロ-5-(メチルスルホニル)フェニル)イソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル 二水素ホスフェート、および
(9) (4-(3-アミノ-4-(4-アミノ-5-(エチルカルバモイル)-2-クロロフェニル)イソキサゾロ[4,5-c]ピリジン-7-イル)-1H-ピラゾール-1-イル)メチル 二水素ホスフェートからなる群から選択される化合物である、請求項1記載の化合物、その薬学的に許容される塩またはそれらの溶媒和物。 - 請求項1~24の何れか一項記載の化合物の薬学的に許容される塩がアルカリ金属塩である、請求項1~24の何れか一項記載の化合物の薬学的に許容される塩またはその溶媒和物。
- 請求項1~25の何れか一項記載の化合物またはその薬学的に許容される塩の溶媒和物が水和物である、請求項1~25の何れか一項記載の化合物またはその薬学的に許容される塩の溶媒和物。
- 一般式(I-1)で示される化合物またはその薬学的に許容される塩および薬学的に許容される担体を含有する医薬組成物。
- 一般式(I-1)で示される化合物もしくはその薬学的に許容される塩を有効成分として含む、がんもしくは感染症の進行抑制、再発抑制および/または治療剤。
- がんが、固形がんまたは血液がんである、請求項28記載の剤。
- 固形がんが、悪性黒色腫、非小細胞肺癌、小細胞肺癌、頭頸部癌、腎細胞癌、乳癌、卵巣癌、卵巣明細胞腺癌、鼻咽頭癌、子宮癌、肛門癌、大腸癌、直腸癌、結腸癌、肝細胞癌、食道癌、胃癌、食道胃接合部癌、膵癌、尿路上皮癌、前立腺癌、卵管癌、原発性腹膜癌、悪性胸膜中皮腫、胆嚢癌、胆管癌、胆道癌、皮膚癌、精巣癌(胚細胞腫瘍)、膣癌、外陰部癌、陰茎癌、小腸癌、内分泌系癌、甲状腺癌、副甲状腺癌、副腎癌、脊椎腫瘍、神経芽細胞腫、髄芽腫、眼網膜芽細胞腫、神経内分泌腫瘍、脳腫瘍および扁平上皮癌から選択される1以上の癌である、請求項29記載の剤。
- 固形がんが、骨・軟部肉腫またはカポジ肉腫である、請求項29記載の剤。
- 血液がんが、多発性骨髄腫、悪性リンパ腫、白血病、中枢神経系原発悪性リンパ腫、骨髄異形成症候群および骨髄増殖症候群から選択される1以上のがんである、請求項29記載の剤。
- さらに1種以上の他の抗がん剤と併用して投与されることを特徴とする、請求項28~32の何れか一項記載の剤。
- 他の抗がん剤が、がん免疫治療薬である、請求項33記載の剤。
- がん免疫治療薬が、抗PD-1抗体または抗PD-L1抗体である、請求項34記載の剤。
- 一般式(I-1)で示される化合物、その薬学的に許容される塩またはそれらの溶媒和物を有効成分として含むSTING作動剤。
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112021006905-4A BR112021006905A2 (pt) | 2018-10-11 | 2019-10-10 | composto, sal e solvato do mesmo e agente agonístico de sting, composição farmacêutica que compreende o dito composto e uso do mesmo para suprimir a progressão de, suprimir a recorrência de e/ou tratar câncer ou doença infecciosa |
AU2019358948A AU2019358948A1 (en) | 2018-10-11 | 2019-10-10 | STING Agonistic Compound |
US17/264,179 US11130773B2 (en) | 2018-10-11 | 2019-10-10 | STING agonistic compound |
IL282129A IL282129B1 (en) | 2018-10-11 | 2019-10-10 | STING agonistic compound |
NZ774859A NZ774859A (en) | 2018-10-11 | 2019-10-10 | Sting agonistic compound |
SG11202103573YA SG11202103573YA (en) | 2018-10-11 | 2019-10-10 | STING Agonistic Compound |
MX2021003958A MX2021003958A (es) | 2018-10-11 | 2019-10-10 | Compuesto agonista de la proteina estimuladora de genes de interferon (sting). |
JP2020543955A JP6784348B2 (ja) | 2018-10-11 | 2019-10-10 | Sting作動化合物 |
CA3115749A CA3115749A1 (en) | 2018-10-11 | 2019-10-10 | Sting agonistic compound |
CN201980067222.6A CN112867721B (zh) | 2018-10-11 | 2019-10-10 | Sting激动性化合物 |
EP19871896.7A EP3868764A4 (en) | 2018-10-11 | 2019-10-10 | Sting-agonist compound |
KR1020217010621A KR20210075992A (ko) | 2018-10-11 | 2019-10-10 | Sting 작동 화합물 |
PH12021550779A PH12021550779A1 (en) | 2018-10-11 | 2021-04-08 | Sting agonistic compound |
ZA2021/02356A ZA202102356B (en) | 2018-10-11 | 2021-04-09 | Sting agonistic compound |
US17/395,643 US11919917B2 (en) | 2018-10-11 | 2021-08-06 | Sting agonistic compound |
US18/339,506 US20230339992A1 (en) | 2018-10-11 | 2023-06-22 | Sting agonistic compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018192276 | 2018-10-11 | ||
JP2018-192276 | 2018-10-11 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/264,179 A-371-Of-International US11130773B2 (en) | 2018-10-11 | 2019-10-10 | STING agonistic compound |
US17/395,643 Continuation US11919917B2 (en) | 2018-10-11 | 2021-08-06 | Sting agonistic compound |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020075790A1 true WO2020075790A1 (ja) | 2020-04-16 |
Family
ID=70164627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2019/039941 WO2020075790A1 (ja) | 2018-10-11 | 2019-10-10 | Sting作動化合物 |
Country Status (16)
Country | Link |
---|---|
US (3) | US11130773B2 (ja) |
EP (1) | EP3868764A4 (ja) |
JP (2) | JP6784348B2 (ja) |
KR (1) | KR20210075992A (ja) |
CN (1) | CN112867721B (ja) |
AU (1) | AU2019358948A1 (ja) |
BR (1) | BR112021006905A2 (ja) |
CA (1) | CA3115749A1 (ja) |
IL (1) | IL282129B1 (ja) |
MX (1) | MX2021003958A (ja) |
NZ (1) | NZ774859A (ja) |
PH (1) | PH12021550779A1 (ja) |
SG (1) | SG11202103573YA (ja) |
TW (1) | TW202028212A (ja) |
WO (1) | WO2020075790A1 (ja) |
ZA (1) | ZA202102356B (ja) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021205631A1 (ja) * | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | Sting作動化合物 |
WO2021206160A1 (ja) * | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | 抗体薬物複合体 |
WO2022086260A1 (ko) * | 2020-10-23 | 2022-04-28 | 아주대학교산학협력단 | 인돌리진 유도체를 유효성분으로 포함하는 인터페론 유전자 자극제 조성물 |
WO2022217022A1 (en) | 2021-04-10 | 2022-10-13 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
WO2022226317A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
WO2022229341A1 (en) | 2021-04-29 | 2022-11-03 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
WO2023280227A2 (en) | 2021-07-06 | 2023-01-12 | Profoundbio Us Co. | Linkers, drug linkers and conjugates thereof and methods of using the same |
US11919917B2 (en) | 2018-10-11 | 2024-03-05 | Ono Pharmaceutical Co., Ltd. | Sting agonistic compound |
WO2024089008A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
WO2024089006A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
WO2024088991A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112877275B (zh) * | 2021-02-04 | 2023-03-31 | 中国农业科学院兰州兽医研究所 | Hdac2基因敲除的bhk-21细胞系及其构建方法和应用 |
WO2023073560A1 (en) | 2021-10-26 | 2023-05-04 | Grant Demartino Industries Llc | Magnetostrictive piezoelectric nanoassembly as cancer chemotherapeutic |
Citations (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2868691A (en) | 1956-03-21 | 1959-01-13 | Riker Laboratories Inc | Self-propelling compositions for inhalation therapy containing a salt of isoproterenol or epinephrine |
US3095355A (en) | 1961-10-12 | 1963-06-25 | Revlon | Aerosol composition |
WO2001014424A2 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
JP2002069061A (ja) * | 2000-08-30 | 2002-03-08 | Canon Inc | オキサゾール化合物及びそれを用いた有機発光素子 |
WO2006007448A2 (en) | 2004-06-17 | 2006-01-19 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions and related methods of use |
WO2006121168A1 (en) | 2005-05-09 | 2006-11-16 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
WO2007005874A2 (en) | 2005-07-01 | 2007-01-11 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
WO2008156712A1 (en) | 2007-06-18 | 2008-12-24 | N. V. Organon | Antibodies to human programmed death receptor pd-1 |
WO2014151634A1 (en) | 2013-03-15 | 2014-09-25 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions |
WO2015034820A1 (en) | 2013-09-04 | 2015-03-12 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
WO2015160641A2 (en) | 2014-04-14 | 2015-10-22 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
WO2016039749A1 (en) | 2014-09-11 | 2016-03-17 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions |
WO2016057624A1 (en) | 2014-10-10 | 2016-04-14 | Bristol-Myers Squibb Company | Immunomodulators |
WO2016077518A1 (en) | 2014-11-14 | 2016-05-19 | Bristol-Myers Squibb Company | Macrocyclic peptides useful as immunomodulators |
WO2016100285A1 (en) | 2014-12-18 | 2016-06-23 | Bristol-Myers Squibb Company | Immunomodulators |
WO2016100608A1 (en) | 2014-12-19 | 2016-06-23 | Bristol-Myers Squibb Company | Immunomodulators |
WO2016126646A1 (en) | 2015-02-04 | 2016-08-11 | Bristol-Myers Squibb Company | Immunomodulators |
WO2016149351A1 (en) | 2015-03-18 | 2016-09-22 | Bristol-Myers Squibb Company | Immunomodulators |
US20170050967A1 (en) | 2015-08-20 | 2017-02-23 | The Board Of Trustees Of The Leland Stanford Junior University | Ganciclovir derivatives for modulating innate and adaptive immunity and for use in immunotherapy |
WO2017066227A1 (en) | 2015-10-15 | 2017-04-20 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US20170146519A1 (en) | 2015-11-20 | 2017-05-25 | Oregon Health & Science University | Sting agonists and methods of selecting sting agonists |
WO2017087777A1 (en) | 2015-11-19 | 2017-05-26 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2017093933A1 (en) | 2015-12-03 | 2017-06-08 | Glaxosmithkline Intellectual Property Development Limited | Cyclic purine dinucleotides as modulators of sting |
WO2017106634A1 (en) | 2015-12-17 | 2017-06-22 | Incyte Corporation | N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators |
WO2017106740A1 (en) | 2015-12-16 | 2017-06-22 | Aduro Biotech, Inc. | Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production |
WO2017112730A1 (en) | 2015-12-22 | 2017-06-29 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2017118762A1 (en) | 2016-01-08 | 2017-07-13 | Rijksuniversiteit Groningen | Inhibitors of the pd-1/pd-l1 protein/protein interaction |
WO2017151830A1 (en) | 2016-03-04 | 2017-09-08 | Bristol-Myers Squibb Company | Immunomodulators |
WO2017175156A1 (en) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
WO2017176608A1 (en) | 2016-04-05 | 2017-10-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80/pd-l1 protein/protein interactions |
WO2017186711A1 (en) | 2016-04-25 | 2017-11-02 | Invivogen | Novel complexes of immunostimulatory compounds, and uses thereof |
WO2017192961A1 (en) | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2017205464A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2017202274A1 (zh) | 2016-05-23 | 2017-11-30 | 中国医学科学院药物研究所 | 烟醇醚类衍生物、及其制法和药物组合物与用途 |
WO2018067423A1 (en) | 2016-10-04 | 2018-04-12 | Merck Sharp & Dohme Corp. | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090105245A1 (en) * | 2006-12-21 | 2009-04-23 | Bingaman David P | Methods for treating macular edema and ocular angiogenesis using an anti-inflammatory agent and a receptor tyrosine kinase inhibitor |
US9969724B2 (en) | 2014-04-16 | 2018-05-15 | Merck Sharp & Dohme Corp. | Factor IXa inhibitors |
JP6692826B2 (ja) | 2015-03-10 | 2020-05-13 | アドゥロ バイオテック,インク. | 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法 |
CN108025051B (zh) | 2015-07-29 | 2021-12-24 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
KR20170050967A (ko) | 2015-11-02 | 2017-05-11 | 경남정보대학교 산학협력단 | 휠체어 |
JP2017146519A (ja) | 2016-02-19 | 2017-08-24 | 富士フイルム株式会社 | 撮像レンズおよび撮像装置 |
KR20170106740A (ko) | 2016-03-14 | 2017-09-22 | 한국전자통신연구원 | 시선 기반 자막 재생 장치 및 방법 |
JP2017186711A (ja) | 2016-03-26 | 2017-10-12 | 幸衛 大竹 | ワイシャツの袖口 |
EP3922279A1 (en) | 2016-08-30 | 2021-12-15 | Dana Farber Cancer Institute, Inc. | Drug delivery compositions and uses thereof |
JP6765949B2 (ja) | 2016-12-12 | 2020-10-07 | 株式会社ディスコ | ウェーハの加工方法 |
JP6535048B2 (ja) | 2017-05-25 | 2019-06-26 | 株式会社Fuji | 電子部品装着機が用いるデータを表示する装置 |
JP2020525465A (ja) | 2017-07-03 | 2020-08-27 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 新規置換イソチアゾロピリドン類、それらを調製する方法、並びに、それらの除草剤及び/又は植物成長調節剤としての使用 |
CA3071537A1 (en) | 2017-08-04 | 2019-02-07 | Merck Sharp & Dohme Corp. | Combinations of pd-1 antagonists and benzo[b]thiophene sting agonists for cancer treatment |
TW202028212A (zh) | 2018-10-11 | 2020-08-01 | 日商小野藥品工業股份有限公司 | Sting促效化合物 |
-
2019
- 2019-10-09 TW TW108136641A patent/TW202028212A/zh unknown
- 2019-10-10 KR KR1020217010621A patent/KR20210075992A/ko active Search and Examination
- 2019-10-10 NZ NZ774859A patent/NZ774859A/en unknown
- 2019-10-10 AU AU2019358948A patent/AU2019358948A1/en active Pending
- 2019-10-10 JP JP2020543955A patent/JP6784348B2/ja active Active
- 2019-10-10 WO PCT/JP2019/039941 patent/WO2020075790A1/ja active Application Filing
- 2019-10-10 MX MX2021003958A patent/MX2021003958A/es unknown
- 2019-10-10 BR BR112021006905-4A patent/BR112021006905A2/pt unknown
- 2019-10-10 EP EP19871896.7A patent/EP3868764A4/en active Pending
- 2019-10-10 IL IL282129A patent/IL282129B1/en unknown
- 2019-10-10 SG SG11202103573YA patent/SG11202103573YA/en unknown
- 2019-10-10 CA CA3115749A patent/CA3115749A1/en active Pending
- 2019-10-10 CN CN201980067222.6A patent/CN112867721B/zh active Active
- 2019-10-10 US US17/264,179 patent/US11130773B2/en active Active
-
2020
- 2020-10-08 JP JP2020170203A patent/JP7380507B2/ja active Active
-
2021
- 2021-04-08 PH PH12021550779A patent/PH12021550779A1/en unknown
- 2021-04-09 ZA ZA2021/02356A patent/ZA202102356B/en unknown
- 2021-08-06 US US17/395,643 patent/US11919917B2/en active Active
-
2023
- 2023-06-22 US US18/339,506 patent/US20230339992A1/en active Pending
Patent Citations (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2868691A (en) | 1956-03-21 | 1959-01-13 | Riker Laboratories Inc | Self-propelling compositions for inhalation therapy containing a salt of isoproterenol or epinephrine |
US3095355A (en) | 1961-10-12 | 1963-06-25 | Revlon | Aerosol composition |
WO2001014424A2 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
JP2002069061A (ja) * | 2000-08-30 | 2002-03-08 | Canon Inc | オキサゾール化合物及びそれを用いた有機発光素子 |
WO2006007448A2 (en) | 2004-06-17 | 2006-01-19 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions and related methods of use |
WO2006121168A1 (en) | 2005-05-09 | 2006-11-16 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
WO2007005874A2 (en) | 2005-07-01 | 2007-01-11 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
WO2008156712A1 (en) | 2007-06-18 | 2008-12-24 | N. V. Organon | Antibodies to human programmed death receptor pd-1 |
WO2014151634A1 (en) | 2013-03-15 | 2014-09-25 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions |
WO2015034820A1 (en) | 2013-09-04 | 2015-03-12 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
WO2015160641A2 (en) | 2014-04-14 | 2015-10-22 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
WO2016039749A1 (en) | 2014-09-11 | 2016-03-17 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions |
WO2016057624A1 (en) | 2014-10-10 | 2016-04-14 | Bristol-Myers Squibb Company | Immunomodulators |
WO2016077518A1 (en) | 2014-11-14 | 2016-05-19 | Bristol-Myers Squibb Company | Macrocyclic peptides useful as immunomodulators |
WO2016100285A1 (en) | 2014-12-18 | 2016-06-23 | Bristol-Myers Squibb Company | Immunomodulators |
WO2016100608A1 (en) | 2014-12-19 | 2016-06-23 | Bristol-Myers Squibb Company | Immunomodulators |
WO2016126646A1 (en) | 2015-02-04 | 2016-08-11 | Bristol-Myers Squibb Company | Immunomodulators |
WO2016149351A1 (en) | 2015-03-18 | 2016-09-22 | Bristol-Myers Squibb Company | Immunomodulators |
US20170050967A1 (en) | 2015-08-20 | 2017-02-23 | The Board Of Trustees Of The Leland Stanford Junior University | Ganciclovir derivatives for modulating innate and adaptive immunity and for use in immunotherapy |
WO2017066227A1 (en) | 2015-10-15 | 2017-04-20 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2017087777A1 (en) | 2015-11-19 | 2017-05-26 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US20170146519A1 (en) | 2015-11-20 | 2017-05-25 | Oregon Health & Science University | Sting agonists and methods of selecting sting agonists |
JP2018516903A (ja) * | 2015-12-03 | 2018-06-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Stingの調節因子としての環状プリンジヌクレオチド |
WO2017093933A1 (en) | 2015-12-03 | 2017-06-08 | Glaxosmithkline Intellectual Property Development Limited | Cyclic purine dinucleotides as modulators of sting |
WO2017106740A1 (en) | 2015-12-16 | 2017-06-22 | Aduro Biotech, Inc. | Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production |
WO2017106634A1 (en) | 2015-12-17 | 2017-06-22 | Incyte Corporation | N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators |
WO2017112730A1 (en) | 2015-12-22 | 2017-06-29 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2017118762A1 (en) | 2016-01-08 | 2017-07-13 | Rijksuniversiteit Groningen | Inhibitors of the pd-1/pd-l1 protein/protein interaction |
WO2017151830A1 (en) | 2016-03-04 | 2017-09-08 | Bristol-Myers Squibb Company | Immunomodulators |
WO2017176608A1 (en) | 2016-04-05 | 2017-10-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80/pd-l1 protein/protein interactions |
WO2017175156A1 (en) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
WO2017186711A1 (en) | 2016-04-25 | 2017-11-02 | Invivogen | Novel complexes of immunostimulatory compounds, and uses thereof |
WO2017192961A1 (en) | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2017202274A1 (zh) | 2016-05-23 | 2017-11-30 | 中国医学科学院药物研究所 | 烟醇醚类衍生物、及其制法和药物组合物与用途 |
WO2017202273A1 (zh) | 2016-05-23 | 2017-11-30 | 中国医学科学院药物研究所 | 苄苯醚类衍生物、及其制法和药物组合物与用途 |
WO2017202276A1 (zh) | 2016-05-23 | 2017-11-30 | 中国医学科学院药物研究所 | 苯醚类衍生物、及其制法和药物组合物与用途 |
WO2017202275A1 (zh) | 2016-05-23 | 2017-11-30 | 中国医学科学院药物研究所 | 溴代苄醚衍生物、及其制法和药物组合物与用途 |
WO2017205464A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2018067423A1 (en) | 2016-10-04 | 2018-04-12 | Merck Sharp & Dohme Corp. | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS |
Non-Patent Citations (8)
Title |
---|
"Comprehensive Organic Transformations: A Guide to Functional Group Preparations", 1999, JOHN WILEY & SONS INC |
ANGEW. CHEM. HIT. ED., vol. 54, 2015, pages 11760 - 11764 |
CAS , no. 1326283-60-6 |
CORRALES L., CELL REP, vol. 11, no. 7, 2015, pages 1018 - 1030 |
DEVAUX L., CURR. OPI. MICROBIOL., vol. 41, 2018, pages 21 - 28 |
HIROKAWA SHOTEN: "Development of Pharmaceuticals", MOLECULAR DESIGN, vol. 7, 1990, pages 163 - 198 |
ONCOTARGET, vol. 8, no. 42, 22 September 2017 (2017-09-22), pages 72167 - 72181 |
SALI T.M., PLOS PATLIOG., vol. 11, no. 12, pages el005324 |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11919917B2 (en) | 2018-10-11 | 2024-03-05 | Ono Pharmaceutical Co., Ltd. | Sting agonistic compound |
WO2021205631A1 (ja) * | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | Sting作動化合物 |
WO2021206160A1 (ja) * | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | 抗体薬物複合体 |
WO2022086260A1 (ko) * | 2020-10-23 | 2022-04-28 | 아주대학교산학협력단 | 인돌리진 유도체를 유효성분으로 포함하는 인터페론 유전자 자극제 조성물 |
WO2022217022A1 (en) | 2021-04-10 | 2022-10-13 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
WO2022226317A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
WO2022229341A1 (en) | 2021-04-29 | 2022-11-03 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
WO2023280227A2 (en) | 2021-07-06 | 2023-01-12 | Profoundbio Us Co. | Linkers, drug linkers and conjugates thereof and methods of using the same |
WO2024089008A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
WO2024089006A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
WO2024088991A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
Also Published As
Publication number | Publication date |
---|---|
IL282129B1 (en) | 2024-04-01 |
JPWO2020075790A1 (ja) | 2021-02-15 |
CN112867721A (zh) | 2021-05-28 |
JP7380507B2 (ja) | 2023-11-15 |
IL282129A (en) | 2021-05-31 |
BR112021006905A2 (pt) | 2021-07-20 |
KR20210075992A (ko) | 2021-06-23 |
US20230339992A1 (en) | 2023-10-26 |
NZ774859A (en) | 2024-01-26 |
JP2021008500A (ja) | 2021-01-28 |
AU2019358948A1 (en) | 2021-05-13 |
MX2021003958A (es) | 2021-05-27 |
PH12021550779A1 (en) | 2021-10-11 |
EP3868764A1 (en) | 2021-08-25 |
US20210363166A1 (en) | 2021-11-25 |
TW202028212A (zh) | 2020-08-01 |
US11919917B2 (en) | 2024-03-05 |
US11130773B2 (en) | 2021-09-28 |
CA3115749A1 (en) | 2020-04-16 |
EP3868764A4 (en) | 2022-06-29 |
ZA202102356B (en) | 2022-07-27 |
US20210253615A1 (en) | 2021-08-19 |
SG11202103573YA (en) | 2021-05-28 |
CN112867721B (zh) | 2023-12-08 |
JP6784348B2 (ja) | 2020-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11919917B2 (en) | Sting agonistic compound | |
US11512087B2 (en) | BRK inhibitory compound | |
WO2017155018A1 (ja) | Trk阻害剤抵抗性の癌治療剤 | |
EP3560926B1 (en) | 6-amino-7,9-dihydro-8h-purin-8-one compounds as brk inhibitors | |
WO2021206160A1 (ja) | 抗体薬物複合体 | |
US20230151024A1 (en) | Sting agonistic compound | |
RU2798265C2 (ru) | Соединение, обладающее агонистической активностью в отношении sting | |
JP6912016B1 (ja) | Sting作動化合物 | |
EP4134098A1 (en) | Method of cancer therapy | |
US20210000830A1 (en) | CANCER TREATMENT METHOD USING Trk INHIBITOR AND KINASE INHIBITOR IN COMBINATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19871896 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020543955 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3115749 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021006905 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2021109317 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2019358948 Country of ref document: AU Date of ref document: 20191010 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019871896 Country of ref document: EP Effective date: 20210511 |
|
ENP | Entry into the national phase |
Ref document number: 112021006905 Country of ref document: BR Kind code of ref document: A2 Effective date: 20210409 |